: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.

Influenza

Free Subscription

Articles published in Vaccine
Retrieve available abstracts of 1174 articles:
HTML format

Single Articles

July 2025

STOUTEN V, Van Evercooren I, Vernemmen C, Braeye T, et al
Averted mortality by COVID-19 vaccination in Belgium between 2021 and 2023.
Vaccine. 2025;60:127290.
PubMed Abstract available

ANDRAWEERA PH, Wang B, Danchin M, Blyth CC, et al
Randomised controlled trials of behavioural nudges delivered through text messages to increase influenza and COVID-19 vaccine uptake among pregnant women (EPIC study) in Australia.
Vaccine. 2025;62:127477.
PubMed Abstract available

EDDY AC, Speaks S, Roth M, Roettger JE, et al
IFITM3-deficient mice as a model for testing influenza virus vaccines via the intramuscular route.
Vaccine. 2025;62:127458.
PubMed Abstract available

JIA M, Cao Y, Mu X, Ren D, et al
School-based interventions to increase influenza vaccination in primary school students.
Vaccine. 2025;62:127442.
PubMed Abstract available

LAZARUS R, Kasstan-Dabush B, Ali I, Mounier-Jack S, et al
Influenza vaccine delivery models in secondary care (hospital) settings: What approaches are used to enhance access for clinical risk groups in England?
Vaccine. 2025;62:127445.
PubMed Abstract available

GILROY J, O'Leary M, Domegan L, O'Connor L, et al
Increasing the uptake of Live Attenuated Influenza Vaccine through a new school-based vaccination programme in Ireland.
Vaccine. 2025;62:127467.
PubMed Abstract available

PIERCE SR, Shi H, Caetano C, Prots DA, et al
Self-amplifying mRNA expressing COBRA hemagglutinin elicits long-lasting, broadly reactive antibodies against seasonal influenza A viruses.
Vaccine. 2025;62:127449.
PubMed Abstract available

OSTROWSKY JT, Vestin NC, Mehr AJ, Ulrich AK, et al
Accomplishments and challenges in developing improved influenza vaccines: An evaluation of three years of progress toward the milestones of the influenza vaccines research and development roadmap.
Vaccine. 2025;61:127431.
PubMed Abstract available

RZYMSKI P, Plesniak R, Piekarska A, Sznajder D, et al
Tracking clinical severity of influenza in adult hospitalized patients in 2024: Data from the FluTer registry in Poland.
Vaccine. 2025;61:127443.
PubMed Abstract available

AUROUX M, Fabacher T, Sauleau E, Arnaud L, et al
Pneumococcal and influenza vaccination coverage and impact on COVID-19 infection severity in patients with inflammatory rheumatic diseases: A French National Healthcare Database analysis.
Vaccine. 2025;61:127439.
PubMed Abstract available

KAHN KE, Santibanez TA, Jain A, Zhou T, et al
Parental reasons for non-receipt of influenza vaccination among children 6 months-17 years and changes over time, 2015-2024.
Vaccine. 2025;61:127415.
PubMed Abstract available

June 2025

SONG Z, Ma Y, Jiao L, Yu R, et al
Lovastatin enhanced immune response to avian influenza vaccine in chickens and changed mRNA expression in the bursa of fabricius.
Vaccine. 2025;61:127438.
PubMed Abstract available

SHINJOH M, Tamura K, Yamaguchi Y, Fukushima H, et al
Influenza vaccination in Japanese children, 2024/25: Effectiveness of inactivated vaccine and limited use of newly introduced live-attenuated vaccine.
Vaccine. 2025;61:127429.
PubMed Abstract available

SAMY A, Alber A, Fife M, Hammond JA, et al
IFITM knockout DF1 cells produce higher influenza and newcastle disease viral yields: a proof of concept for avian origin cell-based vaccine production.
Vaccine. 2025;61:127360.
PubMed Abstract available

MISHINA M, Cao W, Ende Z, Sharma SS, et al
Recombinant quadrivalent influenza vaccine (RIV) induces robust cell-mediated and HA-specific B cell humoral immune responses among healthcare personnel.
Vaccine. 2025;61:127361.
PubMed Abstract available

HANSEN BT, Dahl J, Greve-Isdahl M, Winje BA, et al
Low and inequitable influenza and COVID-19 vaccination coverage among pregnant women in Norway: Nationwide population-based cohort study.
Vaccine. 2025;61:127386.
PubMed Abstract available

PUENTE-MASSAGUER E, Vasilev K, Krammer F
Combination of recombinant neuraminidase with cHA-based inactivated split vaccines improves the breadth of cross-reactivity and protection against influenza viruses in mice.
Vaccine. 2025;61:127388.
PubMed Abstract available

KIM C, Lee D, Oh YW, Jung SJ, et al
Association between parental and child influenza vaccination: A national health survey analysis.
Vaccine. 2025;61:127345.
PubMed Abstract available

May 2025

STEPANEK L, Nakladalova M, Borikova A, Horakova D, et al
Measles-mumps-rubella booster and post-COVID-19 immunity: A retrospective cohort study.
Vaccine. 2025;57:127232.
PubMed Abstract available

DAVE E, Culhane JF, Lundsberg LS, Partridge C, et al
Trends in Tdap and influenza vaccination in pregnancy relative to the coronavirus disease-19 pandemic.
Vaccine. 2025;61:127329.
PubMed Abstract available

YADAV G, Dandu H, Malhotra HS, Jain A, et al
COVID-19 vaccination and utility of booster dose: A community-based cross-sectional study.
Vaccine. 2025;60:127325.
PubMed Abstract available

NASREEN S, Jiang Y, Lu H, Lee A, et al
Risk of Guillain-Barre syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
Vaccine. 2025;60:127291.
PubMed Abstract available

SEILER P, Kaplan BS, Brice DC, Duan S, et al
Altered germinal center responses in mice vaccinated with highly pathogenic avian influenza A(H5N1) virus.
Vaccine. 2025;60:127311.
PubMed Abstract available

LEE N, Nguyen L, Nasreen S, Austin PC, et al
Limited durability of protection conferred by XBB.1.5 vaccines against omicron-associated severe outcomes among community-dwelling adults, Ontario, Canada.
Vaccine. 2025;60:127300.
PubMed Abstract available

MALANGE V, Mohaissen T, Conway KM, Rhoads A, et al
Influenza vaccination during early pregnancy and risk of major birth defects, US Birth Defects Study To Evaluate Pregnancy exposureS, 2014-2019.
Vaccine. 2025;59:127297.
PubMed Abstract available

ALSHURMAN BA, Majowicz SE, Grindrod K, Goh J, et al
Understanding the shift in COVID-19 vaccine hesitancy and its associated factors for primary and booster doses among university students: A cross-sectional study.
Vaccine. 2025;59:127296.
PubMed Abstract available

RAHIMI HK, Jasim AA, Rezahosseini O, Harboe ZB, et al
Immunogenicity and adverse effects of pneumococcal vaccines co-administered with influenza or SARS-CoV-2 vaccines in adults: A systematic review and Meta-analysis.
Vaccine. 2025;59:127293.
PubMed Abstract available

MOHAMED Y, Luey E, Kata ', Tukia O, et al
"The only vaccine that we really question is the new vaccine": A qualitative exploration of the social and behavioural drivers of human papillomavirus (HPV) vaccination in Tonga.
Vaccine. 2025;59:127280.
PubMed Abstract available

GANDHI K, Vijay Y, Page K, Dahari H, et al
Challenges in coverage of future hepatitis C vaccines: Review and potential solutions.
Vaccine. 2025;59:127256.
PubMed Abstract available

SURI RK, Maugeais D, Maithal K
COVID-19 pandemic: A multidimensional analysis and the strategic role played by developing countries vaccine manufacturers.
Vaccine. 2025;59:127271.
PubMed Abstract available

GIANNINI F, Hogan AB, Cameron E, Le H, et al
Estimating the impact of Western Australia's first respiratory syncytial virus immunisation program for all infants: A mathematical modelling study.
Vaccine. 2025;56:127155.
PubMed Abstract available

MANDVIWALA AS, Munje AK, Huckriede ALW, Arankalle VA, et al
Immunogenicity evaluation of respiratory syncytial virus prefusogenic-F based virus-like-particles consisting of G and M proteins in mice.
Vaccine. 2025;56:127203.
PubMed Abstract available

KISLAYA I, Caserta M, Faye SLB, Dia OK, et al
Evaluating the effects of a multisectoral dialogue-based COVID-19 awareness-raising intervention in a limited-resource setting: A quasi-experimental study in Senegal.
Vaccine. 2025;56:127168.
PubMed Abstract available

HASAN Z, Masood KI, Qaiser S, Kanji A, et al
Comparative study of humoral and cellular immunity against SARS-CoV-2 induced by different COVID-19 vaccine types: Insights into protection against wildtype, Delta and JN.1 omicron strains.
Vaccine. 2025;59:127270.
PubMed Abstract available

TIAN X, Zhou Y, Deng P, Xu N, et al
Effectiveness and safety of a novel intranasal influenza vaccine in Chinese children: A phase IV multi-Center, randomized, double-blind, placebo-controlled clinical trial.
Vaccine. 2025;59:127268.
PubMed Abstract available

MYBURGH L, van Loon K, Huijbers EJM, van Beijnum JR, et al
Guided design for the development of an evolution-proof influenza vaccine.
Vaccine. 2025;59:127281.
PubMed Abstract available

LIAW K, Konrath KM, Trachtman AR, Tursi NJ, et al
DNA co-delivery of seasonal H1 influenza hemagglutinin nanoparticle vaccines with chemokine adjuvant CTACK induces potent immunogenicity for heterologous protection in vivo.
Vaccine. 2025;59:127231.
PubMed Abstract available

QUENTIN E, Ahmed I, Duong CH, Tubert-Bitter P, et al
Covid-19 Vaccination During Pregnancy in France: a Descriptive Study of Uptake Using the National Healthcare data System.
Vaccine. 2025;58:127223.
PubMed Abstract available

FITZPATRICK T, Yamoah P, Summerby-Murray D, Cowan J, et al
Neurological adverse events following COVID-19 vaccination among Canadians referred to the special immunization clinic network.
Vaccine. 2025;59:127254.
PubMed Abstract available

NHAM E, Song JY, Sohn JW, Choi WS, et al
Real-world effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine: Analysis over nine months.
Vaccine. 2025;59:127275.
PubMed Abstract available

SCHAFFER AL, Hulme WJ, Horne E, Parker EPK, et al
Effect of the 2022 COVID-19 booster vaccination campaign in people aged 50 years in England: Regression discontinuity analysis in OpenSAFELY-TPP.
Vaccine. 2025;59:127257.
PubMed Abstract available

FURUSE Y, Tabuchi T
Impact of COVID-19 vaccination by implementation timing and coverage rate in relation to misinformation prevalence in Japan.
Vaccine. 2025;59:127273.
PubMed Abstract available

LUPTON D, Whitten T, Tay AK, Beek K, et al
Mental health and psychosocial factors predicting concerns about the COVID-19 vaccine among refugee background and Australian-born women.
Vaccine. 2025;58:127251.
PubMed Abstract available

AVERIN A, Quinn E, Atwood M, Weycker D, et al
Cost-effectiveness of bivalent respiratory syncytial virus Prefusion F (RSVpreF) maternal vaccine among infants in the United States.
Vaccine. 2025;58:127191.
PubMed Abstract available

SASAKI E, Hamaguchi I, Hasegawa H, Takahashi Y, et al
Establishment of a novel adjuvant screening system for the development of intranasal vaccine adjuvants.
Vaccine. 2025;58:127267.
PubMed Abstract available

SOBLE A, Malhame M, Malvolti S, Mantel C, et al
Identification and sizing of the current use cases for seasonal influenza vaccines.
Vaccine. 2025 May 15:127233. doi: 10.1016/j.vaccine.2025.127233.
PubMed Abstract available

MOORE DCBC, Nehab MF, Reis AT, Junqueira-Marinho MF, et al
Childhood vaccine hesitancy: The power of metaphors.
Vaccine. 2025;58:127221.
PubMed Abstract available

PATTYN J, Hanning N, Valckx S, Claessens T, et al
Investigating the state of vaccine confidence among the general public and parents with children up to 13 years in Flanders (Belgium).
Vaccine. 2025;58:127250.
PubMed Abstract available

MERRITT A, Bansal S
Prison Vaccination in a pandemic: Geographic disparities and policy insights.
Vaccine. 2025;58:127218.
PubMed Abstract available

MOU J, LaSalle G, Pflugeisen C, Sherls-Jones J, et al
Practice, beliefs and intent in influenza vaccination among Hispanic patients during the pandemic: An interventional study.
Vaccine. 2025;58:127207.
PubMed Abstract available

PEARCE A, Henery P, Dundas R, Katikireddi SV, et al
Socio-economic inequalities in uptake and timing of childhood vaccination: Taking a life course approach in an administrative cohort in Scotland.
Vaccine. 2025;57:127222.
PubMed Abstract available

WANG-LU H, Valerio Mendoza OM, Chen S, Geldsetzer P, et al
Regional mobility and COVID-19 vaccine hesitancy: Evidence from China.
Vaccine. 2025;58:127179.
PubMed Abstract available

CARTER DM, Bloom CE, Kirchenbaum GA, Tsvetnitsky V, et al
Corrigendum to "Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine" [Vaccine (2015) 33(1) 108-16].
Vaccine. 2025;57:127174.
PubMed

TILMANNE A, Pirson M, Leclercq P, Van Den Bulcke J, et al
Evaluation of the costs of care for pediatric patients hospitalized for RSV: A retrospective cohort study in Belgium.
Vaccine. 2025;55:127065.
PubMed Abstract available

GAGNON D, Gubany C, Ouakki M, Malo B, et al
Factors influencing acceptance of RSV immunization for newborns among pregnant individuals: A mixed-methods study.
Vaccine. 2025;55:127062.
PubMed Abstract available

HAO T, Ryan GE, Lydeamore MJ, Cromer D, et al
Predicting immune protection against outcomes of infectious disease from population-level effectiveness data with application to COVID-19.
Vaccine. 2025;55:126987.
PubMed Abstract available

ADAME BJ, Corman SR, Von Feldt PA, Meneses CM, et al
Reactance as a cause of COVID-19 vaccination hesitancy.
Vaccine. 2025;57:127209.
PubMed Abstract available

ROULEAU I, Issa Kana KDN, Zafack JG, Viger YB, et al
New-onset anesthesia/paresthesia following the administration of COVID-19 vaccines in Quebec, Canada.
Vaccine. 2025;57:127217.
PubMed Abstract available

MASHAMBA M, Msibi T, Tshabalala G, Tsotetsi L, et al
Factors influencing influenza vaccine uptake among adults in Johannesburg, South Africa: A qualitative study.
Vaccine. 2025;57:127133.
PubMed Abstract available

RAHA JR, Kim KH, Le CTT, Bhatnagar N, et al
Intranasal vaccination with multi-neuraminidase and M2e virus-like particle vaccine results in greater mucosal immunity and protection against influenza than intramuscular injection.
Vaccine. 2025;57:127206.
PubMed Abstract available

PADRON-REGALADO E, Escudero Gonzalez NA, Del Carmen Selvera HN
Morbidity of viral vaccine preventable diseases in the Mexican states bordering the U.S., 2014-2023.
Vaccine. 2025;56:127192.
PubMed Abstract available

ASHRAF U, Lee A, Gao Q, Gonzalez JC, et al
Impact of age and prior COVID-19 on the response to influenza a components in the 2020-2021 Fluzone vaccine.
Vaccine. 2025;56:127171.
PubMed Abstract available

BOUADDI O, Khalis M, Abdellatifi M, Seedat F, et al
Behavioural and social drivers of vaccination among child and adult migrants in Morocco: A qualitative interview study.
Vaccine. 2025;56:127166.
PubMed Abstract available

PITTER JG, Mihajlovic J, Nagy D, van der Schans J, et al
Underreported influenza mortality in Central and Eastern Europe hinders the extension of seasonal influenza vaccination programs in older adults.
Vaccine. 2025;56:127184.
PubMed Abstract available

AKMATOVA R, Otorbaeva D, Ebama MS
Impact of the COVID-19 pandemic on influenza knowledge, attitudes, and vaccination practices in at-risk groups in the Kyrgyz Republic: A comparative study.
Vaccine. 2025;56:127159.
PubMed Abstract available

SEFAT KMSR, Kulkarni R, Trinh J, Leekha A, et al
Mucosal vaccines with STING-agonist liposomal formulations inhibit RSV (respiratory syncytial virus) replication in cotton rats.
Vaccine. 2025;56:127183.
PubMed Abstract available

OTORBAEVA D, Akmatova R, Cooley KM, Iwamoto C, et al
Corrigendum to "Post-introduction evaluation (PIE) of the seasonal influenza vaccination program in Kyrgyzstan in 2023" Vaccine 55 (2025) 127052.
Vaccine. 2025;56:127123.
PubMed

KANESHITA S, Chambers CD, Johnson D, Kavanaugh A, et al
Short-term side effects following COVID-19 vaccination in pregnancies complicated by autoimmune inflammatory rheumatic diseases: A prospective cohort study.
Vaccine. 2025;56:127194.
PubMed Abstract available

April 2025

FUJI N, Gonzalez E, Salamone FN, Bajorski P, et al
Comparison of Streptococcus pneumoniae nasopharyngeal colonization, serotype-specific and protein-specific antibody and cytokine levels in young children prior to, during and post COVID-19 pandemic.
Vaccine. 2025;54:126954.
PubMed Abstract available

MOTTA M, Callaghan T, Ross JC, Gargano L, et al
Promoting RSV vaccine confidence through reversal narrative (RN) messaging.
Vaccine. 2025;56:127178.
PubMed Abstract available

PAUL MJ, Hudda MT, Pallett S, Groppelli E, et al
Mucosal immune responses to SARS-CoV-2 infection and COVID-19 vaccination.
Vaccine. 2025;56:127175.
PubMed Abstract available

SHANKER A, Vlaev I
The social influence of the corrections of vaccine misinformation on social media.
Vaccine. 2025;56:127177.
PubMed Abstract available

BAYSAC DJ, Guay M, Chen R, Dube E, et al
Did inequalities in COVID-19 vaccination resolve over time? Insights from the Canadian Community Health Survey.
Vaccine. 2025;56:127153.
PubMed Abstract available

HANSEN BT, Kristoffersen AB, Stecher M
Vaccination readiness among adults in Norway: A cross-sectional survey using the 7C model.
Vaccine. 2025;56:127169.
PubMed Abstract available

SINGLETON KL, Post DJ, Augustine AD, Ison MG, et al
Collaborative influenza vaccine innovation centers (CIVICs) program.
Vaccine. 2025;54:127118.
PubMed Abstract available

ESSINK BJ, Vermeulen W, Andrade C, de Rooij R, et al
Corrigendum to 'A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older' Vaccine 51 (2025) 126791.
Vaccine. 2025;56:127127.
PubMed

FATIMAH MNN, Thian BYZ, Wong CL, Ong HK, et al
Chimeric virus-like particles of nodavirus displaying M2e of human and avian influenza A viruses as a potential dual-use vaccine: Inducing a broader immune response and protecting mice against viral infections.
Vaccine. 2025;56:127165.
PubMed Abstract available

BUSTAMANTE Q, Sparkes D, Findlater L, Munro K, et al
Understanding occupational and attitudinal factors influencing UK healthcare worker decisions for COVID-19 and influenza vaccination: A cross-sectional survey within SIREN.
Vaccine. 2025;56:127160.
PubMed Abstract available

OHNO M, Sekiya T, Obeng-Kyeremeh R, Handabile C, et al
Optimization of the preparation method of inactivated intact virus particle vaccine for COVID-19.
Vaccine. 2025;56:127173.
PubMed Abstract available

LANATA CF, Ochoa TJ, Bancalari EM, Baylor NW, et al
Testing an experimental vaccine during a public health emergency: Lessons from a Peruvian case.
Vaccine. 2025;56:127176.
PubMed Abstract available

HONDA-OKUBO Y, Sakala IG, Li L, Bielefeldt-Ohmann H, et al
Advax(R)-adjuvanted inactivated influenza vaccine provides accelerated protection of mice via early induction of an influenza-specific IgM response.
Vaccine. 2025;56:127144.
PubMed Abstract available

MCGRATH LJ, Khan FL, Lopez SMC, Brouillette MA, et al
2023-2024 COVID-19 vaccine uptake among immunocompromised individuals in two US states.
Vaccine. 2025;56:127120.
PubMed Abstract available

ZHANG X, Shi H, Ross TM
Multivalent H3 COBRA-based influenza vaccine elicits enhanced immune response in a pre-immune elderly ferret model.
Vaccine. 2025;56:127156.
PubMed Abstract available

FINNEY J, Kuraoka M, Song S, Watanabe A, et al
Fluorescence-barcoded cell lines stably expressing membrane-anchored influenza neuraminidases.
Vaccine. 2025;56:127157.
PubMed Abstract available

OLESEN SW, Holmdahl I, Ortega-Sanchez IR, Biggerstaff M, et al
Projecting maximum potential demand for nirsevimab to protect eligible US infants and young children against respiratory syncytial virus in the 2024/2025 season.
Vaccine. 2025;53:127109.
PubMed Abstract available

KADOI K, Toba J, Uehara A, Isoda N, et al
Enhanced sulfate pseudo-affinity chromatography using monolith-like particle architecture for purifying SARS-CoV-2.
Vaccine. 2025;53:126951.
PubMed Abstract available

EYAL N, Wendler D
Assessing the risks of current COVID-19 challenge trials systematically.
Vaccine. 2025;53:126877.
PubMed Abstract available

TAKEUCHI N, Chang B, Ishiwada N, Cho Y, et al
Nationwide population-based surveillance of invasive pneumococcal disease in children in Japan (2014-2022): Impact of 13-valent pneumococcal conjugate vaccine and COVID-19 pandemic.
Vaccine. 2025;54:127138.
PubMed Abstract available

STONER MCD, Michaels J, Stocks JB, Mancuso N, et al
Evaluating concurrency and gaps between self-report and vaccine card data for COVID-19 vaccination.
Vaccine. 2025;54:127136.
PubMed Abstract available

TONG F, Zhou T, Tang L, Wu X, et al
Evaluating the impact of influenza vaccine on preventing stroke hospitalization and death in Chinese elderly hypertensive patients: A retrospective cohort study.
Vaccine. 2025;54:127004.
PubMed Abstract available

WEETS CM, Wilson R, Swadley H, Katz R, et al
Strengthening health security through routine vaccination policy: A comprehensive analysis of childhood vaccination laws across 194 countries.
Vaccine. 2025;54:127121.
PubMed Abstract available

ENTRICAN G, Bredell H, Charlier J, Cunningham AF, et al
Opportunities and challenges for the adoption of novel platform technologies to develop veterinary bacterial vaccines.
Vaccine. 2025;54:127117.
PubMed Abstract available

LEYNS C, McClenaghan E, Rodriguez P, Nguipdop-Djomo P, et al
Hybrid, vaccine-induced and natural immunity against SARS-CoV-2 in traditional food markets in Bolivia (2020-2022): A cross-sectional analysis of a serological survey.
Vaccine. 2025;54:127104.
PubMed Abstract available

ZHANG L, Xia Y, Chu L, Sundaram ME, et al
Differences in seasonal influenza vaccine hesitancy profiles between clinicians practicing traditional Chinese medicine and modern Western medicine: A national cross-sectional survey.
Vaccine. 2025;53:127106.
PubMed Abstract available

CHAN MXJ, Wouters OJ, Chan HY, Terblanche P, et al
Regional cooperation on pandemic preparedness and vaccine equity from an economic, regulatory and legal perspective.
Vaccine. 2025 Apr 10:127107. doi: 10.1016/j.vaccine.2025.127107.
PubMed Abstract available

BRUXVOORT KJ, Sy LS, Contreras R, Lewin B, et al
Development and validation of a clinical prediction tool for non-receipt of updated COVID-19 vaccines.
Vaccine. 2025;53:127074.
PubMed Abstract available

ZASZTOWT-STERNICKA M, Jagielska A, Rzad M, Szymusik I, et al
Immunogenicity of inactivated quadrivalent influenza vaccine in pregnant women, including the level of postvaccination antibodies in umbilical cord blood.
Vaccine. 2025;53:127047.
PubMed Abstract available

LLOYD PC, Acharya G, Zhao H, Shah N, et al
Safety monitoring of health outcomes following influenza vaccination during the 2023-2024 season among U.S. Medicare beneficiaries aged 65 years and older.
Vaccine. 2025;53:127069.
PubMed Abstract available

SASANKAN S, Gathers D, Bellerose A, Pankratz VS, et al
Behaviors, perceptions, and impact of the COVID-19 pandemic and vaccination on oncology patients in New Mexico with substantial representation of racial minorities and rural residents.
Vaccine. 2025;53:127091.
PubMed Abstract available

LA EM, Sweeney C, Davenport E, Bunniran S, et al
Pharmacy and healthcare provider offices as convenient adult vaccination settings in the US: Patient experiences from a survey of recently-vaccinated adults.
Vaccine. 2025;54:127057.
PubMed Abstract available

PRALL S, Lopes A
"Better to die trying": Vaccine perceptions and COVID-19 experiences in rural Namibian pastoralists.
Vaccine. 2025;55:127061.
PubMed Abstract available

SHEARN C, Postavaru GI, Hylton L, Morris H, et al
COVID-19 vaccine decision-making and the role of institutions across the pandemic in UK Black African and Black Caribbean communities.
Vaccine. 2025;53:127071.
PubMed Abstract available

CHEN PL, Richardson RA, Rovito S, Yang G, et al
Live-attenuated pandemic H1N1 influenza vaccines expressing computationally optimized broadly reactive antigens (COBRAs) are immunogenic and protective in mice and ferrets.
Vaccine. 2025;53:127090.
PubMed Abstract available

BERNARD C, Drouin J, Le Vu S, Botton J, et al
COVID-19 vaccination rates among pregnant women in France: A nationwide cohort study.
Vaccine. 2025;53:127070.
PubMed Abstract available

FISHER KA, Goldthwait L, Desrochers O, Zemel M, et al
Reasons for COVID-19 vaccination late in the pandemic: A qualitative study.
Vaccine. 2025;53:127084.
PubMed Abstract available

FLYNN PM, Stull C, Jain VM, Evans MD, et al
A national cross-sectional study of dentists' vaccine hesitancy and intention to provide HPV vaccines following emergency COVID-19 vaccination authorization.
Vaccine. 2025;53:127035.
PubMed Abstract available

FELIX P, Melo AA, Costa JP, Colaco M, et al
Exploring TLR agonists as adjuvants for COVID-19 oral vaccines.
Vaccine. 2025;53:127078.
PubMed Abstract available

MCCOSKER LK, Dyer B, Sudarmana T, Seale H, et al
COVID-19 vaccination uptake in people experiencing homelessness during the first three years of the global COVID-19 vaccination effort: A systematic review and meta-analysis.
Vaccine. 2025;53:127050.
PubMed Abstract available

PAYNE AB, Novosad S, Sung HM, Zhang Y, et al
Effectiveness of 2023-2024 COVID-19 vaccines against COVID-19-associated hospitalizations among adults aged >/=18 years with end stage kidney disease - United States, September 2023-April 2024.
Vaccine. 2025;55:127010.
PubMed Abstract available

OLIVIERI G, Amodio D, Manno EC, Santilli V, et al
Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies.
Vaccine. 2025;51:126853.
PubMed Abstract available

PATRICK R, Mahale P, Ackerson BK, Hong V, et al
Respiratory syncytial virus vaccine uptake among adults aged >/=60 years in a large, integrated healthcare system in Southern California 2023-2024.
Vaccine. 2025;53:127033.
PubMed Abstract available

FORAN AM, Jetten J, Muldoon OT
Religious group membership and conspiracy beliefs influence vaccine uptake: Insights from 20 European countries.
Vaccine. 2025;53:127086.
PubMed Abstract available

ALVES K, Kouassi A, Plested JS, Kalkeri R, et al
Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study.
Vaccine. 2025;55:127046.
PubMed Abstract available

PEREZ MARC G, Coria LM, Ceballos A, Rodriguez JM, et al
Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial.
Vaccine. 2025;54:127045.
PubMed Abstract available

OTORBAEVA D, Akmatova R, Cooley KM, Iwamoto C, et al
Post-introduction evaluation (PIE) of the seasonal influenza vaccination program in Kyrgyzstan in 2023.
Vaccine. 2025;55:127052.
PubMed Abstract available

March 2025

KARAN S, Opdensteinen P, Ma Y, De Oliveira JFA, et al
A replicon-based COVID-19 vaccine candidate delivered by tobacco mosaic virus-like particles.
Vaccine. 2025;53:127063.
PubMed Abstract available

JIANG J, Lam KF, Lau EHY, Yin G, et al
Estimation of trajectory of COVID-19 vaccines effectiveness against infection.
Vaccine. 2025;55:127067.
PubMed Abstract available

NEWBERN EC, Shoaibi A, Haynes K, Blacketer C, et al
A rapid cycle analytics framework for vaccine safety surveillance within a real-world data network: Experience with enhanced surveillance of the Janssen COVID-19 vaccine.
Vaccine. 2025;55:127044.
PubMed Abstract available

CENAT JM, Moshirian Farahi SMM, Dalexis RD, Xu Y, et al
Vaccine hesitancy among racially diverse parents in Canada: The important role of health literacy, conspiracy beliefs and racial discrimination.
Vaccine. 2025;55:127049.
PubMed Abstract available

TIRUNEH YM, Choi J, Cuccaro PM, Martinez J, et al
Sociodemographic and health-related predictors of COVID-19 booster uptake among fully vaccinated adults.
Vaccine. 2025;54:127048.
PubMed Abstract available

FRIVOLD C, Giersing B, Amorij JP, Mvundura M, et al
Identification of potential vaccines for use with microarray patches in low- and middle-income countries: An assessment from the Vaccine Innovation Prioritisation Strategy Alliance.
Vaccine. 2025;55:126996.
PubMed Abstract available

BLACKWELL CK, Bekelman T, Bakre S, Jacobson LP, et al
Sociodemographic differences in parental hesitancy to the COVID-19 vaccine.
Vaccine. 2025;55:127041.
PubMed Abstract available

HARALAMBIEVA IH, Ratishvili T, Goergen KM, Grill DE, et al
Effect of lymphocyte miRNA expression on influenza vaccine-induced immunity.
Vaccine. 2025;55:127023.
PubMed Abstract available

FRANCIS MJ
A rapid human vaccine process development map outlining lessons learnt from ChAdOx1 nCoV-19 vaccine during the COVID-19 pandemic.
Vaccine. 2025;55:127040.
PubMed Abstract available

GOLDMAN RD, Hart RJ, Bone JN, Seiler M, et al
Adverse events among early caregivers' COVID-19 vaccination correlated inversely with intention to vaccinate their children.
Vaccine. 2025;55:127001.
PubMed Abstract available

VACHON A, Keeshan A, Galipeau Y, Crawley AM, et al
Alcohol consumption does not influence SARS-CoV-2 vaccine immunogenicity: A stop the spread Ottawa cohort analysis.
Vaccine. 2025;55:127034.
PubMed Abstract available

KAISER S, Kaiser S, Reis J, Marschalek R, et al
Quantification of objective concentrations of DNA impurities in mRNA vaccines.
Vaccine. 2025;55:127022.
PubMed Abstract available

HAMID S, Simeone RM, Newhams MM, Halasa N, et al
Concordance between parent-reported and documented COVID-19 vaccination status among hospitalized children and adolescents: Implications for vaccine effectiveness estimates, May 2021-October 2023.
Vaccine. 2025;54:126891.
PubMed Abstract available

SHINO MY, Ibarrondo FJ, Yang OO
SARS-CoV-2 spike antibody levels in lung transplantation recipients versus the spectrum in non-immunocompromised persons.
Vaccine. 2025;50:126851.
PubMed Abstract available

THORS V, Vias RD, Bjornsdottir K, Palsdottir EB, et al
Influenza vaccine effectiveness in Iceland 2014-2022: A test-negative design.
Vaccine. 2025;55:126981.
PubMed Abstract available

RASKIN N, Hiligsmann M, Luyten J, Tubeuf S, et al
Socio-demographic differences in citizen' preferences for distributing a scarce, lifesaving resource: A case study using COVID-19 vaccine distribution in Belgium.
Vaccine. 2025;55:126997.
PubMed Abstract available

CHOI J, Feelemyer J, Choe K, Lynch K, et al
Anti-vaccine attitudes and COVID-19 vaccine status at the end of the U.S. public health emergency.
Vaccine. 2025;55:127003.
PubMed Abstract available

HEGMANN TE, Walter EB, Smith MJ, Campbell J, et al
A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone(R) or Flublok(R)) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age.
Vaccine. 2025;54:126991.
PubMed Abstract available

PATTHAMMAVONG C, Wodniak N, Phounphenghack K, Tengbriacheu C, et al
Factors associated with influenza and COVID-19 vaccination among health workers in Lao PDR, 2023.
Vaccine. 2025;54:127006.
PubMed Abstract available

XU J, Davoudpour S, Phillips G 2nd
Applying the health belief model (HBM) to understand COVID-19 vaccine uptake among youth and young adults: Findings from a 6-month follow-up study in the United States.
Vaccine. 2025;54:127002.
PubMed Abstract available

RICCI L, Fery C, Tubach F, Agrinier N, et al
Health care institutions and their physicians are the greatest promoters of COVID-19 vaccine acceptance among health care workers.
Vaccine. 2025;54:127005.
PubMed Abstract available

MYBURGH L, Karsjens H, Blanas A, de Ligt A, et al
Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine.
Vaccine. 2025;54:126989.
PubMed Abstract available

SKOCZYNSKA A, Golebiewska A, Wrobel-Pawelczyk I, Ronkiewicz P, et al
The direct impact of mandatory PCV10 vaccination on invasive pneumococcal disease in Polish children.
Vaccine. 2025;54:126999.
PubMed Abstract available

VEDEL JO, Furtado O, Almeida LL, Nehal KR, et al
Childhood vaccination coverages in rural Guinea-Bissau before and during the early COVID-19 pandemic, a cohort study.
Vaccine. 2025;54:127011.
PubMed Abstract available

BOLU O, Alo OD, Iwara E, Longley AT, et al
Feasibility of cohort event monitoring and assessment of reactogenicity and adverse events among a cohort of AstraZeneca and Moderna COVID-19 vaccine recipients in Nigeria, 2021.
Vaccine. 2025;52:126907.
PubMed Abstract available

MEERAUS W, Postema A, Gray CM, Lee A, et al
Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.
Vaccine. 2025;53:126955.
PubMed Abstract available

DI CHIARA C, Karimi-Shahrbabak E, Peresin J, Farrar DS, et al
A review of Canadian online resources providing information on COVID-19 vaccination for caregivers of children aged 5-11 years.
Vaccine. 2025;54:126990.
PubMed Abstract available

KRAMMER F
Next-generation seasonal influenza virus vaccines need a neuraminidase component.
Vaccine. 2025;54:126994.
PubMed

OTIENO NA, Kalani R, Ayugi J, Nyawanda BO, et al
Seasonal influenza vaccination in Kenya: What determines healthcare Workers' willingness to accept and recommend vaccination?
Vaccine. 2025;54:126963.
PubMed Abstract available

DE SOUZA RA, Barreto FR, de Jesus Lima CCO, da Natividade MS, et al
Efficacy of BCG vaccination on incidence, severity and clinical progression of COVID-19: A BCG-REVAC population analysis.
Vaccine. 2025;54:126911.
PubMed Abstract available

JI C, Senthinathan A, Apajee J, Dubey V, et al
Impact of the COVID-19 pandemic on routine immunization coverage of children and teenagers in Ontario, Canada.
Vaccine. 2025;49:126811.
PubMed Abstract available

DESILVA MB, Vazquez-Benitez G, Seburg EM, Henderson MSG, et al
Pregnant persons perceptions and uptake of prenatal RSV vaccine - Minnesota, 2023-2024.
Vaccine. 2025;54:126958.
PubMed Abstract available

DOWGIER G, Hobbs A, Greenwood D, Shawe-Taylor M, et al
Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1 in the assessment of vaccination and therapeutics.
Vaccine. 2025;54:126960.
PubMed Abstract available

LEE DW, Nasir A, Elbashir S, Jani H, et al
mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice.
Vaccine. 2025;54:126961.
PubMed Abstract available

CARROLL M, Fox HB, Tran A, Chellappan G, et al
SARS-CoV-2 conjugate vaccine elicits robust immune responses that can protect against evolving variants.
Vaccine. 2025;54:126988.
PubMed Abstract available

MOORE M, Anderson L, Schiffer JT, Matrajt L, et al
Durability of COVID-19 vaccine and infection induced immunity: A systematic review and meta-regression analysis.
Vaccine. 2025;54:126966.
PubMed Abstract available

RAJA AI, Connor RI, Ashare A, Weiner JA, et al
Binding and neutralising antibodies to respiratory syncytial virus and influenza A virus in serum and bronchoalveolar lavage fluid of healthy adults in the United States: A cross-sectional study.
Vaccine. 2025;53:126936.
PubMed Abstract available

PEIXOTO DE MIRANDA EJF, Calado RT, Boulos FC, de Sousa Moreira JA, et al
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil.
Vaccine. 2025;52:126680.
PubMed Abstract available

CHU CF, Chang TH, Ho JJ
Comparative analysis of fourteen COVID-19 vaccine injury compensation systems and claim approval rates.
Vaccine. 2025;52:126830.
PubMed Abstract available

ZHAO T, Xu Q, Cai X, Wang M, et al
Global spatio-temporal distribution of coronavirus disease 2019 vaccine hesitancy between 2020 and 2022: A meta-analysis.
Vaccine. 2025;53:126933.
PubMed Abstract available

COTTER LM, Hopkins-Sheets M, Yang S, Passmore SR, et al
Increasing confidence for pediatric COVID-19 and influenza vaccines using messages affirming parental autonomy: A randomized online experiment.
Vaccine. 2025;53:126947.
PubMed Abstract available

TENGATTINI S, Bavaro T, Rinaldi F, Temporini C, et al
Novel tuberculosis vaccines based on TB10.4 and Ag85B: State-of-art and advocacy for good practices.
Vaccine. 2025;53:126932.
PubMed Abstract available

NIU Y, Yan Y, Hu Y, Yang X, et al
A novel tetravalent influenza vaccine based on one chimpanzee adenoviral vector.
Vaccine. 2025;53:126959.
PubMed Abstract available

KEELING MJ, Hill EM, Petrou S, Tran PB, et al
Cost-effectiveness of routine COVID-19 adult vaccination programmes in England.
Vaccine. 2025;53:126948.
PubMed Abstract available

February 2025

RIGAMONTI V, Torri V, Morris SK, Ieva F, et al
Real-world effectiveness of influenza vaccination in preventing influenza and influenza-like illness in children.
Vaccine. 2025;53:126946.
PubMed Abstract available

WANG B, Lassi Z, Andraweera P, Chen G, et al
Pregnant women's choices for preventing respiratory syncytial virus (RSV).
Vaccine. 2025;48:126790.
PubMed Abstract available

ADU P, Popoola T, Iqbal N, Roemer A, et al
A cross-country network analysis of disease infodemics: Looking through the lens of the COVID-19 pandemic.
Vaccine. 2025;48:126733.
PubMed Abstract available

SHEERAH HA, Al-Jedai AH, Al-Jerian NA, Al-Otaiby MA, et al
COVID-19 and influenza hospitalizations and the role of COVID-19 vaccination in the post-pandemic period: A cross-sectional study from Saudi Arabia.
Vaccine. 2025;52:126937.
PubMed Abstract available

MATHUR I, Ruisch A, Conlin M, Oyatoye I, et al
COVID-19 vaccination integration, innovations and key populations: Results from a global survey.
Vaccine. 2025;52:126863.
PubMed Abstract available

DIYA O, Gayed J, Lowry FS, Ma H, et al
A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults >/=18 years old.
Vaccine. 2025;52:126869.
PubMed Abstract available

LEBLANG D, Smith MD, Wesselbaum D
Global perspectives on COVID-19 vaccination: Impacts on well-being and inequality.
Vaccine. 2025;52:126906.
PubMed Abstract available

ANDERSEN KM, Allen KE, Nepal RM, Mateus JS, et al
Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states.
Vaccine. 2025;52:126881.
PubMed Abstract available

FARAH Z, Bazant ES, Basha I, Saleh N, et al
Determinants of seasonal influenza vaccination uptake, intention and recommendations among Lebanese physicians.
Vaccine. 2025;52:126890.
PubMed Abstract available

YE Q, Xiao Z, Bai C, Yao H, et al
Unveiling the multi-characteristic potential of hyper-productive suspension MDCK cells for advanced influenza A virus propagation.
Vaccine. 2025;52:126900.
PubMed Abstract available

DUDLEY MZ, Zapf AJ, Delamater P, Proveaux TM, et al
Attitudes of California school personnel on potential COVID-19 vaccine mandates and state law SB277 to remove nonmedical vaccine exemptions.
Vaccine. 2025;52:126888.
PubMed Abstract available

MACKENZIE LJ, Bousie JA, Newman P, Cunningham J, et al
What three years of COVID-19 vaccine administration reveals about the incidence of shoulder injury related to vaccine administration (SIRVA).
Vaccine. 2025;51:126892.
PubMed Abstract available

ATTI A, England A, Sung J, Foulkes S, et al
Estimating neutralising antibody responses against emerging SARS-CoV-2 variants utilising convalescent sera before the roll-out of XBB-lineage vaccines.
Vaccine. 2025;51:126898.
PubMed Abstract available

MEYERS E, De Rop L, Deschepper E, Duysburgh E, et al
SARS-CoV-2 seroreversion and all-cause mortality in nursing home residents and staff post-primary course vaccination in Belgium between February and December 2021.
Vaccine. 2025;51:126865.
PubMed Abstract available

BERGSTROM F, Gunther F, Britton T
A counterfactual analysis quantifying the COVID-19 vaccination impact in Sweden.
Vaccine. 2025;52:126870.
PubMed Abstract available

ZHAO T, Liu X, Huang X, Wang L, et al
Development and evaluation of mosaic VLPs vaccine for enhanced broad-Spectrum immunity against influenza B virus lineages in mice.
Vaccine. 2025;51:126882.
PubMed Abstract available

TAAFFE J, Goldin S, Lambach P, Sparrow E, et al
Global production capacity of seasonal and pandemic influenza vaccines in 2023.
Vaccine. 2025;51:126839.
PubMed Abstract available

HALL C, Lanning J, Romano CJ, Bukowinski AT, et al
COVID-19 vaccine initiation in pregnancy and risk for adverse neonatal outcomes among United States military service members, January-December 2021.
Vaccine. 2025;51:126894.
PubMed Abstract available

DARWAR R, Huang X, Abayeneh A, Alemayehu Beshah S, et al
Costing approaches for vaccine-preventable disease surveillance: Lessons from Ethiopia and Nepal.
Vaccine. 2025;50:126776.
PubMed Abstract available

APPEL AM, Janbek J, Laursen TM, Gasse C, et al
Dementia and influenza vaccination: Time trends and predictors of vaccine uptake among older adults.
Vaccine. 2025;51:126864.
PubMed Abstract available

KEMP M, Capriola A, Schauer S
RSV immunization uptake among infants and pregnant persons - Wisconsin, October 1, 2023-March 31, 2024.
Vaccine. 2025;47:126674.
PubMed Abstract available

CHANG C, Patel H, Ferrari A, Scalzo T, et al
sa-mRNA influenza vaccine raises a higher and more durable immune response than mRNA vaccine in preclinical models.
Vaccine. 2025;51:126883.
PubMed Abstract available

SMITH DS, Postma M, Fisman D, Mould-Quevedo J, et al
Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: A review of methods and data inputs.
Vaccine. 2025;51:126879.
PubMed Abstract available

VAN DIEMEN PM, Lean FZX, Ramsay A, Mollett BC, et al
Evaluation of a nanoparticle influenza vaccine in the pig model.
Vaccine. 2025;49:126844.
PubMed Abstract available

KIM SY, Song M, Kwon SL
Impact of caregiver vaccination status on child influenza vaccination hesitancy: A time-to-vaccination analysis for 2023-2024 season in the Republic of Korea.
Vaccine. 2025;49:126852.
PubMed Abstract available

ESSINK BJ, Vermeulen W, Andrade C, de Rooij R, et al
A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older.
Vaccine. 2025;51:126791.
PubMed Abstract available

WILLIAMS JTB, Johnson D, Weinshenker D, O'Leary ST, et al
Co-creation of pediatric influenza digital stories via rapid community translation.
Vaccine. 2025;51:126866.
PubMed Abstract available

COTUGNO N, Sanna M, Amodio D, Morrocchi E, et al
Pre-vaccination immune markers predict response to BNT162b2 mRNA vaccine in vulnerable groups - The CONVERS project, report from a pediatric tertiary hospital.
Vaccine. 2025;49:126778.
PubMed Abstract available

O'KENNEDY MM, Reedy SE, Abolnik C, Khan A, et al
Protective efficacy of a bivalent equine influenza H3N8 virus-like particle vaccine in horses.
Vaccine. 2025;50:126861.
PubMed Abstract available

CAPAO A, Araujo MF, Tort LFL, Toledo TS, et al
Impact in the humoral and cellular immune response to SARS-CoV-2 variants after primary vaccination with AZD1222/COVISHIELD protocol in healthy adults.
Vaccine. 2025;50:126785.
PubMed Abstract available

SHARMA A, Kerkhoff AD, Haambokoma M, Shamoya B, et al
Intention to receive new vaccines post-COVID-19 pandemic among adults and health workers in Lusaka, Zambia.
Vaccine. 2025;50:126846.
PubMed Abstract available

FAUSTINI SE, Backhouse C, Duggal NA, Toellner KM, et al
Time of day of vaccination does not influence antibody responses to pneumococcal and annual influenza vaccination in a cohort of healthy older adults.
Vaccine. 2025;49:126770.
PubMed Abstract available

FU Y, Xu Z, Wang Q, Zhang J, et al
Effectiveness and coverage of COVID-19 vaccination among the infection-naive population: A community-based retrospective cohort study in China.
Vaccine. 2025;50:126836.
PubMed Abstract available

ABBAD A, Yueh J, Yellin T, Singh G, et al
Co-administration of seasonal quadrivalent influenza and COVID-19 vaccines leads to enhanced immune responses to influenza virus and reduced immune responses to SARS-CoV-2 in naive mice.
Vaccine. 2025;50:126825.
PubMed Abstract available

SOENS M, Ananworanich J, Hicks B, Lucas KJ, et al
A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults.
Vaccine. 2025;50:126847.
PubMed Abstract available

VAHORA MS, Leao O, da Silveira MF, Domingues MR, et al
Impacts of vaccination, school attendance, and nutrition on SARS-CoV-2 antibody titer in a prospective birth cohort in Brazil.
Vaccine. 2025;49:126838.
PubMed Abstract available

MCCLYMONT E, Wong JMH, Forward L, Blitz S, et al
Acceptance and preference between respiratory syncytial virus vaccination during pregnancy and infant monoclonal antibody among pregnant and postpartum persons in Canada.
Vaccine. 2025;50:126818.
PubMed Abstract available

KANG HS, Kim SY, De Gagne JC, Chae SM, et al
Pregnant women's experiences of and attitudes toward COVID-19 vaccination: A qualitative descriptive study.
Vaccine. 2025;50:126835.
PubMed Abstract available

HONDA-OKUBO Y, Sajkov D, Wauchope B, Turner JV, et al
Immunogenicity and safety study of a single dose of SpikoGen(R) vaccine as a heterologous or homologous intramuscular booster following a primary course of mRNA, adenoviral vector or recombinant protein COVID-19 vaccine in ambulatory adults.
Vaccine. 2025;49:126744.
PubMed Abstract available

DOUA J, Ndembi N, Auerbach J, Kaseya J, et al
Advancing local manufacturing capacities for vaccines within Africa - Opportunities, priorities and challenges.
Vaccine. 2025;50:126829.
PubMed Abstract available

KAN AKC, Mak HWF, Chiang V, Yim JSH, et al
Leveraging COVID-19 vaccine allergy evaluations with coincident drug allergy delabelling: Effectiveness and impact on quality of life.
Vaccine. 2025;50:126849.
PubMed Abstract available

POWELL A, Jones A, Van Hout MC, Montgomery C, et al
Influenza vaccine uptake in socially deprived areas: A multilevel retrospective population-based cross-sectional study using electronic health records in Liverpool, United Kingdom.
Vaccine. 2025;50:126837.
PubMed Abstract available

GE Y, Handel A, Giabbanelli PJ, Lemacks J, et al
Exploring bias due to below-limit-of-detection values in influenza vaccine antibody modeling: A case study and instructional guide for the CIVIC study.
Vaccine. 2025;49:126802.
PubMed Abstract available

January 2025

MCGOLDRICK M, Truong TBQ, Campa C, Ali M, et al
How to accelerate the supply of vaccines to all populations worldwide? Part III: Reflections after the pandemic.
Vaccine. 2025;49:126782.
PubMed Abstract available

GSCHWEND MH, Marchese AM, Poelaert D, Warren B, et al
Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in immunocompromised patients: A targeted literature review.
Vaccine. 2025;49:126777.
PubMed Abstract available

GRAILEY K, Crespo RF, Woldmann L, Chisambi M, et al
Implementing behavioural science-informed letter interventions to increase COVID-19 vaccination uptake in London residents. A difference-in-difference study in London, United Kingdom.
Vaccine. 2025;49:126781.
PubMed Abstract available

YILMAZ IC, Ipekoglu EM, Golcuklu BS, Bildik T, et al
A phase I/II study of CpG/alum-adjuvanted mammalian-derived quadruple antigen carrying virus-like particle COVID-19 vaccine.
Vaccine. 2025;49:126787.
PubMed Abstract available

HASHIMOTO M, Tsujii K, Nakajima-Yoshida H, Akiyama N, et al
A-910823, a squalene-based emulsion adjuvant, enhances robust and broad immune responses of quadrivalent influenza vaccine in ferrets.
Vaccine. 2025;49:126780.
PubMed Abstract available

MWENDA JM, Mandomando I, Worwui AK, Gacic-Dobo M, et al
A decade of rotavirus vaccination in the World Health Organization African Region: An in-depth analysis of vaccine coverage from 2012 to 2023.
Vaccine. 2025 Jan 30:126768. doi: 10.1016/j.vaccine.2025.126768.
PubMed Abstract available

WIEGAND RE, Devine O, Wallace M, Ortega-Sanchez IR, et al
Estimating COVID-19 associated hospitalizations, ICU admissions, and in-hospital deaths averted in the United States by 2023-2024 COVID-19 vaccination: A conditional probability, causal inference, and multiplier-based approach.
Vaccine. 2025;49:126808.
PubMed Abstract available

KHAN A, Zhu Y, Babcock HM, Busse LW, et al
COVID-19 and influenza vaccine Hesitancy among adults hospitalized in the United States, 2019-2022.
Vaccine. 2025 Jan 29:126806. doi: 10.1016/j.vaccine.2025.126806.
PubMed Abstract available

ITO S, Tsuchida N, Kusunoki S, Kaneko Y, et al
Safety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe acute respiratory syndrome coronavirus 2 vaccination in Japan.
Vaccine. 2025;49:126754.
PubMed Abstract available

LAO G, Feng J, Wu L, Su W, et al
Development of a genetically modified full-length human respiratory syncytial virus preF protein vaccine.
Vaccine. 2025;49:126799.
PubMed Abstract available

ROPER LE, Link-Gelles R, Surie D, DeCuir J, et al
A framework for monitoring RSV prevention product effectiveness in the United States.
Vaccine. 2025;45:126633.
PubMed Abstract available

GEBRECHERKOS Y, Hodgson D
Cost-effectiveness of anti-viral treatment for infants with RSV disease in the United Kingdom.
Vaccine. 2025;45:126647.
PubMed Abstract available

MYEMBA DT, Smets L, Sunguya BF, Vandaele N, et al
Challenges and strategies for sustainable and resilient immunization systems in sub-Saharan Africa: A comprehensive scoping review.
Vaccine. 2025;45:126639.
PubMed Abstract available

EURICH DT, Weaver O, McDermott C, Soprovich A, et al
Describing COVID-19 immunizations for First Nations people on-reserve in Alberta using real-time integration of point of care and provincial data.
Vaccine. 2025;45:126614.
PubMed Abstract available

CONLIN K, Jenkin D, de Whalley P, Weckx LY, et al
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.
Vaccine. 2025;45:126582.
PubMed Abstract available

OKA E, Ueda Y, Yagi A, Machida M, et al
Challenges to promoting maternal respiratory syncytial virus vaccination in Japan.
Vaccine. 2025;48:126767.
PubMed Abstract available

PROSSER LA, Perroud J, Chung GS, Gebremariam A, et al
The cost-effectiveness of vaccination against COVID-19 illness during the initial year of vaccination.
Vaccine. 2025;48:126725.
PubMed Abstract available

LIAO Z, Deng L, Luo J, Shi M, et al
Association between adults' vaccine literacy and their intention to recommend older family members for influenza vaccine.
Vaccine. 2025;48:126757.
PubMed Abstract available

CLAESSENS T, Eagan RL, Hendrickx G, Van Damme P, et al
Navigating vaccine confidence: A mixed methods study investigating healthcare providers' perspectives across four non-EU European regions.
Vaccine. 2025;47:126694.
PubMed Abstract available

RAINERI D, Mazzucca CB, Moia R, Bruna R, et al
Impairment of the T cell memory response in chronic lymphocytic leukemia patients after SARS-CoV-2 vaccination.
Vaccine. 2025;48:126723.
PubMed Abstract available

TRANTER I, Judd D, Stickley M, Vasant B, et al
Promoting aged care COVID-19 and influenza vaccination through education of Australian residential aged care staff: A mixed methods project evaluation.
Vaccine. 2025;48:126742.
PubMed Abstract available

SHAH RM, Parzen-Johnson S, Sun S, Patel SJ, et al
Childhood opportunity index and vaccine uptake in pediatric COVID-19 hospitalizations.
Vaccine. 2025;48:126734.
PubMed Abstract available

DOS SANTOS CVB, Coelho LE, de Noronha TG, Goedert GT, et al
The impact of vaccination on the length of stay of hospitalized COVID-19 patients in Brazil.
Vaccine. 2025;48:126735.
PubMed Abstract available

DE OLIVEIRA PMN, Hartmann K, Bhamare C, Lucchesi MBB, et al
Active vaccine safety surveillance in low- and middle-income countries: Challenges for vaccine manufacturers from emerging countries.
Vaccine. 2025;48:126727.
PubMed Abstract available

ZHANG Y, Li X, Yang Y, Yin Y, et al
Impact of SARS-CoV-2 inactivated vaccine on symptoms following omicron variant breakthrough infection.
Vaccine. 2025;48:126722.
PubMed Abstract available

COROMINAS J, Garriga C, Prenafeta A, Moros A, et al
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.
Vaccine. 2025;47:126685.
PubMed Abstract available

MARCHESE AM, Beyhaghi H, Rousculp MD, Huang V, et al
Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST).
Vaccine. 2025;44:126569.
PubMed Abstract available

FILIMONOVIC J, Stosic M, Gazibara T, Dotlic J, et al
The trend in national childhood immunization program coverage throughout Serbian communities in Kosovo and Metohija from 2003 to 2022: pre-COVID-19 period vs. COVID-19 pandemic.
Vaccine. 2025;44:126576.
PubMed Abstract available

HARTEVELD LM, van Leeuwen LM, Euser SM, Smit LJ, et al
Respiratory syncytial virus (RSV) prevention: Perception and willingness of expectant parents in the Netherlands.
Vaccine. 2025;44:126541.
PubMed Abstract available

DE LIMA EDS, Antunes MOB, de Souza JS, Jones MH, et al
Effectiveness of BNT162b2 and CoronaVac against COVID-19-related severe outcomes among children and adolescents: A Brazilian nationwide cohort study.
Vaccine. 2025;44:126550.
PubMed Abstract available

FREY SE, Brady R, Jackson L, Goepfert P, et al
Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59(R).
Vaccine. 2025;47:126702.
PubMed Abstract available

HONDA-OKUBO Y, Vaghasiya U, Petrovsky N
Immunogenicity in mice and non-human primates of an Advax-CpG55.2-adjuvanted recombinant hemagglutinin seasonal quadrivalent influenza vaccine.
Vaccine. 2025;47:126707.
PubMed Abstract available

SHIELDS T, King KD, Cripps S, Edwards SA, et al
Perspectives on vaccination among unvaccinated members of a Canadian indigenous population.
Vaccine. 2025;47:126665.
PubMed Abstract available

CASPERSEN IH, Skodvin SN, Blix K, Robertson AH, et al
Post-COVID symptoms after SARS-CoV-2 omicron infection and the effect of booster vaccination: A population-based cohort study.
Vaccine. 2025;47:126664.
PubMed Abstract available

LE N, McMann TJ, Wenzel C, Li Z, et al
COVID-19 pediatric vaccine Hesitancy: Themes and interactions with verified twitter accounts.
Vaccine. 2025;47:126688.
PubMed Abstract available

EL SAHLY HM, Anderson EJ, Jackson LA, Neuzil KM, et al
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens.
Vaccine. 2025;47:126689.
PubMed Abstract available

DUAN Y, Suo L, Li X, Bai C, et al
Association between underlying conditions, multimorbidity, and COVID-19 vaccination status of adults aged >/=80 years old in Beijing, China.
Vaccine. 2025;47:126677.
PubMed Abstract available

ALVARADO-FACUNDO E, Herrup R, Wang W, Colombo RE, et al
Comparison of neuraminidase inhibiting antibody responses elicited by egg- and cell-derived influenza vaccines.
Vaccine. 2025;46:126669.
PubMed Abstract available

ANSELEM O, Charlier C, Viaud M, Lelong N, et al
Barriers to influenza vaccination during pregnancy in France: A national population-based study.
Vaccine. 2025;47:126671.
PubMed Abstract available

GIERSING B, Mo AX, Hwang A, Baqar S, et al
Meeting summary: Global vaccine and immunization research forum, 2023.
Vaccine. 2025;46:126686.
PubMed Abstract available

HAEBERER M, Lopez-Ibanez de Aldecoa A, Seabroke S, Ramirez Agudelo JL, et al
Economic burden of children hospitalized with respiratory syncytial virus infection in Spain, 2016-2019.
Vaccine. 2025;43.
PubMed Abstract available

DERMENCHYAN A, Choi KR, Bokhoor PR, Cho DJ, et al
Receipt of respiratory vaccines among patients with heart failure in a multicenter health system registry.
Vaccine. 2025;46:126682.
PubMed Abstract available

December 2024

PILAPITIYA D, Lee WS, Vu MN, Kelly A, et al
Mucosal vaccination against SARS-CoV-2 using recombinant influenza viruses delivering self-assembling nanoparticles.
Vaccine. 2024;46:126668.
PubMed Abstract available

CHOI YJ, Jung J, Kang M, Choi MJ, et al
Corrigendum to The risk of pregnancy-related adverse outcomes after COVID-19 vaccination: propensity score-matched analysis with influenza vaccination.
Vaccine. 2024;46:126676.
PubMed

NAZARENO AL, Wood JG, Muscatello DJ, Homaira N, et al
Estimating the cost-effectiveness of maternal respiratory syncytial virus (RSV) vaccination in Australia: A dynamic and economic modelling analysis.
Vaccine. 2024;46:126651.
PubMed Abstract available

MALTEZOU HC, Poland GA, de Lejarazu RO
Influenza vaccination for children in Europe: The health of every child matters.
Vaccine. 2024 Dec 27:126675. doi: 10.1016/j.vaccine.2024.126675.
PubMed

ZHANG J, Zhang L, Li J, Ma J, et al
Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season.
Vaccine. 2024;46:126662.
PubMed Abstract available

MA Y, Dong C, Kim JK, Zhu W, et al
Impact of influenza immune imprinting on immune responses to subsequent vaccinations in mice.
Vaccine. 2024;46:126670.
PubMed Abstract available

HAEBERER M, Lopez-Ibanez de Aldecoa A, Seabroke S, Ramirez Agudelo JL, et al
Hospitalization cost estimates of respiratory syncytial virus and influenza infections in adults in Spain, 2016-2019.
Vaccine. 2024;46:126683.
PubMed Abstract available

AI L, Gao Z, Lv H, Zhang J, et al
Immunogenicity and safety of live attenuated influenza vaccine in children aged 3-17 years in China.
Vaccine. 2024;46:126653.
PubMed Abstract available

GRIMES DR
Tortured confessions? Potentially erroneous statistical inferences may underpin misleading claims of harms in reanalyses of COVID-19 and HPV vaccines.
Vaccine. 2024 Dec 25:126657. doi: 10.1016/j.vaccine.2024.126657.
PubMed Abstract available

SAVULESCU C, Prats-Uribe A, Brolin K, Uuskula A, et al
Relative effectiveness of the second booster COVID-19 vaccines against laboratory confirmed SARS-CoV-2 infection in healthcare workers: VEBIS HCW VE cohort study (1 October 2022-2 May 2023).
Vaccine. 2024;45:126615.
PubMed Abstract available

SHELDENKAR A, Ling TP, Schulz PJ, Chen MI, et al
Trust in government vaccine recommendations during the Covid-19 pandemic in Singapore: A longitudinal survey study.
Vaccine. 2024;45:126643.
PubMed Abstract available

CAMPANELLA S, Volpe T, Safar Y, Lunsky Y, et al
"They need to speak a language everyone can understand": Accessibility of COVID-19 vaccine information for Canadian adults with intellectual and developmental disabilities.
Vaccine. 2024;45:126618.
PubMed Abstract available

WERTHNER Q, Faehrmann L, Och K, Bragazzi NL, et al
Client satisfaction, safety, and insights from a three-season survey on influenza vaccinations delivered at community pharmacies in Germany.
Vaccine. 2024;45:126650.
PubMed Abstract available

FRAIHA ALS, da Silva Santos BSA, Aguilar NR, Gallinari GC, et al
Immunization and challenge trials in a murine model using different inactivated recombinant vaccines against H1N1 swine influenza virus circulating in Brazil.
Vaccine. 2024;45:126638.
PubMed Abstract available

WANG J, Tonnies T, Brinks R
Seasonal influenza vaccination coverage and the social determinants of influenza vaccination among people over 50 with diabetes in Europe: Analyzing population-based SHARE data for the 2019-2020 and 2021-2022 influenza seasons.
Vaccine. 2024;45:126646.
PubMed Abstract available

YANG J, Yao YL, Lv XY, Geng LH, et al
The Safety and Efficacy of inactivated COVID-19 vaccination in couples undergoing assisted reproductive technology: A prospective cohort study.
Vaccine. 2024;45:126635.
PubMed Abstract available

SUN JW, Dodge LE, Kim EJ, Zhou L, et al
Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United States.
Vaccine. 2024;45:126629.
PubMed Abstract available

PERRIER Q, Noble J, Bonadona A, Augier C, et al
Timing of rejection events preceded by Covid-19 mRNA vaccination in recipients of solid organ transplants.
Vaccine. 2024;45:126617.
PubMed Abstract available

MOGHTADERI A, Callaghan T, Luo Q, Motta M, et al
Evidence on trends in uptake of childhood vaccines and association with COVID-19 vaccination rates.
Vaccine. 2024;45:126631.
PubMed Abstract available

WILLIAMS JTB, Ritger C, Holliman BD, Huebschmann AG, et al
Staff and caregivers' perceptions of digital storytelling to increase influenza vaccine confidence in an urban safety-net healthcare system.
Vaccine. 2024;45:126572.
PubMed Abstract available

KARACHALIOU M, Espinosa A, Farre X, Blay N, et al
Mental illness and antibody responses after COVID-19 vaccination in a prospective population-based study in Catalonia.
Vaccine. 2024;45:126591.
PubMed Abstract available

SLAMANIG S, Lemus N, Lai TY, Singh G, et al
A single immunization with intranasal Newcastle disease virus (NDV)-based XBB.1.5 variant vaccine reduces disease and transmission in animals against matched-variant challenge.
Vaccine. 2024;45:126586.
PubMed Abstract available

XIA M, Huang P, Vago FS, Jiang W, et al
Pseudovirus nanoparticles targeting the receptor binding HA1 domains of influenza viruses elicited high HA1-specific antibody responses and protected mice against mortality caused by influenza virus challenges.
Vaccine. 2024 Dec 7:126585. doi: 10.1016/j.vaccine.2024.126585.
PubMed Abstract available

BODY A, Lal L, Srihari S, MacIntyre CR, et al
Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer.
Vaccine. 2024 Dec 7:126547. doi: 10.1016/j.vaccine.2024.126547.
PubMed Abstract available

CUNNINGHAM-ERVES J, Sanderson M, Jin SW, Davis J, et al
Predictors of HPV vaccination coverage among adolescents in Tennessee during the COVID-19 pandemic: A cross-sectional study.
Vaccine. 2024 Dec 7:126581. doi: 10.1016/j.vaccine.2024.126581.
PubMed Abstract available

KAPLAN BS, Souza CK, Kimble JB, Brand MW, et al
A neuraminidase-based inactivated influenza virus vaccine significantly reduced virus replication and pathology following homologous challenge in swine.
Vaccine. 2024 Dec 6:126574. doi: 10.1016/j.vaccine.2024.126574.
PubMed Abstract available

SANKAR C, Meyer JC, Schonfeldt M, Gunter H, et al
Vaccine safety surveillance in South Africa through COVID-19: A journey to systems strengthening.
Vaccine. 2024 Dec 6:126535. doi: 10.1016/j.vaccine.2024.126535.
PubMed Abstract available

HODGSON D, Sanchez-Ovando S, Carolan L, Liu Y, et al
Quantifying the impact of pre-vaccination titre and vaccination history on influenza vaccine immunogenicity.
Vaccine. 2024 Dec 4:126579. doi: 10.1016/j.vaccine.2024.126579.
PubMed Abstract available

VYSE A, Wright H, Begier E
Estimating adult accident and emergency attendances in English hospitals attributed to respiratory syncytial virus.
Vaccine. 2024;42:126412.
PubMed Abstract available

AVERIN A, Sato R, Begier E, Gessner BD, et al
Annual public health and economic burden of medically attended respiratory syncytial virus illnesses among US adults.
Vaccine. 2024;42:126323.
PubMed Abstract available

FOTAKIS EA, Picasso E, Sacco C, Petrone D, et al
Impact of the 2023/24 autumn-winter COVID-19 seasonal booster campaign in preventing severe COVID-19 cases in Italy (October 2023-March 2024).
Vaccine. 2024;42:126375.
PubMed Abstract available

PRY JM, McCullough K, Lai KW, Lim E, et al
Defining long COVID using a population-based SARS-CoV-2 survey in California.
Vaccine. 2024;42:126358.
PubMed Abstract available

CHUN J, Yoon D, Nowakowska A, Lee HD, et al
Delivery of SARS-CoV-2 spike and membrane genes in a single Baculoviral vector enhance the immune breadth against SARS-CoV-2 variants of concern.
Vaccine. 2024;42:126355.
PubMed Abstract available

CANETTI M, Barda N, Lustig Y, Weiss-Ottolenghi Y, et al
Risk factors and correlates of protection against XBB SARS-CoV-2 infection among health care workers.
Vaccine. 2024;42:126308.
PubMed Abstract available

November 2024

GONG S, Beukema M, De Vries-Idema J, Huckriede A, et al
Assessing human B cell responses to influenza virus vaccines and adjuvants in a PBMC-derived in vitro culture system.
Vaccine. 2024;44:126563.
PubMed Abstract available

PICHE-RENAUD PP, Drover SSM, Austin PC, Morris SK, et al
COVID-19 vaccine effectiveness against severe omicron-related outcomes in children aged 5 to 11 years in Ontario: A Canadian immunization research network (CIRN) study.
Vaccine. 2024 Nov 30:126539. doi: 10.1016/j.vaccine.2024.126539.
PubMed Abstract available

COSMA C, Radi A, Cattano R, Zanobini P, et al
Exploring Chatbot contributions to enhancing vaccine literacy and uptake: A scoping review of the literature.
Vaccine. 2024;44:126559.
PubMed Abstract available

FLORES D, Luna EM
The effectiveness of vaccines against COVID-19 in Mexico: A time series approach.
Vaccine. 2024;44:126565.
PubMed Abstract available

THIEM VD, Anh DD, Ha VH, Van Thom N, et al
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial.
Vaccine. 2024;44:126542.
PubMed Abstract available

WANG Q, Yang L, Li L, Xiu S, et al
Investigating parental perceptions of respiratory syncytial virus (RSV) and attitudes to RSV vaccine in Jiangsu, China: Insights from a cross-section study.
Vaccine. 2024;44:126570.
PubMed Abstract available

GEMANDER N, Kemlin D, Depickere S, Kelkar NS, et al
COVID-19 vaccine responses are influenced by distinct risk factors in naive and SARS-CoV-2 experienced hemodialysis recipients.
Vaccine. 2024;44:126544.
PubMed Abstract available

BLUKACZ A, Obach A, Vasquez P, Campana C, et al
Determinants of COVID-19 and non-COVID-19 vaccine confidence in low- and middle-income countries: A systematic review of qualitative evidence and thematic synthesis.
Vaccine. 2024;44:126546.
PubMed Abstract available

AMODIO D, Angelidou A, Cotugno N, Sherman AC, et al
Biomarkers of vaccine safety and efficacy in vulnerable populations: Lessons from the fourth international precision vaccines conference.
Vaccine. 2024;43.
PubMed Abstract available

CHOI YJ, Jung J, Kang M, Choi MJ, et al
The risk of pregnancy-related adverse outcomes after COVID-19 vaccination: Propensity score-matched analysis with influenza vaccination.
Vaccine. 2024;44:126506.
PubMed Abstract available

DEAN NE, Halloran ME, Zarnitsyna VI
Poor vaccine responders mask the true trend in vaccine effectiveness against progression to severe disease.
Vaccine. 2024;43.
PubMed Abstract available

LEE M, Qin C, Lee Y, Deng J, et al
COVID-19 vaccine acceptance and 5C psychological antecedents amid the omicron surge in South Korea and China.
Vaccine. 2024;43.
PubMed Abstract available

DE OLIVEIRA LA, de Morais IRB, Marchioro SB, de Almeida GB, et al
Assessment of the BNT162B2 COVID-19 vaccine immune response in Brazilian indigenous adolescents.
Vaccine. 2024;43.
PubMed Abstract available

MEELDIJK A, Vandeberg L, Akkermans R, Hautvast J, et al
How text message reminders increase COVID-19 booster vaccine uptake: Two randomized controlled trials.
Vaccine. 2024;43.
PubMed Abstract available

MAO J, Kang HJ, Eom GD, Yoon KW, et al
Vaccine efficacy induced by 2020-2021 seasonal influenza-derived H3N1 virus-like particles co-expressing M2e5x or N2.
Vaccine. 2024;43.
PubMed Abstract available

VASQUEZ WF, Trudeau JM
Americans' willingness to give to global immunization programs: Political heterogeneity in preferences for program management and response to priming communications.
Vaccine. 2024;42:126126.
PubMed Abstract available

KIRK B, Bush C, Toyip A, Mues KE, et al
Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged >/= 65 years in the United States.
Vaccine. 2024;42:126113.
PubMed Abstract available

BONNIN FA, Talarico LB, Ferolla FM, Acosta PL, et al
Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infants.
Vaccine. 2024;42:126119.
PubMed Abstract available

LOCKMAN A, Callaghan T, Blackburn CC, Colwell B, et al
Vaccine spillover effects in Africa: A cross-national study of vaccine spillover and confidence in Kenya, Nigeria, and South Africa.
Vaccine. 2024;43.
PubMed Abstract available

JASTORFF A, Gymnopoulou E, Salas J, Merrall E, et al
Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial.
Vaccine. 2024;43.
PubMed Abstract available

REGAN AK, Couture MC, Callaghan T, Agnew B, et al
Modification and validation of a vaccine hesitancy scale for adolescent COVID-19 vaccination.
Vaccine. 2024;43.
PubMed Abstract available

LOPEZ-MACIAS C, Torres M, Armenta-Copca B, Wacher NH, et al
Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 "Patria" recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico.
Vaccine. 2024;43.
PubMed Abstract available

GWAK E, Choe SA, Bolormaa E, Choe YJ, et al
Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations in South Korea.
Vaccine. 2024;43.
PubMed Abstract available

MATTES F, Dratva J, Schmelzer S, Wagner A, et al
The association between service experience in vaccination centers and expectation confirmation as a driver of future vaccination intentions: Results from a survey among users of a Swiss mass COVID-19 vaccination center.
Vaccine. 2024;43.
PubMed Abstract available

AGUIRRE-CAMACHO A, Hidalgo B, Rash JA
Exposure to objective/sensationalist information moderates associations between psychological factors and COVID-19 anti-vaccination attitudes: An experimental study.
Vaccine. 2024;43.
PubMed Abstract available

LEWIS NM, Harker EJ, Leis A, Zhu Y, et al
Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses - IVY Network, September 1, 2022-March 30, 2023.
Vaccine. 2024;43.
PubMed Abstract available

WILLIAMS E, Echeverri Tribin F, Carreno JM, Krammer F, et al
Proteomic signatures of vaccine-induced and breakthrough infection-induced host responses to SARS-CoV-2.
Vaccine. 2024;43.
PubMed Abstract available

DENG Y, Hayes KN, Zhao Y, Chachlani P, et al
Variation in the time to complete the primary COVID-19 vaccine series by race, ethnicity, and geography among older US adults.
Vaccine. 2024;43.
PubMed Abstract available

STEFFENS MS, Bolsewicz KT, King C, Bullivant B, et al
Australian parents' experiences with adolescent age-based vaccinations during the COVID-19 pandemic.
Vaccine. 2024;43.
PubMed Abstract available

LE MARCHAND C, Singson JRC, Clark A, Shah D, et al
Multisystem inflammatory syndrome in children (MIS-C) cases by vaccination status in California.
Vaccine. 2024;43.
PubMed Abstract available

DELARUELLE K, Lermytte E, Bockstal M, Vuolanto P, et al
Unraveling COVID-19 vaccine hesitancy in Europeans 50 and older through a lens of preventive practices.
Vaccine. 2024;43.
PubMed Abstract available

KIM SA, Maeda M, Murata F, Fukuda H, et al
Effect of COVID-19 vaccination on the risk of developing post-COVID conditions: The VENUS study.
Vaccine. 2024;43.
PubMed Abstract available

CHARLAND K, Quach C, Papenburg J, Pierce L, et al
Parental decisions regarding the vaccination of children and adolescents against SARS-CoV-2 from 2020 to 2023: A descriptive longitudinal study of parents and children in Montreal, Canada.
Vaccine. 2024;43.
PubMed Abstract available

October 2024

KASAMATSU A, Yahata Y, Fukushima W, Sakamoto H, et al
Estimating influenza vaccine effectiveness among older adults using an integrated administrative database and the implications of potential bias: A population-based cohort study in Japan.
Vaccine. 2024;42:126488.
PubMed Abstract available

SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Akache B, et al
SARS-CoV-2 spike-based virus-like particles incorporate influenza H1/N1 antigens and induce dual immunity in mice.
Vaccine. 2024;42:126463.
PubMed Abstract available

HOFSTETTER AM, Klein EJ, Strelitz B, Selvarangan R, et al
On-time childhood vaccination before and during the COVID-19 pandemic in seven communities: Findings from the New Vaccine Surveillance Network.
Vaccine. 2024;42:126455.
PubMed Abstract available

MACINTYRE CR, Akhtar Z, Moa A
Corrigendum to "Influenza B/Yamagata - extinct, eradicated or hiding? [Vaccine 42/26 (2024) 126450]".
Vaccine. 2024 Oct 29:126486. doi: 10.1016/j.vaccine.2024.126486.
PubMed

LEIS AM, Wagner A, Flannery B, Chung JR, et al
Evaluation of test-negative design estimates of influenza vaccine effectiveness in the context of multiple, co-circulating, vaccine preventable respiratory viruses.
Vaccine. 2024;42:126493.
PubMed Abstract available

WHITE TM, Lazarus JV, Rabin KH, Ratzan SC, et al
Emerging global patterns of COVID-19 vaccine information fatigue in 23 countries in 2023.
Vaccine. 2024;42:126475.
PubMed Abstract available

EBERHARDT J, Al-Qerem W, Ling J
Comparing COVID-19 booster vaccine acceptance in the United Kingdom, Germany, Austria, and Jordan: The role of protection motivation theory, conspiracy beliefs, social media use and religiosity.
Vaccine. 2024;42:126474.
PubMed Abstract available

MCGREGOR R, Paterson A, Lavender B, Hooker C, et al
The SARS-CoV-2 neutralising antibody profile of New Zealand adults in 2023: Impact of vaccination and infection.
Vaccine. 2024;42:126482.
PubMed Abstract available

LENTAKIS E, Seale H, Lazarus R, Mounier-Jack S, et al
Exploring the delivery of adult vaccination outside of primary care settings: A mixed methods scoping review.
Vaccine. 2024;42:126458.
PubMed Abstract available

HO TC, Chuang SC, Hung KC, Chang CC, et al
Exploring risk factors for Raynaud's phenomenon post COVID-19 vaccination.
Vaccine. 2024;42:126470.
PubMed Abstract available

LENTAKIS E, Seale H, Lazarus R, Mounier-Jack S, et al
Exploring the attitudes and practices of adult service users and providers towards vaccination in non-primary care settings: A mixed methods scoping review.
Vaccine. 2024;42:126472.
PubMed Abstract available

MOHD HISHAM AA, Mat Yassim AS, Suppian R, Azlan M, et al
Comparable and sustained levels of S1-RBD-IgG and S1-RBD-IgA in BNT162b2 homologous and CoronaVac-BNT162b2 heterologous booster vaccination: A 22-month prospective study in Malaysia.
Vaccine. 2024;42:126471.
PubMed Abstract available

JORDAN E, Jenkins V, Silbernagl G, Chavez MPV, et al
A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study.
Vaccine. 2024;42:126427.
PubMed Abstract available

TUFFY KM, Ahani B, Domachowske JB, Furuno K, et al
Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY).
Vaccine. 2024;42:126276.
PubMed Abstract available

ROWE M, Collier AY, Barouch DH
Insights from an observational translational research program during the COVID-19 pandemic: Four years of experience.
Vaccine. 2024;42:126306.
PubMed Abstract available

PHAM-HUY A, Bowes J, Russell K, Amira A, et al
Short- and long-term outcomes of cardiac adverse events following COVID-19 immunization managed in a Canadian pediatric center.
Vaccine. 2024;42:126090.
PubMed Abstract available

SINTAYEHU K, Shaum A, Bonger ZT, Dagnachew Zeleke E, et al
Applicability of selected Brighton Collaboration case definitions in low-resource settings: A prospective hospital-based active surveillance in Addis Ababa, Ethiopia.
Vaccine. 2024;42:126079.
PubMed Abstract available

GOLDIN S, Moen A, Moss WJ, Nuzzo J, et al
The 2020 immunization programme landscape: Piloting an assessment metric to evaluate the maturity of national immunization programmes across the life course.
Vaccine. 2024;42 Suppl 4:125541.
PubMed Abstract available

NG AJJ, Teo DCH, Dorajoo SR, Yap AJY, et al
Acute autoimmune hepatitis following COVID-19 mRNA vaccination: A population-based study using electronic health records in Singapore.
Vaccine. 2024;42:126462.
PubMed Abstract available

DARKO DM, Seaneke SK, Karikari-Boateng E, Nkansah E, et al
Safety of mRNA COVID-19 vaccines among persons 15- years and above in Ghana: A cohort event monitoring study.
Vaccine. 2024;42:126460.
PubMed Abstract available

AB RAHMAN N, King TL, Peariasamy KM, Sivasampu S, et al
Risk of major adverse cerebro-cardiovascular events following BNT162b2, CoronaVac, and ChAdOx1 vaccination and SARS-CoV-2 infection: A self-controlled case-series study.
Vaccine. 2024;42:126465.
PubMed Abstract available

SHARFF KA, Tandy TK, Lewis PF, Johnson ES, et al
Incidence of ischemic stroke after COVID-19 bivalent booster vaccination in an integrated health system.
Vaccine. 2024;42:126440.
PubMed Abstract available

WICKLINE MM, Carpenter PA, Harris JR, Iribarren SJ, et al
Vaccine hesitancy and routine revaccination among adult HCT survivors in the United States: A convergent mixed methods analysis.
Vaccine. 2024;42:126374.
PubMed Abstract available

HARRACHE A, Saker K, Mokdad B, Generenaz L, et al
Anti-RBD IgG dynamics following infection or vaccination.
Vaccine. 2024;42:126464.
PubMed Abstract available

MACINTYRE CR, Akhtar Z, Moa A
Influenza B/Yamagata cannot currently be declared extinct.
Vaccine. 2024 Oct 18:126450. doi: 10.1016/j.vaccine.2024.126450.
PubMed

MA SH, Chen TL, Ou WF, Chao WC, et al
The risk of postherpetic neuralgia in COVID-19 vaccination-associated herpes zoster: A retrospective cohort study using TriNetX.
Vaccine. 2024;42:126451.
PubMed Abstract available

EVIATAR T, Ziv A, Oved A, Miller-Barmak A, et al
Longitudinal safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in children aged 4-11 years with juvenile-onset autoimmune inflammatory rheumatic diseases: A prospective multicenter study.
Vaccine. 2024;42:126426.
PubMed Abstract available

NAZARENO AL, Newall AT, Muscatello DJ, Hogan AB, et al
Modelling the epidemiological impact of maternal respiratory syncytial virus (RSV) vaccination in Australia.
Vaccine. 2024;42:126418.
PubMed Abstract available

SANO K, Kurosawa T, Horikawa K, Kimura Y, et al
Cellular and humoral immunity and IgG subclass distribution after omicron XBB.1.5 monovalent vaccination in Japan.
Vaccine. 2024;42:126452.
PubMed Abstract available

NUZHATH T, Colwell B, Callaghan T, Hotez P, et al
Pediatric COVID-19 vaccine hesitancy among pregnant and post-partum women: A mixed-method study.
Vaccine. 2024;42:126420.
PubMed Abstract available

EIDEN AL, Drakeley S, Modi K, Mackie D, et al
Attitudes and beliefs of healthcare providers toward vaccination in the United States: A cross-sectional online survey.
Vaccine. 2024;42:126437.
PubMed Abstract available

COCKERILL R, Horney JA, Penta SC, Silver A, et al
Factors associated with COVID-19 vaccination or intent to be vaccinated across three U.S. states.
Vaccine. 2024;42:126457.
PubMed Abstract available

TOP KA, Shulha HP, Muller MP, Valiquette L, et al
Participant-reported neurological events following immunization in the Canadian National Vaccine Safety Network-COVID-19 vaccine (CANVAS-COVID) study.
Vaccine. 2024;42:126445.
PubMed Abstract available

HSIEH HC, Chen CC, Liu WC, Wu SC, et al
Intranasal booster with SARS-CoV-2 RBD protein fused to E. coli enterotoxin a subunit after primary mRNA vaccination in mice.
Vaccine. 2024;42:126448.
PubMed Abstract available

SEDAGHAT M, Karami B, Najafi F, Shadmani FK, et al
Gender differences in adverse effects following the second dose of AstraZeneca COVID-19 vaccine: a cross-sectional study among healthcare workers.
Vaccine. 2024;42:126424.
PubMed Abstract available

LITAO L, Feng C, Hongyu Z, Wenbin C, et al
Field production efficiency investigation of broilers immunized with a turkey herpesvirus vector vaccine expressing hemagglutinin from H9N2 subtype avian influenza virus.
Vaccine. 2024;42:126436.
PubMed Abstract available

DOYON-PLOURDE P, Farley R, Krishnan R, Tunis M, et al
Direct quantitative comparison of benefits and risks of COVID-19 vaccines used in National Immunization Technical Advisory Groups Guidance during the first two years of the pandemic.
Vaccine. 2024;42:126406.
PubMed Abstract available

TAAFFE J, Ostrowsky JT, Mott J, Goldin S, et al
Advancing influenza vaccines: A review of next-generation candidates and their potential for global health impact.
Vaccine. 2024;42:126408.
PubMed Abstract available

MWAMBA G, Gibson EM, Toko C, Tunda C, et al
Effective integration of COVID-19 vaccination with routine immunization: A case study from Kinshasa, DRC.
Vaccine. 2024 Oct 4:126392. doi: 10.1016/j.vaccine.2024.126392.
PubMed Abstract available

PASCOE KM, Bishop S, Ci X, Ramirez M, et al
Factors that shape COVID-19 pediatric vaccine decision-making in rural agricultural communities: A qualitative study.
Vaccine. 2024;42:126389.
PubMed Abstract available

HOJO-SOUZA NS, de Castro JT, Rivelli GG, Azevedo PO, et al
SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concern.
Vaccine. 2024;42:126394.
PubMed Abstract available

ALANSARI KDH, Buhl C, Thabit AK, Badr AF, et al
Validation of the Arabic translation of the vaccination attitudes examination (VAX) scale.
Vaccine. 2024;42:126411.
PubMed Abstract available

EARP M, Meng L, Black CL, Carter RJ, et al
Using regression tree analysis to examine demographic and geographic characteristics of COVID-19 vaccination trends over time, United States, May 2021-April 2022, National Immunization Survey Adult COVID Module.
Vaccine. 2024;42:126372.
PubMed Abstract available

REN J, Gao Q, Zhou X, Chen L, et al
Identification of gene and protein signatures associated with long-term effects of COVID-19 on the immune system after patient recovery by analyzing single-cell multi-omics data using a machine learning approach.
Vaccine. 2024;42:126253.
PubMed Abstract available

RAMIREZ MA, Loaiza RA, Martinez-Balboa Y, Bruneau N, et al
Co-administration of recombinant BCG and SARS-CoV-2 proteins leads to robust antiviral immunity.
Vaccine. 2024;42:126203.
PubMed Abstract available

GALLANT AJ, Steenbeek A, Halperin SA, Parsons Leigh J, et al
Operationalizing the Behaviour Change Wheel and APEASE criteria to co-develop recommendations with stakeholders to address barriers to school-based immunization programs.
Vaccine. 2024;42:126226.
PubMed Abstract available

MENG Q, Wang B, Du Q, Zhang X, et al
Seroprevalence of B. pertussis infection and the changes of specific antibody levels in health care workers during the first two years of COVID-19 in Wuhu, China.
Vaccine. 2024;42:126239.
PubMed Abstract available

GUINAZU G, Dvorkin J, Mahmud S, Baral R, et al
Evaluation of the potential impact and cost-effectiveness of respiratory syncytial virus (RSV) prevention strategies for infants in Argentina.
Vaccine. 2024;42:126234.
PubMed Abstract available

LANGER S, Holzapfel S, August L, Badura A, et al
Parental knowledge and attitudes to infant immunization in the context of RSV: All about confidence?
Vaccine. 2024;42:126050.
PubMed Abstract available

CHOI YJ, Song JY, Wie SH, Choi WS, et al
Real-world effectiveness of influenza vaccine over a decade during the 2011-2021 seasons-Implications of vaccine mismatch.
Vaccine. 2024;42:126381.
PubMed Abstract available

PATRICK-SMITH M, Emary K, Hodgson SH, Thomas TM, et al
Roles and responsibilities of participants, researchers, and the media in the communication of vaccine trials: Experience from the United Kingdom's first COVID-19 vaccine trial.
Vaccine. 2024;42:126391.
PubMed Abstract available

September 2024

LYU X, Liu X, Hong H
Validation of the Chinese version of the vaccine conspiracy beliefs scale during COVID-19 pandemic and its correlates.
Vaccine. 2024;42:126395.
PubMed Abstract available

SOTOODEH A, Hedberg P, Granath F, Alfven T, et al
Sociodemographic determinants of COVID-19 vaccination in adolescents in Stockholm, Sweden.
Vaccine. 2024;42:126388.
PubMed Abstract available

ENGLAND A, Sung J, Deulofeu M, Soler LF, et al
Variant-specific neutralising antibodies levels induced by the PHH-1 V SARS-CoV-2 vaccine (Bimervax(R)) by HIPRA.
Vaccine. 2024;42:126386.
PubMed Abstract available

LAZARUS R, Harris R, Thirard R, Baos S, et al
Comparison of assays used to detect antibody response in COVID-19 vaccine trials: Results from of a UK multi-Centre randomised controlled trial to determine the immunogenicity responses of COVID-19 vaccines administered concomitantly with seasonal inf
Vaccine. 2024;42:126369.
PubMed Abstract available

AL-DAHIR S, Hassan TAL, Moss W, Khalil A, et al
The impact of coronavirus pandemic shutdowns on immunization completion in Hadeetha, Anbar, Iraq: A case-study of vaccine completion in a recovering healthcare system.
Vaccine. 2024 Sep 21:126383. doi: 10.1016/j.vaccine.2024.126383.
PubMed Abstract available

BERNADIN O, Cochin M, Driouich JS, Laprie C, et al
Preclinical evaluation in hamster model of the mRNA COVID-19 vaccine candidate AfriVac 2121 (Wuhan) produced under the WHO/MPP mRNA Technology Transfer Programme.
Vaccine. 2024;42:126378.
PubMed Abstract available

LAEMMLE-RUFF I, Fryk JJ, Shenton P, Clothier HJ, et al
Detailed review of mortality reported following COVID-19 vaccination in Victoria, Australia: 2021-2023.
Vaccine. 2024;42:126368.
PubMed Abstract available

GOLDIN S, Brooks D, Jorgensen P, Wijesinghe P, et al
Seasonal influenza vaccination: A global review of national policies in 194 WHO member states in 2022.
Vaccine. 2024;42:126274.
PubMed Abstract available

IMRAN M, Mills C, McDermott KW, Dean A, et al
Relative effectiveness of adjuvanted versus non-adjuvanted influenza vaccines in older adults with risk factors for influenza complications during the 2019-2020 U.S. influenza season.
Vaccine. 2024;42:126316.
PubMed Abstract available

WEE LE, Malek MIBA, Tan J, Chiew C, et al
Risk of death and cardiovascular events following COVID-19 vaccination or positive SARS-CoV-2 test amongst adult Singaporeans during omicron transmission.
Vaccine. 2024;42:126356.
PubMed Abstract available

ROELS S, Bruckner M, Sadoff J, Cardenas V, et al
Pre- and post-Ad26.COV2.S booster dose antibody levels predict COVID-19 disease risk.
Vaccine. 2024;42:126159.
PubMed Abstract available

ESTRELLA-PORTER P, Blanco-Calvo C, Lameiras-Azevedo AS, Juaneda J, et al
Effectiveness of nirsevimab introduction against respiratory syncytial virus in the Valencian Community: A preliminary assessment.
Vaccine. 2024;42:126030.
PubMed Abstract available

REICHERZ F, Li S, Watts AA, Goldfarb DM, et al
Bordetella pertussis infection following relaxation of COVID-19 non-pharmaceutical interventions in 2021-2023 in Vancouver metropolitan area, British Columbia, Canada.
Vaccine. 2024;42:126004.
PubMed Abstract available

SHEN AK, Gutu V, Druc A, Ebama M, et al
An evaluation of the National Influenza Vaccination Program in the Republic of Moldova, 2023-2024.
Vaccine. 2024;42:126322.
PubMed Abstract available

MEANEY-DELMAN D, Carroll S, Polen K, Jatlaoui TC, et al
Planning for the future of maternal immunization: Building on lessons learned from the COVID-19 pandemic.
Vaccine. 2024;42 Suppl 3.
PubMed Abstract available

JONES-JACK N, El Kalach R, Yassanye D, Link-Gelles R, et al
Advancing public health informatics during the COVID-19 pandemic: Lessons learned from a public-private partnership with pharmacies.
Vaccine. 2024;42 Suppl 3:125667.
PubMed Abstract available

HEINS MJ, Spreeuwenberg P, Caini S, Hooiveld M, et al
Measuring the impact of influenza vaccination in the Netherlands using retrospective observational primary care, hospitalisation and mortality data.
Vaccine. 2024;42:126244.
PubMed Abstract available

KRAUSE KD, D'Avanzo PA, Karr AG, Rhem C, et al
Vaccination uptake in LGBTQ adults in two US states: Findings from the QVax study.
Vaccine. 2024;42:126320.
PubMed Abstract available

SHIU EYC, Cheng SMS, Martin-Sanchez M, Au NYM, et al
Durability for 12 months of antibody response to a booster dose of monovalent BNT162b2 in adults who had initially received 2 doses of inactivated vaccine.
Vaccine. 2024;42:126317.
PubMed Abstract available

VAN HEESBEEN R, Bastian AR, Omoruyi E, Rosen J, et al
Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study.
Vaccine. 2024;42:126273.
PubMed Abstract available

BAFFOUR AWUAH G, Tanaka LF, Eberl M, Donnachie E, et al
Analysis of health claims data on vaccination coverage in older adults in Bavaria, Germany: Influenza, pneumococcus and herpes zoster.
Vaccine. 2024;42:126354.
PubMed Abstract available

CHANG JY, Chang M, Huang S, Bosco J, et al
COVID-19 vaccine uptake in a predominantly minoritized cohort hospitalized during the early pandemic in New York City.
Vaccine. 2024;42:126260.
PubMed Abstract available

GAUDOUEN H, Tattevin P, Thibault V, Menard G, et al
Determinants of influenza and COVID vaccine uptake in healthcare workers: A cross-sectional survey during the post-pandemic era in a network of academic hospitals in France.
Vaccine. 2024;42:126272.
PubMed Abstract available

REGAN AK, Sullivan SG, Arah OA
Maternal influenza vaccination and associated risk of fetal loss: A claims-based prospective cohort study.
Vaccine. 2024;42:126256.
PubMed Abstract available

BLASCO A, Royuela A, Garcia-Gomez S, Gomez-Lozano N, et al
Association of SARS-CoV-2 immunoserology and vaccination status with myocardial infarction severity and outcome.
Vaccine. 2024;42:126305.
PubMed Abstract available

WOO EJ, Miller ER, Stroud E
Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse Event Reporting System (2003-2024).
Vaccine. 2024;42:126290.
PubMed Abstract available

HOXIE I, Vasilev K, Clark JJ, Bushfield K, et al
A recombinant N2 neuraminidase-based CpG 1018(R) adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters.
Vaccine. 2024;42:126269.
PubMed Abstract available

GROOM HC, Biel FM, Crane B, Sun E, et al
Disparities in COVID-19 vaccination receipt by race, ethnicity, and social determinants of health among a large patient population in a network of community-based healthcare centers.
Vaccine. 2024;42:126288.
PubMed Abstract available

HUTTON DW, Prosser LA, Rose AM, Mercon K, et al
Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus.
Vaccine. 2024;42:126294.
PubMed Abstract available

POH XY, Torres-Ruesta A, Yoong T, Wong N, et al
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial.
Vaccine. 2024;42:126275.
PubMed Abstract available

KIM C, Dunphy C, Duggar C, Pike J, et al
Jurisdiction-level costs of the initial phase of the COVID-19 vaccination program in the United States, December 20, 2020-May 31, 2021.
Vaccine. 2024;42:126287.
PubMed Abstract available

BONNER C, Taba M, Fajardo MA, Batcup C, et al
Using health literacy principles to improve understanding of evolving evidence in health emergencies: Optimisation and evaluation of a COVID-19 vaccination risk-benefit calculator.
Vaccine. 2024;42:126296.
PubMed Abstract available

LIU S, van Dijk LLA, den Hartog Y, Hoek R, et al
mRNA-based COVID-19 vaccination of lung transplant recipients with prior SARS-CoV-2 infection induces durable SARS-CoV-2-specific antibodies and T cells.
Vaccine. 2024;42:126250.
PubMed Abstract available

BOTTON J, Bertrand M, Jabagi MJ, Duranteau L, et al
Risk of heavy menstrual bleeding following COVID-19 vaccination: A nationwide case-control study.
Vaccine. 2024;42:126252.
PubMed Abstract available

COLEMAN BL, Gutmanis I, Bondy SJ, Harrison R, et al
Canadian health care providers' and education workers' hesitance to receive original and bivalent COVID-19 vaccines.
Vaccine. 2024;42:126271.
PubMed Abstract available

August 2024

MACKAY H, Gretton JD, Chyderiotis S, Elliott S, et al
Confidence and barriers: Analysis of factors associated with timely routine childhood vaccination in Canada during the COVID-19 pandemic.
Vaccine. 2024;42:126236.
PubMed Abstract available

GUARNIERI V, Macucci C, Mollo A, Trapani S, et al
Impact of respiratory syncytial virus on older children: Exploring the potential for preventive strategies beyond the age of 2 years.
Vaccine. 2024;42:126170.
PubMed Abstract available

AIZAWA Y, Sato I, Abe Y, Sasagawa F, et al
Impact of the emergence of severe acute respiratory syndrome coronavirus 2 omicron variants on routine childhood immunization in Japan.
Vaccine. 2024;42:126137.
PubMed Abstract available

MAI W, Shen J, Ma F, Zhu J, et al
Specific humoral immune response and XBB variants re-infection risk of hemodialysis patients after Omicron BA.5 infection in China.
Vaccine. 2024;42:126108.
PubMed Abstract available

EYAWO O, Ugoji UC, Pan S, Oyibo P, et al
Predictors of the willingness to accept a free COVID-19 vaccine among households in Nigeria.
Vaccine. 2024;42:126225.
PubMed Abstract available

BRESEE JS, Lafond KE
The partnership for international vaccine initiatives: The importance and opportunity to develop influenza vaccination programs in low- and middle-income countries.
Vaccine. 2024 Aug 29:126255. doi: 10.1016/j.vaccine.2024.126255.
PubMed

HARADA Y, Takahashi H, Fujimoto T, Horikoshi F, et al
Evaluation of a qualified MDCK cell line for virus isolation to develop cell-based influenza vaccine viruses with appropriate antigenicity.
Vaccine. 2024;42:126242.
PubMed Abstract available

LLABRE MM, Timpano KR, Broos HC, Leite RO, et al
Lessons from a longitudinal community-based investigation of adherence to guidelines and intent to vaccinate during the COVID-19 pandemic.
Vaccine. 2024;42:126265.
PubMed Abstract available

PATHER S, Charpentier N, van den Ouweland F, Rizzi R, et al
A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine.
Vaccine. 2024;42:126165.
PubMed Abstract available

FERREIRA-SILVA SN, Soares MEM, Vasconcelos R, Barbieri C, et al
COVID-19 vaccine hesitancy: Meaning relations between responses in an epidemiological study and twitter messages.
Vaccine. 2024;42:126247.
PubMed Abstract available

SINGH D, Damasevicius R, Kumar V, Bagnoli F, et al
Editorial: ML-driven vaccine against COVID-19: Developmental challenges and foresight.
Vaccine. 2024;42:126267.
PubMed

VIELOT NA, Kelly NK, Ludema C, Rosenberg M, et al
Patterns and predictors of COVID-19 vaccination among young adults at 44 US sites: Secondary analysis of a randomized, controlled, open-label trial, March - December 2021.
Vaccine. 2024;42:126237.
PubMed Abstract available

UNAGAMI K, Yoshikawa M, Egawa H, Ohfuji S, et al
Delayed peak antibody titers after the second dose of SARS-CoV-2 vaccine in solid organ transplant recipients: Prospective cohort study.
Vaccine. 2024;42:126221.
PubMed Abstract available

SHINJOH M, Yaginuma M, Yamaguchi Y, Tamura K, et al
Effectiveness of inactivated influenza vaccine in children during the 2023/24 season: The first season after relaxation of intensive COVID-19 measures.
Vaccine. 2024;42:126241.
PubMed Abstract available

ADAMS L, Prasinou AK, Hadley L, Ramsay M, et al
Estimating the potential number of cases prevented by infant/ toddler immunisation with a MenACWY vaccine.
Vaccine. 2024;42:126240.
PubMed Abstract available

OGAR CK, Gilbert HN, Bloem LT, Leopold C, et al
Patient-reported outcomes of adverse events after COVID-19 vaccination in Nigeria: A mixed methods study.
Vaccine. 2024;42:126196.
PubMed Abstract available

ESPOSITO GL, Fassio F, Girardi D, Picasso E, et al
"REAl LIfe" observational study on the effectiveness of Evusheld prophylaxis against SARS-CoV-2 omicron variants in vaccine non-responder immunocompromised patients (REALISE).
Vaccine. 2024;42:126208.
PubMed Abstract available

SANFTENBERG L, Bader F, Rottenkolber M, Sebastiao M, et al
Associations of mental health with vaccination readiness in informal caregivers and the vaccination status of their care recipients during the Covid-19 pandemic - A cross sectional analysis.
Vaccine. 2024;42:126218.
PubMed Abstract available

HERNANDEZ-BERNAL F, Noa-Romero E, Quintana-Guerra J, Chavez-Chong CO, et al
Efficacy and safety of Abdala COVID-19 subunit vaccine in children and adolescents: An open-label, single-arm, phase 2 trial (MENIQUE).
Vaccine. 2024;42:126223.
PubMed Abstract available

IHENETU G, Aylin P, Novov V, Skirrow H, et al
Uptake of COVID-19 vaccines and association with hospitalisation due to COVID-19 in pregnancy: Retrospective cohort study.
Vaccine. 2024 Aug 13:126214. doi: 10.1016/j.vaccine.2024.126214.
PubMed Abstract available

WALDEN J, Stanek JR, Young J, Griffith MM, et al
Influenza vaccine uptake among youth with sickle cell disease who are seen in clinic before and after the COVID-19 pandemic.
Vaccine. 2024;42:126212.
PubMed Abstract available

GRAF DD, Westphal L, Hallgreen CE
The life cycle of vaccines evaluated by the European Medicines Agency.
Vaccine. 2024;42:126186.
PubMed Abstract available

GOMEZ-ACEBO I, Barquin-Ruiz A, Llorente S, Alonso-Molero J, et al
The impact of the COVID-19 pandemic on childhood vaccination rates and the role of sociodemographic factors: A cohort study.
Vaccine. 2024;42:126207.
PubMed Abstract available

BAJPAI D, Bose S, Saxena N, Kulkarni B, et al
Antibody response to non-mRNA SARS-CoV-2 vaccine in kidney transplant recipients.
Vaccine. 2024 Aug 8:126206. doi: 10.1016/j.vaccine.2024.126206.
PubMed Abstract available

GAO Y, Yang X, Li X, Chen H, et al
Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion inactivated influenza vaccine in healthy population aged 9-59 years: A randomized, double-blind, controlled, phase IV clinical trial.
Vaccine. 2024;42:126182.
PubMed Abstract available

D'SOUZA S, Ghatole B, Raghuram H, Sukhija S, et al
Understanding structural inequities in Covid-19 vaccine access and uptake among disability, transgender and gender-diverse communities in India.
Vaccine. 2024 Aug 7:126174. doi: 10.1016/j.vaccine.2024.126174.
PubMed Abstract available

GEORGE G, Strauss M, Lansdell E, Nota P, et al
Factors associated with COVID-19 vaccine uptake among south African health care workers.
Vaccine. 2024;42:126181.
PubMed Abstract available

BRONSTEIN MV, Kummerfeld E, MacDonald A 3rd, Vinogradov S, et al
Identifying psychological predictors of SARS-CoV-2 vaccination: A machine learning study.
Vaccine. 2024;42:126198.
PubMed Abstract available

BOKEL J, Martins-Goncalves R, Grinsztejn E, Mendes-de-Almeida DP, et al
Anti-PF4 positivity and platelet activation after Ad26.COV2.S vaccination in Brazil.
Vaccine. 2024 Aug 5:126175. doi: 10.1016/j.vaccine.2024.126175.
PubMed Abstract available

MCCARRON M, Marcenac P, Yau TS, Lafond KE, et al
Healthcare personnel acceptance and recommendations for influenza vaccine in twelve low- and middle-income countries: A pooled analysis from 2018 to 2020.
Vaccine. 2024 Aug 2:125670. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

AUGELLO M, Wagenhauser I, Krone M, Dauby N, et al
Should SARS-CoV-2 serological testing be used in the decision to deliver a COVID-19 vaccine booster? A pro-con assessment.
Vaccine. 2024 Aug 2:126184. doi: 10.1016/j.vaccine.2024.126184.
PubMed Abstract available

JIANG M, Zhang H, Yao X, Wang Y, et al
Immunization-related stress and stress-related responses of mucosal versus intramuscular COVID-19 vaccination among adults in China.
Vaccine. 2024 Aug 1:126150. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WOOLFORK MN, Haire K, Farinu O, Ruffin J, et al
A health equity science approach to assessing drivers of COVID-19 vaccination coverage disparities over the course of the COVID-19 pandemic, United States, December 2020-December 2022.
Vaccine. 2024 Aug 1:126158. doi: 10.1016/j.vaccine.2024.126158.
PubMed Abstract available

July 2024

MATSUMOTO N, Sasaki A, Kadowaki T, Mitsuhashi T, et al
Kinetics of SARS-CoV-2 antibody titers after booster vaccinations during an Omicron surge in Japan.
Vaccine. 2024;42:126156.
PubMed Abstract available

ASUPOTO O, Li X, Hemberg JL, Emerson A, et al
COVID-19 and influenza vaccine uptake in women with criminal-legal system involvement.
Vaccine. 2024 Jul 30:126176. doi: 10.1016/j.vaccine.2024.126176.
PubMed Abstract available

GE Y, Lu Y, Allen JD, Einav T, et al
Pre-existing immunity to influenza aids ferrets in developing stronger and broader H3 vaccine-induced antibody responses.
Vaccine. 2024 Jul 29:126149. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ELYASS J, Desalegn A, Trinh NTH, Orangzeb S, et al
Individual and familial factors associated with mRNA COVID-19 vaccine uptake in pregnancy: A large-scale registry-based linkage study.
Vaccine. 2024 Jul 29:126171. doi: 10.1016/j.vaccine.2024.126171.
PubMed Abstract available

TAHSIN A, Bhattacharjee P, Al Saba A, Yasmin T, et al
Genetic and epigenetic analyses of IFN-gamma gene proximal promoter region underlying positive correlation between persistently high anti-SARS-CoV-2 IgG and IFN-gamma among COVID-19 vaccinated Bangladeshi adults.
Vaccine. 2024 Jul 29:126157. doi: 10.1016/j.vaccine.2024.126157.
PubMed Abstract available

GEBRETEKLE GB, Yeung MW, Ximenes R, Cernat A, et al
Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants.
Vaccine. 2024 Jul 29:126164. doi: 10.1016/j.vaccine.2024.126164.
PubMed Abstract available

MOTAGHI S, Pullenayegum E, Morgan RL, Loeb M, et al
The role of influenza Hemagglutination-Inhibition antibody as a vaccine mediator in children.
Vaccine. 2024 Jul 28:126122. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SULEMAN A, Vicente P
COVID-19 vaccination reluctance across Europe: Lessons for the future.
Vaccine. 2024 Jul 27:126168. doi: 10.1016/j.vaccine.2024.126168.
PubMed Abstract available

KHANAFER N, Oudot S, Maligeay M, Planckaert C, et al
A quick access to information on influenza burden and prevention in Lyon university hospital: A prospective QR code-based information campaign in 2022-2023.
Vaccine. 2024 Jul 26:126160. doi: 10.1016/j.vaccine.2024.126160.
PubMed Abstract available

JENA D, Ghosh A, Jha A, Prasad P, et al
Impact of vaccination on SARS-CoV-2 evolution and immune escape variants.
Vaccine. 2024 Jul 26:126153. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WILLIAMS LR, Emary KRW, Phillips DJ, Hay J, et al
Implementation and adherence to regular asymptomatic testing in a COVID-19 vaccine trial.
Vaccine. 2024 Jul 26:126167. doi: 10.1016/j.vaccine.2024.126167.
PubMed Abstract available

BILGIN GM, Munira SL, Lokuge K, Glass K, et al
Mathematical modelling of the 100-day target for vaccine availability after the detection of a novel pathogen: A case study in Indonesia.
Vaccine. 2024 Jul 26:126163. doi: 10.1016/j.vaccine.2024.126163.
PubMed Abstract available

ATAULLAHJAN A, Piche-Renaud PP, Shahrbabak EK, Fadaleh SA, et al
Weighing the risks and benefits: Parental perspectives on COVID-19 vaccines for 5- to 11-year-old children.
Vaccine. 2024 Jul 26:126154. doi: 10.1016/j.vaccine.2024.126154.
PubMed Abstract available

JIMENEZ-SEPULVEDA N, Gras-Valenti P, Chico-Sanchez P, Castro-Garcia JM, et al
Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain.
Vaccine. 2024;42:4011-4021.
PubMed Abstract available

WAGENHAUSER I, Almanzar G, Forg FB, Stein A, et al
Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of basic immunity show similar immunogenicity regarding long-term spike-specific cellular immunity in healthcare workers.
Vaccine. 2024 Jul 20:126132. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ZOU GQ, Li K, Yan C, Li YQ, et al
Aluminum hydroxide and immunostimulatory glycolipid adjuvant combination for enhanced COVID-19 subunit vaccine immunogenicity.
Vaccine. 2024 Jul 20:126145. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SANADA T, Honda T, Kohara M
Modeling of anti-spike IgG and neutralizing antibody waning after anti-SARS-CoV-2 mRNA vaccination.
Vaccine. 2024 Jul 19:126146. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ANDERSON S, Kuter BJ, Brien K, Bauerle Bass S, et al
Perceptions of vaccine requirements among students at four Pennsylvania universities.
Vaccine. 2024 Jul 17:S0264-410X(24)00801-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

JIN CHOI S, Lee W, Cheol Kim S, Jo HY, et al
Longitudinal multiomic profiling and corticosteroid modulation of the immediate innate immune response to an adenovirus-vector vaccine.
Vaccine. 2024 Jul 17:S0264-410X(24)00774-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SANTIBANEZ TA, Black CL, Zhou T, Srivastav A, et al
Parental hesitancy about COVID-19, influenza, HPV, and other childhood vaccines.
Vaccine. 2024 Jul 16:S0264-410X(24)00802-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LIU G, Pang Y, Lv M, Lu M, et al
Effectiveness of influenza vaccination on hospitalization outcomes among older patients with diabetes.
Vaccine. 2024 Jul 16:S0264-410X(24)00806-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ERIKSSON M, Nylen S, Gronvik KO
Passive immunization of mice with IgY anti-H5N1 protects against experimental influenza virus infection and allows development of protective immunity.
Vaccine. 2024 Jul 16:S0264-410X(24)00796-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

STEENACKERS K, Hanning N, Bruckers L, Desombere I, et al
Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine schedules in healthy adults: The IMCOVAS randomized clinical trial.
Vaccine. 2024 Jul 16:S0264-410X(24)00773-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LUNA-MUSCHI A, Carmo Borges I, Dos Santos Barboza A, de Faria E, et al
Duration of vaccine protection against breakthrough infections during five COVID-19 waves among healthcare workers primarily vaccinated with CoronaVac.
Vaccine. 2024 Jul 16:S0264-410X(24)00752-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

TAKAHASHI Y, Tanaka H, Taniguchi C, Ogata T, et al
Efficiency of indirect protection of COVID-19 vaccination and interactions between indirect and direct protection on household transmission.
Vaccine. 2024 Jul 16:S0264-410X(24)00749-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HATFIELD K, Wiegand R, Reddy S, Patel A, et al
Effectiveness of COVID-19 bivalent vaccination against SARS-CoV-2 infection among residents of US nursing homes, November 2022 - March 2023.
Vaccine. 2024 Jul 16:S0264-410X(24)00754-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

STEFANIZZI P, Di Lorenzo A, Capodiferro L, Moscara L, et al
Increasing vaccination coverage among healthcare workers: Active call and mandatory laws. Data from a large general hospital in Southern Italy.
Vaccine. 2024 Jul 15:S0264-410X(24)00739-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

FISMAN DN, Simmons AE, Tuite AR
Case-cohort design as an efficient approach to evaluating COVID-19 vaccine effectiveness, waning, heterologous immune effect and optimal dosing interval.
Vaccine. 2024 Jul 13:S0264-410X(24)00797-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

JAJOU R, Lieber T, van Puijenbroek EP, Mulder E, et al
GP consultations for menstrual disorders after COVID-19 vaccination - A self-controlled cohort study based on routine healthcare data from the Netherlands.
Vaccine. 2024 Jul 13:S0264-410X(24)00793-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LE BAGOUSSE-BERNARD A, Dussart C, Pin P, Tazarourte K, et al
Mass COVID-19 vaccination center: Optimizing the vaccination pathway during a 12 month timeframe.
Vaccine. 2024 Jul 12:S0264-410X(24)00742-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HUANG WT, Law B, Tran H, Schonborn L, et al
Validation of the newly proposed Brighton Collaboration case definition for vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine. 2024 Jul 12:S0264-410X(24)00794-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LI J, Gong L, Li J, Gong Z, et al
Low neutralization of SARS-CoV-2 Omicron BA.5.2.48 and XBB.1 sub-variants in response to breakthrough infection by booster.
Vaccine. 2024;42:3751-3755.
PubMed Abstract available

HOEVE CE, Huiberts AJ, de Gier B, Andeweg SP, et al
COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study.
Vaccine. 2024 Jul 11:S0264-410X(24)00783-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GARCIA S, Shin M, Gill M, He Z, et al
Identifying the intersection of parental HPV and COVID-19 vaccine hesitancy to inform health messaging interventions in community-based settings.
Vaccine. 2024 Jul 11:S0264-410X(24)00792-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SARTORI AL, Buffarini R, Machado da Silva A, Amaral de Andrade Leao O, et al
Child COVID-19 vaccine uptake among participants of the 2015 Pelotas (Brazil) Birth Cohort Study.
Vaccine. 2024 Jul 11:S0264-410X(24)00746-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KOUASSI KS, Chisupa E, Clarke A, Massenon I, et al
Pandemic-related resilience in HPV vaccination programmes - Perspectives from selected countries in Africa on what it will take to vaccinate 90 % of girls by 2030.
Vaccine. 2024;42 Suppl 2:S33-S36.
PubMed Abstract available

BANG JY, Kim YJ, Seo YJ, Hong SH, et al
Reduced cell-mediated immune response in hyperglycemic NOD mice following influenza vaccination.
Vaccine. 2024 Jul 8:S0264-410X(24)00757-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

JITENDER, Vikram Kumar B, Singh S, Verma G, et al
Mammalian cell expressed recombinant trimeric spike protein is a potent vaccine antigen and confers near-complete protection against SARS-CoV-2 infection in Hamster.
Vaccine. 2024 Jul 8:S0264-410X(24)00740-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KORCHINSKI I, Marquez C, McClymont E, Av-Gay G, et al
Maternal-infant transfer of SARS-CoV-2 antibodies following vaccination in pregnancy: A prospective cohort study.
Vaccine. 2024 Jul 8:S0264-410X(24)00785-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WACHINGER J, Renosa MDC, Endoma V, Landicho-Guevarra J, et al
Routines, disruptions, revised decisions: A biographical analysis of vaccination trajectories among Filipino caregivers.
Vaccine. 2024 Jul 6:S0264-410X(24)00736-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ARAUJO-CHAVERON L, Olivier C, Pellissier G, Bouvet E, et al
Analyzing the 7C psychological antecedents of vaccine acceptance throughout the COVID-19 pandemic among healthcare sector workers in France: A repeated cross-sectional study (CappVac-Cov).
Vaccine. 2024 Jul 6:S0264-410X(24)00744-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

NOWALK MP, Smith KJ, Raviotta JM, Wateska A, et al
Cost-effectiveness of recombinant influenza vaccine compared with standard dose influenza vaccine in adults 18-64 years of age.
Vaccine. 2024 Jul 5:S0264-410X(24)00748-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KAFADAR AH, Sabatini S, Jones KA, Dening T, et al
Categorising interventions to enhance vaccine uptake or reduce vaccine hesitancy in the United Kingdom: A systematic review and meta-analysis.
Vaccine. 2024 Jul 2:S0264-410X(24)00733-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HOULE SKD, Waite NM, Vernon-Wilson E, Dolovich L, et al
Uptake and outcomes of VaxCheck, an adult life-course vaccination service: A study among community pharmacists.
Vaccine. 2024 Jul 1:S0264-410X(24)00737-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

June 2024

PLEY C, Kampmann B
Opportunities and challenges to the development and deployment of vaccines for pregnant women in Germany.
Vaccine. 2024 Jun 28:S0264-410X(24)00735-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ROOZEN GVT, Granger A, van Binnendijk RS, den Hartog G, et al
Intradermal fractional dose vaccination as a method to vaccinate individuals with suspected allergy to mRNA COVID-19 vaccines.
Vaccine. 2024 Jun 28:S0264-410X(24)00734-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BHELLA S, Wilkin AM, Hueniken K, Vijenthira A, et al
COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies.
Vaccine. 2024 Jun 28:S0264-410X(24)00715-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KELLY JA, Walsh JL, Quinn K, Amirkhanian YA, et al
Factors predicting primary and booster COVID-19 vaccination in a community sample of African American men and women in the United States Midwest.
Vaccine. 2024 Jun 27:S0264-410X(24)00729-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

COULIBALY D, Douba A, N'Guessan K, N'Gattia AK, et al
Intent to receive flu vaccine and influenza vaccination coverage among health professionals during 2019, 2020 and 2021 campaigns in Cote d'Ivoire.
Vaccine. 2024 Jun 25:S0264-410X(24)00717-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

YOO YM, Katz MA, Greenberg D, Marcenac P, et al
Knowledge, attitudes, and practices associated with influenza vaccine uptake among healthcare personnel in Israel during three influenza seasons, 2016-2019.
Vaccine. 2024 Jun 25:S0264-410X(24)00705-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CHATZILENA A, Hyams C, Challen R, Marlow R, et al
Winter 2022-23 influenza vaccine effectiveness against influenza-related hospitalised aLRTD: A test-negative, case-control study.
Vaccine. 2024 Jun 24:S0264-410X(24)00713-8. doi: 10.1016/j.vaccine.2024.
PubMed

LE GARS M, Sadoff J, Cardenas V, Heerwegh D, et al
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial.
Vaccine. 2024 Jun 24:S0264-410X(24)00401-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HELARY A, Botelho-Nevers E, Bonneton M, Khennouf L, et al
Factors, motivations and barriers associated with eagerness to volunteer in COVID-19 vaccine clinical trials in France: A mixed-method study.
Vaccine. 2024 Jun 22:S0264-410X(24)00662-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

FITZPATRICK T, Yamoah P, Lacuesta G, Sadarangani M, et al
Revaccination outcomes among adolescents and adults with suspected hypersensitivity reactions following COVID-19 vaccination: A Canadian immunization research network study.
Vaccine. 2024 Jun 22:S0264-410X(24)00719-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

RIMAL RN, Ganjoo R, Jamison A, Parida M, et al
Social norms, vaccine confidence, and interpersonal communication as predictors of vaccination intentions: Findings from slum areas in Varanasi, India.
Vaccine. 2024 Jun 21:S0264-410X(24)00666-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MCDERMID P, Abdi I, Mustafa K, Blazek K, et al
Examining the influence of community leaders and other community actors on immunisation practices in Australia: A national cross-sectional study.
Vaccine. 2024;42:3647-3654.
PubMed Abstract available

ZHANG X, Monnat SM
Watchful, skeptics, and system distrusters: Characteristics associated with different types of COVID-19 vaccine hesitancy among U.S. working-age adults.
Vaccine. 2024 Jun 19:S0264-410X(24)00721-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CHENG TM, Chen YS, Wei KC, Chang YC, et al
Assessment of the herpes zoster risk among renal transplant recipients administered the influenza vaccine.
Vaccine. 2024 Jun 18:S0264-410X(24)00716-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

YAZDAN PANAH M, Vaheb S, Mokary Y, Afshari-Safavi A, et al
Comparing the consequences of COVID-19 vaccination between central nervous system (CNS) demyelinating diseases and other neurological disorders.
Vaccine. 2024 Jun 16:S0264-410X(24)00702-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DESLAURIERS F, Hoq M, Kaufman J, Enticott J, et al
Comparison of parent-reported motivators of non-vaccination for children 5-11 years old in Australia and Canada: Results of the iCARE study.
Vaccine. 2024 Jun 15:S0264-410X(24)00698-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

JIANG X, Wang J, Li C, Yeoh EK, et al
Relationship between parental acceptance of the COVID-19 vaccine and attitudes towards measles vaccination for children: A cross-sectional study.
Vaccine. 2024 Jun 15:S0264-410X(24)00708-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

TING DK, Rosychuk RJ, Hau JP, Righolt CH, et al
Leveraging a clinical emergency department dataset to estimate two-dose COVID-19 vaccine effectiveness and duration of protection in Canada.
Vaccine. 2024 Jun 14:S0264-410X(24)00699-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DAVEY SA, Hampson C, Christodoulaki ME, Gaffiero D, et al
Investigating the predictors of COVID-19 vaccine decision-making among parents of children aged 5-11 in the UK.
Vaccine. 2024 Jun 13:S0264-410X(24)00646-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

QUIROGA R, Gastellu S, Fernandez B, Ottaviani R, et al
The impact of COVID-19 childhood and adolescent vaccination on mortality in Argentina.
Vaccine. 2024 Jun 12:S0264-410X(24)00665-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CARDENAS V, Le Gars M, Truyers C, Ruiz-Guinazu J, et al
Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.
Vaccine. 2024;42:3536-3546.
PubMed Abstract available

SHERMAN AC, van Haren SD, Borberg E, Swank Z, et al
Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series.
Vaccine. 2024 Jun 10:S0264-410X(24)00695-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MANANDHAR P, Katz J, Lama TP, Khatry SK, et al
COVID-19 vaccine hesitancy, trust, and communication in Sarlahi District, Nepal.
Vaccine. 2024 Jun 10:S0264-410X(24)00661-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

OTSUKI T, Akada S, Anami A, Kosaka K, et al
Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial.
Vaccine. 2024 Jun 8:S0264-410X(24)00668-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BADLIS S, Yu H, Klusaritz H, S L Tan A, et al
Engaging Trusted Messengers to Increase COVID-19 Pediatric Vaccine Uptake in Philadelphia: Lessons from the VaxUpPhillyFamilies program.
Vaccine. 2024 Jun 8:S0264-410X(24)00664-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BRADY K, Lee A, Bassler J, Young Pierce J, et al
Human papillomavirus vaccine beliefs and intentions Post-COVID-19 vaccine release among mothers in Alabama.
Vaccine. 2024 Jun 8:S0264-410X(24)00673-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SRITIPSUKHO P, Sinlapamongkolkul P, Satdhabudha A, Chaiyakulsil C, et al
Immunogenicity during 6 months after SARS-CoV-2 infection is significantly different depending on previous COVID-19 vaccine regimens and a booster dose received.
Vaccine. 2024 Jun 7:S0264-410X(24)00652-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

VILLENA R, Izquierdo G, Wilhelm J, Garcia C, et al
Dynamics of multisystem inflammatory syndrome in children associated to COVID-19 in Chile: Epidemiologic trends during pandemic, before and after children vaccination.
Vaccine. 2024 Jun 7:S0264-410X(24)00640-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

JAYAWARDANA S, Esquivel M, Oreskovic T, Mossialos E, et al
Gender differences in COVID-19 preventative measures and vaccination rates in the United States: A longitudinal survey analysis.
Vaccine. 2024 Jun 7:S0264-410X(24)00671-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

R MUGALI R, Ip H, Zikusooka A, Vong L, et al
Striving for equitable vaccination coverage: Leveraging rapid coverage and community assessments during the COVID-19 pandemic to reach missed populations in Cambodia.
Vaccine. 2024 Jun 7:S0264-410X(24)00642-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

YOUNES S, Nicolai E, Younes N, Pieri M, et al
Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting.
Vaccine. 2024 Jun 5:S0264-410X(24)00669-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GOBIN S, Sahakyan G, Kusi Appiah M, Manukyan A, et al
Costs of in- and outpatient respiratory disease and the seasonal influenza vaccination program in Armenia - 2020-2021.
Vaccine. 2024 Jun 4:S0264-410X(24)00623-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LANIECE DELAUNAY C, Melo A, Maurel M, Mazagatos C, et al
Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.
Vaccine. 2024 Jun 4:S0264-410X(24)00644-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KAWASUJI H, Morinaga Y, Tani H, Yamada H, et al
Low pre-infection levels of neutralizing antibody in breakthrough infections after bivalent BA.4-5 vaccine and practical application of dried blood spots.
Vaccine. 2024 Jun 4:S0264-410X(24)00656-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

FENG J, Du Y, Chen L, Su W, et al
A quadrivalent recombinant influenza Hemagglutinin vaccine induced strong protective immune responses in animal models.
Vaccine. 2024 Jun 3:S0264-410X(24)00624-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

FABIANI M, Mateo-Urdiales A, Sacco C, Fotakis EA, et al
Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged >/=60 years: Estimates over calendar time and by time since administration during prevalent circulation of different O
Vaccine. 2024 Jun 3:S0264-410X(24)00653-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BEJKO D, Ernst C, Vergison A, Stranges S, et al
High vaccine effectiveness against severe COVID-19 outcomes and population preventable fraction during the Omicron era in Luxembourg: A nationwide retrospective risk factor analysis.
Vaccine. 2024 Jun 1:S0264-410X(24)00636-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

May 2024

KUPEK E
Avoidable COVID-19-related deaths and hospitalizations in Brazil, 2020-2023.
Vaccine. 2024;42:3437-3444.
PubMed Abstract available

EDOKA I, Silal S, Jamieson L, Meyer-Rath G, et al
A cost-effectiveness analysis of South Africa's COVID-19 vaccination programme.
Vaccine. 2024 May 31:S0264-410X(24)00595-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

VASHIST K, Yankey D, Elam-Evans LD, Mu Y, et al
Changes in vaccine hesitancy among parents of children aged 6 months - 17 Years, National Immunization Surveys, 2019-2022.
Vaccine. 2024 May 27:S0264-410X(24)00596-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BEGUM T, Efstathiou N, Bailey C, Guo P, et al
Cultural and social attitudes towards COVID-19 vaccination and factors associated with vaccine acceptance in adults across the globe: A systematic review.
Vaccine. 2024 May 27:S0264-410X(24)00600-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LUSTIG Y, Barda N, Weiss-Ottolenghi Y, Indenbaum V, et al
Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines.
Vaccine. 2024 May 27:S0264-410X(24)00635-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

TREHARNE A, Patel Murthy B, Zell ER, Jones-Jack N, et al
Impact of the COVID-19 pandemic on routine childhood vaccination in 9 U.S. jurisdictions.
Vaccine. 2024 May 25:S0264-410X(24)00603-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MARANTOS T, Kyriazopoulou E, Angelakis E, Kitsos D, et al
Immunogenicity of a seasonal influenza and a pneumococcal polysaccharide vaccine in multiple sclerosis patients under disease modifying therapies: A single-center prospective study.
Vaccine. 2024 May 24:S0264-410X(24)00617-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BAK J, Hasan Q, Kissa J, Mere MO, et al
Deployment of COVID-19 vaccine in the WHO Eastern Mediterranean Region 2021-23: How do we switch to a life course approach?
Vaccine. 2024 May 24:S0264-410X(24)00560-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LYNETTE EJEZIE C, Cuccaro P, Savas LS, Shegog R, et al
Regional differences in provider recommendation of HPV vaccines among 13-to-17 year old adolescents from 2019 to 2021.
Vaccine. 2024 May 24:S0264-410X(24)00581-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BENEDICT KPOZEHOUEN E, Raina Macintyre C, Tan TC
Coverage of influenza, pneumococcal and zoster vaccination and determinants of influenza and pneumococcal vaccination among adults with cardiovascular diseases in community.
Vaccine. 2024 May 23:S0264-410X(24)00619-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

EIBERG MF, Rezahosseini O, Bukan KB, Charlotte Arp B, et al
Changes in vaccination uptake against pneumococcal disease, influenza, and coronavirus disease 2019 (COVID-19) before and after a Head and Neck cancer diagnosis.
Vaccine. 2024 May 23:S0264-410X(24)00566-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

TSAMPALIEROS A, Zemek R, Barrowman N, Langlois MA, et al
Hybrid immunity after BNT162b2 Covid-19 vaccine administration in children aged 5 to 11 years.
Vaccine. 2024 May 23:S0264-410X(24)00588-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CARNALLA M, Stern D, Arantxa Colchero M, Rangel-Moreno K, et al
Who is getting COVID-19 boosters? A latent class analysis in a nationally representative sample of Mexican adults 60 years and over.
Vaccine. 2024;42:3273-3276.
PubMed Abstract available

RAMOS-DUARTE VA, Orlowski A, Jaquenod de Giusti C, Corigliano MG, et al
Safe plant Hsp90 adjuvants elicit an effective immune response against SARS-CoV2-derived RBD antigen.
Vaccine. 2024;42:3355-3364.
PubMed Abstract available

ZHANG WX, Zhang Y, Du J, Shi W, et al
Effectiveness of momentary intervention on influenza vaccination among the elderly in China: From willingness to action.
Vaccine. 2024 May 22:S0264-410X(24)00591-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

PROSPER P, Rodriguez Puertas R, Guerin DMA, Branda MM, et al
Computational method for designing vaccines applied to virus-like particles (VLPs) as epitope carriers.
Vaccine. 2024 May 22:S0264-410X(24)00584-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ZHOU H, Zhao W, Ma R, Zheng Y, et al
Mixed methods examination of risk perception on vaccination intentions: The perspective of doctor-patient communication.
Vaccine. 2024 May 22:S0264-410X(24)00565-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

VAN DER PLAS JL, Haijema BJ, Leenhouts K, Paul Zoeteweij J, et al
Safety, reactogenicity and immunogenicity of an intranasal seasonal influenza vaccine adjuvanted with gram-positive matrix (GEM) particles (FluGEM): A randomized, double-blind, controlled, ascending dose study in healthy adults and elderly.
Vaccine. 2024 May 20:S0264-410X(24)00370-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KARIMI-SHAHRBABAK E, Di Chiara C, Farrar DS, Abu Fadaleh SM, et al
COVID-19 vaccine acceptance and uptake among caregivers of children aged 5-11?years in Ontario, Canada: A cross-sectional survey.
Vaccine. 2024 May 20:S0264-410X(24)00553-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MACHIDA M, Fukushima S, Saitoh A, Inoue S, et al
Uptake among four indicated vaccines by adults aged 65 years and older in Japan, 2023.
Vaccine. 2024 May 20:S0264-410X(24)00592-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GARG R, Liu Q, Van Kessel J, Asavajaru A, et al
Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern.
Vaccine. 2024 May 19:S0264-410X(24)00586-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

YANG T, Tong F, Tang L, Li P, et al
Repeated vaccination does not appear to significantly weaken the protective effect of influenza vaccine in the elderly: A test-negative case-control study in China.
Vaccine. 2024 May 17:S0264-410X(24)00593-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ANN COSTA CLEMENS S, Weckx L, Milan EP, Smolenov I, et al
Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice.
Vaccine. 2024 May 17:S0264-410X(24)00555-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

URQUIDI C, Sepulveda-Penaloza A, Valenzuela MT, Ponce A, et al
Vaccine effectiveness in reducing COVID-19-related hospitalization after a risk-age-based mass vaccination program in a Chilean municipality: A comparison of observational study designs.
Vaccine. 2024 May 14:S0264-410X(24)00538-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MUANGNOICHAROEN S, Wiangcharoen R, Lawpoolsri S, Nanthapisal S, et al
Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.
Vaccine. 2024 May 13:S0264-410X(24)00556-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

EJNAR HANSEN M, David Pickering S
The role of religion and COVID-19 vaccine uptake in England.
Vaccine. 2024;42:3215-3219.
PubMed Abstract available

DINH THIEM V, Van Anh PT, Van Men C, Hung DT, et al
A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial.
Vaccine. 2024 May 10:S0264-410X(24)00523-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MALTEZOU HC, Gamaletsou MN, Giannouchos TV, Koukou DM, et al
Effectiveness of COVID-19 booster vaccination, morbidity and absenteeism among healthcare personnel during the 2022-2023 season dominated by Omicron BA.5 and BA.2 subvariants.
Vaccine. 2024 May 9:S0264-410X(24)00522-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SHANI M, Hermesh I, Feldhamer I, Reges O, et al
The association between BNT162b2 vaccinations and incidence of immune-mediated comorbidities.
Vaccine. 2024 May 9:S0264-410X(24)00536-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LEE KY, Song KH, Lee KH, Baek JY, et al
Persistent differences in the immunogenicity of the two COVID-19 primary vaccines series, modulated by booster mRNA vaccination and breakthrough infection.
Vaccine. 2024 May 9:S0264-410X(24)00539-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KIM DH, Lee SH, Kim J, Lee J, et al
Efficacy of live and inactivated recombinant Newcastle disease virus vaccines expressing clade 2.3.4.4b H5 hemagglutinin against H5N1 highly pathogenic avian influenza in SPF chickens, Broilers, and domestic ducks.
Vaccine. 2024 May 8:S0264-410X(24)00527-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

TIPPINS A, Acevedo JC, Palomeque FS, Coy KC, et al
Strategies to strengthen COVID-19 vaccine uptake and improve vaccine equity in U.S. Territories and Freely Associated States during the first six months of vaccine rollout.
Vaccine. 2024 May 7:S0264-410X(24)00541-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KIM J, Chang J
Cross-protective efficacy and safety of an adenovirus-based universal influenza vaccine expressing nucleoprotein, hemagglutinin, and the ectodomain of matrix protein 2.
Vaccine. 2024 May 6:S0264-410X(24)00481-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CAO A, Ueta M, Uchibori M, Murakami M, et al
Trust in governments, public health institutions, and other information sources as determinants of COVID-19 vaccine uptake behavior in Japan.
Vaccine. 2024 May 6:S0264-410X(24)00520-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

JEARANAIWITAYAKUL T, Sunintaboon P, Kittiayuwat A, Limthongkul J, et al
Intranasal immunization with the bivalent SARS-CoV-2 vaccine effectively protects mice from nasal infection and completely inhibits disease development.
Vaccine. 2024 May 6:S0264-410X(24)00519-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SOE P, Wong H, Naus M, Muller MP, et al
mRNA COVID-19 vaccine safety among older adults from the Canadian National Vaccine Safety Network.
Vaccine. 2024 May 6:S0264-410X(24)00535-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SHI XC, Gruber JF, Ondari M, Lloyd PC, et al
Assessment of potential adverse events following the 2022-2023 seasonal influenza vaccines among U.S. adults aged 65 years and older.
Vaccine. 2024 May 3:S0264-410X(24)00478-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MAUREL M, Mazagatos C, Goerlitz L, Oroszi B, et al
Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe.
Vaccine. 2024 May 3:S0264-410X(24)00497-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BENEDICT KPOZEHOUEN E, Macintyre CR, Tan TC
Determinants of uptake of influenza, zoster and pneumococcal vaccines in patients with cardiovascular diseases.
Vaccine. 2024 May 3:S0264-410X(24)00445-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HU H, Ma F, Gong L, Wang Y, et al
Immunogenicity and safety of a recombinant Omicron BA.4/5-Delta COVID-19 vaccine ZF2202-A in Chinese adults.
Vaccine. 2024 May 3:S0264-410X(24)00495-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ADINUGROHO I, Stafford T, Bentall RP
The correlation between conspiracy mentality and vaccine intentions is moderated by social events: Evidence from longitudinal data during COVID-19 pandemic in the UK.
Vaccine. 2024 May 3:S0264-410X(24)00510-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CHRISTOU-ERGOS M, Bleicher K, Leask J
Factors associated with vaccination intention and uptake over time in a sample of older Australians.
Vaccine. 2024 May 3:S0264-410X(24)00508-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BAGLIVO F, De Angelis L, Magri M, De Nicola I, et al
The impact of COVID-19 vaccination campaign on pediatric vaccine uptake based on parents' attitudes towards mandatory and recommended vaccination in Southern Italy.
Vaccine. 2024 May 3:S0264-410X(24)00513-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MARINTHE G, Brown G, Cristea M, Kutlaca M, et al
Predicting vaccination hesitancy: The role of basic needs satisfaction and institutional trust.
Vaccine. 2024 May 3:S0264-410X(24)00507-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

EHRLICH KB, Lyle SM, Corallo KL, Lavner JA, et al
Changes in depressive symptoms and antibody production following influenza vaccination in adolescents and adults.
Vaccine. 2024 May 2:S0264-410X(24)00505-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

April 2024

FLEARY SA, Shahn Z, Teasdale CA
Effects of parental childhood cultural health environment on children's influenza and COVID-19 vaccination status.
Vaccine. 2024 Apr 29:S0264-410X(24)00515-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

NIESSEN FA, Bruijning-Verhagen PCJL, Bonten MJM, Knol MJ, et al
Vaccine effectiveness against COVID-19 related hospital admission in the Netherlands by medical risk condition: A test-negative case-control study.
Vaccine. 2024 Apr 29:S0264-410X(24)00432-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GUDOORU K, Nguyen K, Le K, Sarabu V, et al
Collective good and individual choice: Perceptions on COVID-19 vaccine mandate among COVID-19 vaccinated individuals.
Vaccine. 2024 Apr 27:S0264-410X(24)00479-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DORJEE K, Namdon T, Topgyal S, Gyatso U, et al
Association between Covishield vaccine and menstrual disturbance. Findings from a cross-sectional study among participants of Zero TB cohort in India.
Vaccine. 2024 Apr 27:S0264-410X(24)00500-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LYTRAS T, Athanasiadou M, Demetriou A, Stylianou D, et al
Authors' reply: Excess mortality in Cyprus during the COVID-19 vaccination campaign.
Vaccine. 2024 Apr 25:S0264-410X(24)00506-1. doi: 10.1016/j.vaccine.2024.
PubMed

XIE Z, Stallings-Smith S, Patel S, Case S, et al
COVID-19 booster vaccine uptake and reduced risks for long-COVID: A cross-sectional study of a U.S. adult population.
Vaccine. 2024 Apr 25:S0264-410X(24)00509-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

PIASECKI AM, Hall DM, Zajac J, Miller SA, et al
A programmatic update on COVID-19 vaccination in rural communities in the United States.
Vaccine. 2024 Apr 25:S0264-410X(24)00469-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

FUJITA DM, da Silva Nali LH, da Costa RR, de Andrade Junior HF, et al
Low vaccine coverage and varicella outbreaks in Brazil - 2019-2022.
Vaccine. 2024 Apr 24:S0264-410X(24)00435-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SELLIES AJ, Knol MJ, de Melker HE, Bruijning-Verhagen PCJL, et al
Non-specific effects of the inactivated influenza vaccine. A test-negative study: The inactivated influenza vaccine and SARS-CoV-2 infections.
Vaccine. 2024 Apr 23:S0264-410X(24)00468-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SONG S, Madewell ZJ, Liu M, Miao Y, et al
A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants.
Vaccine. 2024 Apr 22:S0264-410X(24)00476-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MUSA S, Merdrignac L, Skocibusic S, Nedic R, et al
BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and older during the Delta-dominant period in the Federation of Bosnia and Herzegovina, a test-negative case-control study.
Vaccine. 2024 Apr 20:S0264-410X(24)00471-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LIEVRE G, Sicsic J, Galmiche S, Charmet T, et al
Are the 7C psychological antecedents associated with COVID-19 vaccine behaviours beyond intentions? A cross-sectional study on at-least-one-dose and up-to-date vaccination status, and uptake speed among adults in France.
Vaccine. 2024 Apr 19:S0264-410X(24)00438-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

INGRAO F, Ngabirano E, Rauw F, Dauphin G, et al
Immunogenicity and protective efficacy of a multivalent herpesvirus vectored vaccine against H9N2 low pathogenic avian influenza in chicken.
Vaccine. 2024 Apr 18:S0264-410X(24)00452-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WON H, Kim JA, Jeong NY, Choi NK, et al
Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly.
Vaccine. 2024 Apr 18:S0264-410X(24)00400-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

RICKE IJ, Spaulding AB, Rajtar NN, Benton EM, et al
Predictors of willingness to receive updated 2023-2024 COVID-19 booster vaccines among a convenience sample in Minnesota.
Vaccine. 2024 Apr 18:S0264-410X(24)00480-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ORANGZEB S, Desalegn A, Trinh NTH, Zhao J, et al
COVID-19 vaccine uptake among children and adolescents in Norway: A comprehensive registry-based cohort study of over 800,000 individuals.
Vaccine. 2024 Apr 18:S0264-410X(24)00464-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

TRINITE B, Durr E, Pons-Grifols A, O'Donnell G, et al
VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice.
Vaccine. 2024 Apr 18:S0264-410X(24)00473-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

VAN DER POL S, Zeevat F, Postma MJ, Boersma C, et al
Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations.
Vaccine. 2024 Apr 17:S0264-410X(24)00465-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BEITARI S, Yi S, Sharma S, Yung R, et al
Exploring COVID-19 vaccine uptake and hesitancy among vulnerable populations in inner city Vancouver, Canada: Insights into characteristics and clinical outcomes.
Vaccine. 2024 Apr 17:S0264-410X(24)00477-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

PEREIRA ET, Iasulaitis S, Greco BC
Analysis of causal relations between vaccine hesitancy for COVID-19 vaccines and ideological orientations in Brazil.
Vaccine. 2024 Apr 16:S0264-410X(24)00436-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LEE N, Hong Y, Kirkpatrick CE, Hu S, et al
COVID-19 vaccination communication: Effects of vaccine conspiracy beliefs and message framing among black and white participants.
Vaccine. 2024 Apr 16:S0264-410X(24)00402-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DEAL A, Crawshaw AF, Salloum M, Hayward SE, et al
Understanding the views of adult migrants around catch-up vaccination for missed routine immunisations to define strategies to improve coverage: A UK in-depth interview study.
Vaccine. 2024 Apr 16:S0264-410X(24)00406-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GEE J, Shimabukuro TT, Su JR, Shay D, et al
Overview of U.S. COVID-19 vaccine safety surveillance systems.
Vaccine. 2024 Apr 16:S0264-410X(24)00224-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MARTINEZ JL, Lemus N, Lai TY, Mishra M, et al
The immunodominance of antigenic site Sb on the H1 influenza virus hemagglutinin increases with high immunoglobulin titers of the cohorts and with young age, but not sex.
Vaccine. 2024 Apr 15:S0264-410X(24)00451-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MELNIKOW J, Padovani A, Zhang J, Miller M, et al
Patient concerns and physician strategies for addressing COVID-19 vaccine hesitancy.
Vaccine. 2024 Apr 15:S0264-410X(24)00437-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WONG IOL, Wong C, Mak N, Dai A, et al
Assessment of the impact of the vaccine pass policy on COVID-19 vaccine hesitancy and uptake among Chinese adults in Hong Kong.
Vaccine. 2024 Apr 15:S0264-410X(24)00449-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BAKER J, Aliabadi N, Munjal I, Jiang Q, et al
Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 study.
Vaccine. 2024 Apr 13:S0264-410X(24)00387-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SUKIK L, Chemaitelly H, Ayoub HH, Coyle P, et al
Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient.
Vaccine. 2024 Apr 13:S0264-410X(24)00440-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

NOLAN MB, Chrenka E, Walker P, Steiner A, et al
COVID-19 vaccine uptake among non-US-born populations in the United States, 2020-2022.
Vaccine. 2024 Apr 11:S0264-410X(24)00443-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KAINTH MK, Sembajwe GN, Ahn H, Qian M, et al
Despite mandated primary series, health care personnel still hesitant about COVID-19 vaccine and immunizing children.
Vaccine. 2024 Apr 11:S0264-410X(24)00442-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LEE JS, Choi H, Shin SH, Hwang MJ, et al
Characterization of Brighton Collaboration criteria for myocarditis and pericarditis following COVID-19 vaccine in Korean adolescents.
Vaccine. 2024 Apr 11:S0264-410X(24)00446-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

PITTS PJ, Poland GA
Addressing vaccine hesitancy: Learning from the successes and failures of the COVID-19 pandemic.
Vaccine. 2024 Apr 10:S0264-410X(24)00396-7. doi: 10.1016/j.vaccine.2024.
PubMed

AKMATOVA R, Ebama MS, Temirbekov S, Alymkulova V, et al
A comparative analysis of knowledge, attitude, and practice (KAP) towards influenza and influenza vaccination among healthcare workers in Kyrgyzstan prior to and during the COVID-19 pandemic.
Vaccine. 2024 Apr 9:S0264-410X(24)00420-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

THAI H, Audet EC, Koestner R
Motivation for COVID-19 Vaccination: Applying a Self-Determination Theory Perspective to a Global Health Crisis.
Vaccine. 2024 Apr 9:S0264-410X(24)00439-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

Immunization agenda 2030: A global strategy to leave no one behind.
Vaccine. 2024;42 Suppl 1:S5-S14.
PubMed

ZHU J, Cole CB, Fihman J, Adjagba A, et al
Opportunities to accelerate immunization progress in middle-income countries.
Vaccine. 2024;42 Suppl 1:S98-S106.
PubMed Abstract available

BLANC DC, Grundy J, Sodha SV, O'Connell TS, et al
Immunization programs to support primary health care and achieve universal health coverage.
Vaccine. 2024;42 Suppl 1:S38-S42.
PubMed Abstract available

SAXENIAN H, Alkenbrack S, Freitas Attaran M, Barcarolo J, et al
Sustainable financing for Immunization Agenda 2030.
Vaccine. 2024;42 Suppl 1:S73-S81.
PubMed Abstract available

CERNUSCHI T, Malvolti S, Hall S, Debruyne L, et al
The quest for more effective vaccine markets - Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic.
Vaccine. 2024;42 Suppl 1:S64-S72.
PubMed Abstract available

KONERU A, Wells K, Amanda Carnes C, Drumhiller K, et al
A survey of state and local practices encouraging pediatric COVID-19 vaccination of children ages 6 months through 11 years.
Vaccine. 2024 Apr 8:S0264-410X(24)00369-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CHARD AN, Machingaidze C, Loayza S, Gharpure R, et al
Estimating averted illnesses from influenza vaccination for children and pregnant women - El Salvador, Panama, and Peru, 2011-2018.
Vaccine. 2024 Apr 6:S0264-410X(24)00419-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ARCHER H, McCoy SI, Sears D, Kwan A, et al
Indirect vaccine effectiveness in an outbreak of Alpha B.1.1.7 variant in a California state Prison, May 2021.
Vaccine. 2024 Apr 6:S0264-410X(24)00368-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SCHULTZE A, Martin I, Messina D, Bots S, et al
A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases.
Vaccine. 2024 Apr 5:S0264-410X(24)00330-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BAUM HE, Thirard R, Halliday A, Baos S, et al
Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial.
Vaccine. 2024 Apr 4:S0264-410X(24)00367-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

NURDIN A, Movieta Nency Y, Maddeppungeng M, Sekartini R, et al
Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial.
Vaccine. 2024 Apr 3:S0264-410X(24)00399-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WU CY, Kao SE, Tseng YC, Hou JT, et al
Pilot-scale production of a highly efficacious and stable monoglycosylated influenza split virus vaccine.
Vaccine. 2024;42:2220-2228.
PubMed Abstract available

LASRADO N, Rossler A, Rowe M, Collier AY, et al
Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1.
Vaccine. 2024;42:2117-2121.
PubMed Abstract available

March 2024

GONG JD, Barnboym E, O'Mara M, Gurevich N, et al
Self-reported determinants of COVID-19 vaccine acceptance among persons with and without autoimmune disease.
Vaccine. 2024 Mar 30:S0264-410X(24)00373-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MALTEZOU HC, Kontogianni S, Michailidou E, Vergadi E, et al
Effectiveness of COVID-19 vaccination against school absenteeism in children and adolescents hospitalized with COVID-19.
Vaccine. 2024 Mar 30:S0264-410X(24)00397-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HUF SW, Grailey K, Crespo RF, Woldmann L, et al
Testing the impact of differing behavioural science informed text message content in COVID-19 vaccination invitations on vaccine uptake: A randomised clinical trial.
Vaccine. 2024 Mar 28:S0264-410X(24)00365-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DALEY MF, Reifler LM, Shoup JA, Glanz JM, et al
Influenza vaccination accuracy among adults: Self-report compared with electronic health record data.
Vaccine. 2024 Mar 25:S0264-410X(24)00339-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BIEGUS J, Szenborn L, Zymlinski R, Zakliczynski M, et al
The early safety profile of simultaneous vaccination against influenza and Respiratory Syncytial Virus (RSV) in patients with high-risk heart failure.
Vaccine. 2024 Mar 25:S0264-410X(24)00366-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

VOLKMANN AM, Goldin S, McMurren B, Gapare C, et al
Leveraging seasonal influenza health worker vaccination programmes for COVID-19 vaccine Introduction: A global qualitative analysis.
Vaccine. 2024 Mar 25:S0264-410X(23)01490-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

DAHL BA, Tritter B, Butryn D, Dahlke M, et al
Global VAX: A U.S. contribution to global COVID-19 vaccination efforts, 2021-2023.
Vaccine. 2024 Mar 23:S0264-410X(24)00359-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MORGAN G, Casalino S, Chowdhary S, Frangione E, et al
COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study.
Vaccine. 2024 Mar 22:S0264-410X(24)00317-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CONDIE J, Northstone K, Major-Smith D, Halstead I, et al
Exploring associations between the Big Five personality traits and cognitive ability with COVID-19 vaccination hesitancy and uptake among mothers and offspring in a UK prospective cohort study.
Vaccine. 2024 Mar 22:S0264-410X(24)00305-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KLUWER B, Gleditsch R, Rydland KM, Mamelund SE, et al
Higher educational attainment associated with higher confidence in influenza vaccination in Norway.
Vaccine. 2024 Mar 21:S0264-410X(24)00338-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

PRICE O, Dietze P, Maher L, Dore GJ, et al
High COVID-19 vaccine uptake following initial hesitancy among people in Australia who inject drugs.
Vaccine. 2024 Mar 21:S0264-410X(24)00337-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MOFFETT KW, Seserman K, Margolis KA, Kranzler EC, et al
Differences in social media use by COVID-19 vaccination status.
Vaccine. 2024 Mar 20:S0264-410X(24)00318-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SASI A, Dandotiya J, Kaushal J, Ganguly S, et al
Humoral and cellular immunity to SARS-CoV-2 following vaccination with non-mRNA vaccines in adolescent/young adults with cancer: A prospective cohort study.
Vaccine. 2024 Mar 20:S0264-410X(24)00329-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HILL-BATORSKI L, Bowen R, Bielefeldt-Ohmann H, Moser MJ, et al
Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge.
Vaccine. 2024 Mar 19:S0264-410X(24)00327-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KRASILNIKOV I, Isaev A, Djonovic M, Ivanov A, et al
Transformative vaccination: A pentavalent shield against COVID-19 and influenza with betulin-based adjuvant for enhanced immunity.
Vaccine. 2024 Mar 19:S0264-410X(23)01421-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LLOYD PC, Lufkin B, Moll K, Ogilvie RP, et al
Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017-2020.
Vaccine. 2024;42:2004-2010.
PubMed Abstract available

LANG JC, Kura K, Garba SM, Elbasha EH, et al
Comparison of a static cohort model and dynamic transmission model for respiratory syncytial virus intervention programs for infants in England and Wales.
Vaccine. 2024;42:1918-1927.
PubMed Abstract available

SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Durocher Y, et al
CHO cells for virus-like particle and subunit vaccine manufacturing.
Vaccine. 2024 Mar 18:S0264-410X(24)00321-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CAMPAGNA R, Dominelli F, Zingaropoli MA, Ciurluini F, et al
COVID-19 vaccination in cancer patients: Immune responses one year after the third dose.
Vaccine. 2024 Mar 17:S0264-410X(24)00304-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

FIX J, Christopher Mast T, Smith K, Baker N, et al
Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
Vaccine. 2024 Mar 16:S0264-410X(24)00323-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

COTTON SA, Subramanian A, Hughes TD, Huang Y, et al
The effect of SARS-COV-2 variant on non-respiratory features and mortality among vaccinated and non-fully vaccinated patients.
Vaccine. 2024 Mar 14:S0264-410X(24)00195-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CAMERON DB, Grage L, Van Wyck R, Edwards A, et al
Identifying trusted local sources and predicting behavior change pathways according to COVID-19 vaccination status: Results of a 2022 statewide survey of Alaskan adults.
Vaccine. 2024 Mar 14:S0264-410X(24)00314-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

EL SALIBI N, Abdulrahim S, El Haddad M, Abi Zeid B, et al
Predicting intention to vaccinate against COVID-19 in older Syrian refugees in Lebanon: Findings from a multi-wave study.
Vaccine. 2024 Mar 13:S0264-410X(24)00213-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MCCOSKER LK, Ware RS, Seale H, Hooshmand D, et al
The effect of a financial incentive on COVID-19 vaccination uptake, and predictors of uptake, in people experiencing homelessness: A randomized controlled trial.
Vaccine. 2024 Mar 13:S0264-410X(24)00307-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

RUSS S, Myers C, Licherdell E, Bowden A, et al
Sociodemographic and Occupational Characteristics Associated with Early and Continued COVID-19 Vaccine Uptake Among Healthcare Personnel: Monroe County, NY.
Vaccine. 2024 Mar 12:S0264-410X(24)00306-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SHIJIA YAN A, Jay Sehgal N
Partisan divide and Racial/Ethnic disparities in COVID-19 vaccine hesitancy among Parents/Guardians and vaccine uptake among children in the U.S.
Vaccine. 2024 Mar 11:S0264-410X(24)00309-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MORO PL, Carlock G, Fifadara N, Habenicht T, et al
Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023.
Vaccine. 2024 Mar 9:S0264-410X(24)00262-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LUISI M, Geana MV, Pei J
Pandemic antecedents - Exploring predictivity and relationships between COVID-19 vaccine uptake and influenza, shingles, and HPV vaccination.
Vaccine. 2024 Mar 8:S0264-410X(24)00275-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ST-LOUIS P, Martin C, Khatri V, Bourgault S, et al
Intranasal delivery of a self-adjuvanted nanovaccine composed of the curli filaments and the highly conserved M2e epitope confers protection against influenza a virus in mice.
Vaccine. 2024 Mar 8:S0264-410X(24)00222-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SU YW, Qiu YZ, Wang YH, Xu Y, et al
Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial.
Vaccine. 2024 Mar 8:S0264-410X(24)00277-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

Expression of Concern: "Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine" [Vaccine [33/1], 1 January 2015, Pages 108-116].
Vaccine. 2024;42:1851.
PubMed

MENG L, Harris L, Shaw L, Lymon H, et al
Social and demographic factors associated with receipt of a COVID-19 vaccine initial booster dose and with interval between primary series completion and initial booster dose uptake among persons aged >/= 12 years, United States, August 2021-October 2
Vaccine. 2024 Mar 6:S0264-410X(24)00271-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KARRAS J, Harrison M, Steffens M, Abdi I, et al
"COVID is a huge jigsaw puzzle that I am trying to make sense of myself": Exploring the perceptions towards the COVID-19 vaccine communication strategy in Australia amongst unvaccinated Australian adults.
Vaccine. 2024 Mar 6:S0264-410X(24)00276-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WONG WHS, Leung DL, Yip KM, So HK, et al
Effectiveness of inactivated COVID-19 vaccine CoronaVac in children aged less than 3 years old during Omicron wave in Hong Kong.
Vaccine. 2024 Mar 6:S0264-410X(24)00226-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

RAETHKE M, van Hunsel F, Luxi N, Lieber T, et al
Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study.
Vaccine. 2024 Mar 6:S0264-410X(24)00273-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CHEN D, Cowling BJ, Ainslie KEC, Lin Y, et al
Association of COVID-19 vaccination with duration of hospitalization in older adults in Hong Kong.
Vaccine. 2024 Mar 5:S0264-410X(24)00252-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

YASHAR-GERSHMAN SG, Rosenberg AT, Sawhney M, Fernanda Machicao M, et al
Developing a novel screening tool to address pediatric COVID-19 vaccine hesitancy at point of care.
Vaccine. 2024 Mar 1:S0264-410X(24)00228-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

February 2024

YADEGARYNIA D, Keyvanfar A, Keyvani H, Tehrani S, et al
Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial.
Vaccine. 2024 Feb 29:S0264-410X(24)00249-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KOHLI M, Maschio M, Lee A, Igarashi A, et al
Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine.
Vaccine. 2024 Feb 29:S0264-410X(24)00117-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CHATHAM-STEPHENS K, Carter RJ, Duggar C, Woodworth KR, et al
An overview of the COVID-19 pediatric vaccine program - The U.S. experience vaccinating children ages 6 months through 17 years.
Vaccine. 2024 Feb 29:S0264-410X(24)00166-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GUO J, Chen X, Guo Y, Liu M, et al
Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: A systematic review, meta-analysis and meta-regression of test-negative design studies.
Vaccine. 2024 Feb 28:S0264-410X(24)00218-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MARINDA E, Mathentamo Q, Coulson N, Parker S, et al
Impact evaluation of a youth led intervention to increase COVID-19 vaccine uptake in Kwazulu-Natal, South Africa.
Vaccine. 2024 Feb 28:S0264-410X(24)00211-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

YANG XY, Liu T, Jiang SC, Zhang ZW, et al
Antibodies against SARS-CoV-2 non-structural protein 3 cross-react with human muscle cells and neuroglial cells.
Vaccine. 2024;42:1259-1267.
PubMed Abstract available

JABBAR F, Kadhim KA, Alhilfi RA, Chitheer A, et al
Intensification of integrated immunization services to recover routine vaccination coverage and bring COVID-19 vaccine to the population of Iraq in 2022.
Vaccine. 2024 Feb 27:S0264-410X(24)00197-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KRISTINSDOTTIR I, Haraldsson A, Thors V
Influenza vaccination in pregnant women in Iceland 2010-2020 and the burden of influenza in pregnant women and their infants.
Vaccine. 2024 Feb 26:S0264-410X(24)00205-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MUNDO ORTIZ A, Nasri B
Socio-demographic determinants of COVID-19 vaccine uptake in Ontario: Exploring differences across the Health Region model.
Vaccine. 2024 Feb 26:S0264-410X(24)00204-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

NEWALL AT, Nazareno AL, Muscatello DJ, Boettiger D, et al
The association between influenza vaccination uptake and influenza and pneumonia-associated deaths in the United States.
Vaccine. 2024 Feb 24:S0264-410X(24)00113-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MURPHY C, Kwan MYW, Chan ELY, Wong JSC, et al
Influenza vaccine effectiveness against hospitalizations associated with influenza A(H3N2) in Hong Kong children aged 9 months to 17 years, June-November 2023.
Vaccine. 2024 Feb 22:S0264-410X(24)00215-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SHETTY AN, Morgan HJ, Phuong LK, Mallard J, et al
Audiovestibular adverse events following COVID-19 vaccinations.
Vaccine. 2024 Feb 22:S0264-410X(24)00210-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

XU S, Sy LS, Hong V, Farrington P, et al
Mortality risk after COVID-19 vaccination: A self-controlled case series study.
Vaccine. 2024 Feb 21:S0264-410X(24)00191-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SHOUKAT A, Bawden CE, Rost G, LeBlanc JJ, et al
Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
Vaccine. 2024 Feb 16:S0264-410X(24)00200-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CHERRY N, Adisesh A, Burstyn I, Charlton C, et al
Determinants of SARS-CoV-2 IgG response and decay in Canadian healthcare workers: A prospective cohort study.
Vaccine. 2024;42:1168-1178.
PubMed Abstract available

JIN F, Qiu Y, Wu Z, Wang YH, et al
Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial.
Vaccine. 2024 Feb 15:S0264-410X(24)00124-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MZIOU E, Hchaichi A, Letaief H, Dhaouadi S, et al
Vaccine effectiveness against COVID-19: A test negative case-control study in Tunisia, August 2021.
Vaccine. 2024 Feb 15:S0264-410X(24)00174-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ROCKSON ADJEI M, Longsignikuu A, Saeed Iddris I, Nang Suuri T, et al
Trend of measles-rubella vaccination coverage and impact on measles epidemiology in the Savannah Region, Ghana; 2018-2022: A secondary data analysis.
Vaccine. 2024 Feb 15:S0264-410X(24)00170-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KIM HK, Park SK, Choe SA, Gwak ES, et al
Risk of SARS-CoV-2 breakthrough infection following NVX-CoV2373 and BNT162b2 vaccinations in Korean Adults: A population-based observational study.
Vaccine. 2024 Feb 15:S0264-410X(24)00168-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KUTER BJ, Brien K, Anderson S, Bass SB, et al
COVID-19 vaccine perspectives and uptake among university students three years into the pandemic.
Vaccine. 2024 Feb 15:S0264-410X(24)00162-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

OKOLI GN, Righolt CH, Zhang G, Van Caeseele P, et al
A population-based, province-wide, record-linkage interrupted time series analysis of impact of the universal seasonal influenza vaccination policy on seasonal influenza vaccine uptake among 5-64-year-olds in the province of Manitoba, Canada.
Vaccine. 2024 Feb 14:S0264-410X(24)00104-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BATHEJA A, Balkrishnan R
Rhode Island as a model for promoting flu vaccination in the United States.
Vaccine. 2024 Feb 14:S0264-410X(24)00161-0. doi: 10.1016/j.vaccine.2024.
PubMed

KLASSEN AC, Lee G, Chiang S, Murray R, et al
Did the COVID-19 experience change U.S. parents' attitudes towards HPV vaccination? Results from a national survey.
Vaccine. 2024 Feb 14:S0264-410X(24)00142-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DUGGAR C, Santoli JM, Noblit C, Moore LB, et al
U.S. COVID-19 vaccine distribution strategies, systems, performance, and lessons learned, December 2020 - May 2023.
Vaccine. 2024 Feb 14:S0264-410X(24)00167-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DONATO F, Pilotto A, Foca E, Tresoldi M, et al
The impact of time since SARS-Cov-2 vaccination, age, sex and comorbidities on COVID-19 outcome in hospitalized patients with SARS-CoV-2 infection.
Vaccine. 2024 Feb 13:S0264-410X(24)00147-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HEARN EB, Kehinde G, Sambamoorthi U
Food insecurity and COVID-19 vaccine hesitancy among adults in the United States (US).
Vaccine. 2024 Feb 13:S0264-410X(24)00102-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

AMDISEN L, Pedersen L, Abildgaard N, Benn CS, et al
The coverage of influenza vaccination and predictors of influenza non-vaccination in Danish cancer patients: A nationwide register-based cohort study.
Vaccine. 2024 Feb 12:S0264-410X(24)00155-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

VALENTIN J, Ingrao F, Rauw F, Lambrecht B, et al
Protection conferred by an H5 DNA vaccine against highly pathogenic avian influenza in chickens: The effect of vaccination schedules.
Vaccine. 2024 Feb 12:S0264-410X(23)01422-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MORGAN HJ, Clothier HJ, Sepulveda Kattan G, Boyd JH, et al
Acute disseminated encephalomyelitis and transverse myelitis following COVID-19 vaccination - A self-controlled case series analysis.
Vaccine. 2024 Feb 12:S0264-410X(24)00126-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

FAKSOVA K, Walsh D, Jiang Y, Griffin J, et al
COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
Vaccine. 2024 Feb 12:S0264-410X(24)00127-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WHITAKER HJ, Hassell K, Hoschler K, Power L, et al
Influenza vaccination during the 2021/22 season: A data-linkage test-negative case-control study of effectiveness against influenza requiring emergency care in England and serological analysis of primary care patients.
Vaccine. 2024 Feb 10:S0264-410X(24)00150-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LIJESKIC O, Bauman N, Markovic M, Srbljanovic J, et al
SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost.
Vaccine. 2024 Feb 10:S0264-410X(24)00110-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WEI J, Tan TC, Moa AM, MacIntyre CR, et al
Cost-benefit of influenza vaccination in preventing sudden cardiac arrest amongst Australian adults.
Vaccine. 2024 Feb 9:S0264-410X(24)00154-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BUEKENS P, Berrueta M, Ciapponi A, Bardach A, et al
Safe in pregnancy: A global living systematic review and meta-analysis of COVID-19 vaccines in pregnancy.
Vaccine. 2024 Feb 9:S0264-410X(24)00158-0. doi: 10.1016/j.vaccine.2024.
PubMed

MARKOWITZ LE, Hopkins RH Jr, Broder KR, Lee GM, et al
COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemic.
Vaccine. 2024 Feb 9:S0264-410X(23)01505-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

WADAPURKAR R, Singh S, Singh A
Leveraging the immunoinformatics approach for designing the SARS-CoV-2 omicron-specific antigenic cassette of mRNA vaccine.
Vaccine. 2024 Feb 8:S0264-410X(24)00111-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

RANDELL M, Sheel M, Dynes M, Li M, et al
Influence of the COVID-19 pandemic on caregiver beliefs and experiences of routine childhood immunisation in Indonesia.
Vaccine. 2024;42:812-818.
PubMed Abstract available

KOLANDAI K, Milne B, von Randow M, Bullen C, et al
Public opinion on global COVID-19 vaccine procurement and distribution policies: A nationally representative survey in Aotearoa New Zealand 2022.
Vaccine. 2024 Feb 6:S0264-410X(24)00115-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MAEDA M, Murata F, Fukuda H
The age-specific impact of COVID-19 vaccination on medical expenditures and hospitalization duration after breakthrough infection: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study.
Vaccine. 2024 Feb 5:S0264-410X(24)00106-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MIYAMOTO S, Suzuki T
Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development.
Vaccine. 2024 Feb 2:S0264-410X(24)00112-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

RIVERS P, Porter C, LeClair LB, Jeddy Z, et al
Longitudinal parental perception of COVID-19 vaccines for children in a multi-site, cohort study.
Vaccine. 2024 Feb 2:S0264-410X(24)00010-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BENNETT JC, Luiten KG, O'Hanlon J, Han PD, et al
Utilizing a university testing program to estimate relative effectiveness of monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against symptomatic SARS-CoV-2 infection.
Vaccine. 2024 Feb 1:S0264-410X(24)00103-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DATTA S, Vattiato G, Maclaren OJ, Hua N, et al
The impact of Covid-19 vaccination in Aotearoa New Zealand: A modelling study.
Vaccine. 2024 Feb 1:S0264-410X(24)00128-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

January 2024

SOOD S, Matar MM, Kim J, Kinsella M, et al
Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer.
Vaccine. 2024 Jan 31:S0264-410X(24)00077-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HUANG Y, Shi H, Forgacs D, Ross TM, et al
Flu-COVID combo recombinant protein vaccines elicited protective immune responses against both influenza and SARS-CoV-2 viruses infection.
Vaccine. 2024 Jan 30:S0264-410X(23)01543-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

JI Y, Sui X, Miao W, Wang C, et al
Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.
Vaccine. 2024 Jan 30:S0264-410X(24)00097-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SHAPIRO BEN DAVID S, Baruch Gez S, Adler L, Kovatch R, et al
Short term safety of BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine among children aged 5-11 years, a nationwide parental survey.
Vaccine. 2024 Jan 27:S0264-410X(24)00067-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BALSELLS E, Vicente M, Reyes S, Figueroa M, et al
Impact of the 'Health on Wheels' (HoW) strategy on COVID-19 vaccination coverage in hard-to-reach communities in Alta Verapaz, Guatemala, 2022.
Vaccine. 2024 Jan 27:S0264-410X(24)00033-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

OKPANI AI, Adu P, Paetkau T, Lockhart K, et al
Are COVID-19 vaccination mandates for healthcare workers effective? A systematic review of the impact of mandates on increasing vaccination, alleviating staff shortages and decreasing staff illness.
Vaccine. 2024 Jan 27:S0264-410X(24)00052-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

FILIPAS DK, Labban M, Beatrici E, Stone BV, et al
Exploring preventive care practices among unvaccinated individuals in the United States during the COVID-19 pandemic.
Vaccine. 2024;42:441-447.
PubMed Abstract available

TAKALANI A, Robinson M, Jonas P, Bodenstein A, et al
Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa.
Vaccine. 2024 Jan 25:S0264-410X(24)00078-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

RUSS S, Bennett N, van Wijngaarden E, Hill E, et al
Influence of Community Determinants on Barriers and Facilitators to COVID-19 Vaccine Uptake: Regional Stakeholders' Perspectives.
Vaccine. 2024 Jan 24:S0264-410X(24)00051-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LIU R, Fan Y, Patel A, Liu H, et al
The association between influenza vaccination, cardiovascular mortality and hospitalization: A living systematic review and prospective meta-analysis.
Vaccine. 2024 Jan 23:S0264-410X(24)00053-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

RATTAY K, Thierry JM, Yeargin-Allsopp M, Griffin-Blake S, et al
Lessons learned: COVID-19 vaccinations and people with disabilities.
Vaccine. 2024 Jan 23:S0264-410X(24)00028-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ABAD N, Bonner KE, Kolis J, Brookmeyer KA, et al
Strengthening COVID-19 vaccine confidence & demand during the US COVID-19 emergency response.
Vaccine. 2024 Jan 23:S0264-410X(24)00029-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HAMAD SAIED M, van Straalen JW, de Roock S, Verduyn Lunel FM, et al
Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort study.
Vaccine. 2024 Jan 22:S0264-410X(24)00059-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

PAL R, Ferrari MG, Honda-Okubo Y, Wattay L, et al
Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates.
Vaccine. 2024 Jan 22:S0264-410X(24)00034-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GEINITZ H, Silberberger E, Spiegl K, Feichtinger J, et al
SARS-CoV-2 vaccination willingness and humoral vaccination response in radiation oncology patients.
Vaccine. 2024 Jan 20:S0264-410X(24)00004-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HILL PL, Morstead T, Pfund GN, Burrow AL, et al
Examining changes in sense of purpose before, during, and after COVID-19 vaccination.
Vaccine. 2024 Jan 20:S0264-410X(24)00027-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MITCHELL MM, Klott A, Scholtes J, Braden BB, et al
Mixed-methods examination of attitudes and behaviors related to COVID-19 vaccines among parents of children with autism and autistic adults.
Vaccine. 2024 Jan 19:S0264-410X(24)00013-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HICKEN A, Jones P, Menon A, Rozek LS, et al
Can endorsement by religious leaders move the needle on vaccine hesitancy?
Vaccine. 2024 Jan 18:S0264-410X(24)00006-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MEMEDOVICH A, Orr T, Hollis A, Salmon C, et al
Social network risk factors and COVID-19 vaccination: A cross-sectional survey study.
Vaccine. 2024 Jan 18:S0264-410X(24)00005-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GRIMA AA, Kwong JC, Richard L, Reid J, et al
The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.
Vaccine. 2024 Jan 17:S0264-410X(24)00023-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LEMMER Y, Chapman R, Abolnik C, Smith T, et al
Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters.
Vaccine. 2024 Jan 17:S0264-410X(24)00036-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

FIEBELKORN AP, Adelsberg S, Anthony R, Ashenafi S, et al
The role of funded partnerships in working towards decreasing COVID-19 vaccination disparities, United States, March 2021-December 2022.
Vaccine. 2024 Jan 17:S0264-410X(23)01507-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

FAN J, Song Y, Cong S, Millman AJ, et al
Assessing interventions to encourage primary care health workers to recommend influenza vaccination and the impact on vaccination uptake for persons with Non-Communicable diseases in China.
Vaccine. 2024 Jan 16:S0264-410X(24)00011-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HARALAMBIEVA IH, Monroe JM, Ovsyannikova IG, Warner ND, et al
Restricted Omicron-specific cross-variant memory B-cell immunity after a 3rd dose/booster of monovalent Wuhan-Hu-1-containing COVID-19 mRNA vaccine.
Vaccine. 2024 Jan 16:S0264-410X(24)00032-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KING ML
How manufacturing won or lost the COVID-19 vaccine race.
Vaccine. 2024 Jan 15:S0264-410X(23)01477-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MCADAM E, Hayashi K, Barker B, Reddon H, et al
COVID-19 vaccination among young people who use drugs in Vancouver, Canada.
Vaccine. 2024 Jan 14:S0264-410X(24)00009-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

NAUTA J
Estimand for non-inferiority influenza vaccine immunogenicity trials.
Vaccine. 2024 Jan 13:S0264-410X(24)00014-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

RATISHVILI T, Quach HQ, Haralambieva IH, Suryawanshi YR, et al
A multifaceted approach for identification, validation, and immunogenicity of naturally processed and in silico-predicted highly conserved SARS-CoV-2 peptides.
Vaccine. 2024;42:162-174.
PubMed Abstract available

VAN ROEKEL C, Labuschagne L, Pijpers J, van Roon A, et al
Factors associated with COVID-19 autumn 2022 booster uptake in the Netherlands among older adults aged >/= 60 years and younger adults with chronic conditions.
Vaccine. 2024;42:146-155.
PubMed Abstract available

PARK SI, Park S, Lee K, Kwak HW, et al
Intranasal immunization with the recombinant measles virus encoding the spike protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters.
Vaccine. 2024;42:69-74.
PubMed Abstract available

REN S, Chen Q, Zhang Y, Yi L, et al
Modeling the optimal seasonal monoclonal antibody administration strategy for respiratory syncytial virus (RSV) prevention based on age-season specific hospitalization rate of RSV in Suzhou, China, 2016-2022.
Vaccine. 2024;42:352-361.
PubMed Abstract available

GOLDIN S, Moen A, Moss WJ, Nuzzo J, et al
Assessing the relationship between existing childhood, adolescent and adult immunization programmes and national COVID-19 vaccination capacities in 2021.
Vaccine. 2024 Jan 11:S0264-410X(23)01484-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

QURESHI NS, Miller LG, Judge SP, Tran NDT, et al
Characterizing predictors of COVID-19 vaccine refusal in an urban southern California jail population.
Vaccine. 2024 Jan 9:S0264-410X(24)00017-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HINSON-ENSLIN AM, Espinoza LE
The mental health symptoms of individuals with sensory disabilities and the reasons that lead to COVID-19 vaccine refusal and hesitancy.
Vaccine. 2024 Jan 9:S0264-410X(24)00012-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SHARP M, Lozano P, Southworth A, Peters A, et al
Mixed methods approach to understanding COVID-19 vaccine hesitancy among immigrants in the Chicago.
Vaccine. 2024 Jan 9:S0264-410X(23)01508-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

STELETOU E, Giannouchos T, Dimitriou G, Karatza A, et al
Parental concerns and vaccine hesitancy against COVID-19 vaccination for children in Greece: A cross-sectional survey.
Vaccine. 2024 Jan 6:S0264-410X(24)00003-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

STONE ND, Parker Fiebelkorn A, Guo A, Mothershed E, et al
Challenges and opportunities during the COVID-19 vaccination efforts in long-term care.
Vaccine. 2024 Jan 5:S0264-410X(23)01510-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KRANZLER EC, Ihongbe TO, Marshall MC, Denison B, et al
Racial and ethnic differences in COVID-19 vaccine readiness among adults in the United States, January 2021-April 2023.
Vaccine. 2024 Jan 4:S0264-410X(23)01537-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BUHL C, Jacobsen R, Almarsdottir AB, Abtahi S, et al
Public's perspective on COVID-19 adenovirus vector vaccines after thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions - A cross-sectional study in six EU member states.
Vaccine. 2024 Jan 4:S0264-410X(23)01511-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CHARPIGNON ML, Gupta S, Shahnaz Majumder M
Massachusetts companion program bolsters COVID-19 vaccine rates among seniors.
Vaccine. 2024 Jan 3:S0264-410X(23)01494-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

DAVIDSON AM, Burns S, White LA, Perlman M, et al
"I shall not poison my child with your human experiment": Investigating predictors of parents' hesitancy about vaccinating younger children (<12) in Canada.
Vaccine. 2024 Jan 2:S0264-410X(23)01519-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

AGASSE E, Rodriguez GF, Vilarino V, Galli JH, et al
Social determinants of health and vaccine uptake in pregnancy: Disparities in a diverse, predominately foreign-born population.
Vaccine. 2024 Jan 2:S0264-410X(23)01515-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

VASHI MD, Watkins M
Missed opportunities: Reducing zero dose children amongthe urban poor after COVID, Mumbai India, 2022.
Vaccine. 2024;42:59-63.
PubMed Abstract available

December 2023

RUBIO-CASILLAS A, Rodriguez-Quintero CM, Redwan EM, Gupta MN, et al
Do vaccines increase or decrease susceptibility to diseases other than those they protect against?
Vaccine. 2023 Dec 28:S0264-410X(23)01506-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BARZEN G, Rieber F, Stangl K, Hahn K, et al
mRNA vaccines for COVID-19 are safe and clinically effective in patients with cardiac amyloidosis.
Vaccine. 2023 Dec 28:S0264-410X(23)01487-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

OLIVER SE, Wallace M, Twentyman E, Moulia DL, et al
Development of COVID-19 vaccine policy - United States, 2020-2023.
Vaccine. 2023 Dec 28:S0264-410X(23)01466-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

GHARPURE R, Akumu AO, Dawa J, Gobin S, et al
Costs of seasonal influenza vaccine delivery in a pediatric demonstration project for children aged 6-23 months - Nakuru and Mombasa Counties, Kenya, 2019-2021.
Vaccine. 2023 Dec 27:S0264-410X(23)01475-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

FONSECA HAR, Zimerman A, Monfardini F, Guimaraes HP, et al
In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: A prespecified analysis of the VIP-ACS trial.
Vaccine. 2023 Dec 27:S0264-410X(23)01531-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SHENTON P, Schrader S, Smith J, Alafaci A, et al
Long term follow up and outcomes of Covid-19 vaccine associated myocarditis in Victoria, Australia: A clinical surveillance study.
Vaccine. 2023 Dec 27:S0264-410X(23)01516-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SURTEES TC, Granade CJ, Wells C, Banks M, et al
CDC COVID-19 vaccination program: Healthcare provider compliance with COVID-19 vaccine requirements and recommendations.
Vaccine. 2023 Dec 27:S0264-410X(23)01467-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

NGUYEN KH, Coy KC, Black CL, Scanlon P, et al
Comparison of adult hesitancy towards COVID-19 vaccines and vaccines in general in the USA.
Vaccine. 2023 Dec 23:S0264-410X(23)01488-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SEPPALA E, Dahl J, Veneti L, Rydland KM, et al
Covid-19 and influenza vaccine effectiveness against associated hospital admission and death among individuals over 65 years in Norway: A population-based cohort study, 3 October 2022 to 20 June 2023.
Vaccine. 2023 Dec 22:S0264-410X(23)01496-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KACHKO A, Selvaraj P, Liu S, Kim J, et al
Vaccine-associated respiratory pathology correlates with viral clearance and protective immunity after immunization with self-amplifying RNA expressing the spike (S) protein of SARS-CoV-2 in mouse models.
Vaccine. 2023 Dec 22:S0264-410X(23)01498-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LO E, Brousseau N, Defay F, Fortin E, et al
Neighborhood-level vaccine impact on COVID-19 infection and hospital admission in Quebec, Canada, during the Delta and early Omicron periods.
Vaccine. 2023 Dec 22:S0264-410X(23)01489-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KURIYAMA K, Murakami K, Sugiura K, Sakui S, et al
Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial.
Vaccine. 2023 Dec 20:S0264-410X(23)01482-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LINK-GELLES R, Britton A, Fleming-Dutra KE
Building the U.S. COVID-19 vaccine effectiveness program: Past successes and future directions.
Vaccine. 2023 Dec 20:S0264-410X(23)01435-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

WOLFF M, Charpentier P, Canals A, Vial C, et al
Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study.
Vaccine. 2023 Dec 19:S0264-410X(23)01481-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MIRIERI H, Nasimiyu C, Dawa J, Mburu C, et al
Resilience of routine childhood immunization services in two counties in Kenya in the face of the COVID-19 pandemic.
Vaccine. 2023;41:7695-7704.
PubMed Abstract available

STUMPF J, Anders L, Siepmann T, Schwobel J, et al
9-Month observational Dia-Vacc study of vaccine type influence on SARS-CoV-2 immunity in dialysis and kidney transplant patients.
Vaccine. 2023 Dec 18:S0264-410X(23)01479-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ARASHIRO T, Miwa M, Nakagawa H, Takamatsu J, et al
COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy, invasive mechanical ventilation, and death in Japan: A multicenter case-control study (MOTIVATE study).
Vaccine. 2023 Dec 18:S0264-410X(23)01480-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

DAWA J, Jalang'o R, Mirieri H, Kalani R, et al
Comparing performance of year-round and campaign-mode influenza vaccination strategies among children aged 6-23 months in Kenya: 2019-2021.
Vaccine. 2023 Dec 16:S0264-410X(23)01380-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

JACKSON LA, Stapleton JT, Walter EB, Chen WH, et al
Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults.
Vaccine. 2023 Dec 16:S0264-410X(23)01434-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

JIANG W, Lu C, Yan X, Tucker JD, et al
Vaccine confidence mediates the association between a pro-social pay-it-forward intervention and improved influenza vaccine uptake in China: A mediation analysis.
Vaccine. 2023 Dec 15:S0264-410X(23)01392-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ZHAN XY, Chen Y, Zhang X, Shi Q, et al
Characterization of SARS-CoV-2-specific humoral immunity and associated factors in the healthy population post-vaccination.
Vaccine. 2023 Dec 15:S0264-410X(23)01465-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BAJRACHARYA D, Jansen RJ
Observations of COVID-19 vaccine coverage and vaccine hesitancy on COVID-19 outbreak: An American ecological study.
Vaccine. 2023 Dec 15:S0264-410X(23)01441-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BURNS KE, Dube E, Godinho Nascimento H, Meyer SB, et al
Examining vaccine hesitancy among a diverse sample of Canadian adults.
Vaccine. 2023 Dec 15:S0264-410X(23)01476-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

DONG C, Ma Y, Zhu W, Wang Y, et al
Influenza immune imprinting synergizes PEI-HA/CpG nanoparticle vaccine protection against heterosubtypic infection in mice.
Vaccine. 2023 Dec 14:S0264-410X(23)01485-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

FERRONI E, Gennaro N, Maifredi G, Leoni O, et al
Access to SARS-CoV-2 vaccination in immigrants in Italy, by geographical area of origin.
Vaccine. 2023 Dec 13:S0264-410X(23)01387-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CAO Z, Yu R, Yuan Q, Ji W, et al
Impact of the COVID-19 pandemic on routine vaccination coverage under varying prevalence Conditions: A cohort study in Beijing, China.
Vaccine. 2023 Dec 13:S0264-410X(23)01447-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SCHARF LG, Adeniyi K, Augustini E, Boyd D, et al
Monitoring and reporting the US COVID-19 vaccination effort.
Vaccine. 2023 Dec 13:S0264-410X(23)01438-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

O'NEIL SS, Pendl-Robinson EL, Carosella EA, Sullivan BD, et al
The importance of community-specific survey data in understanding behavioral and social drivers of COVID-19 vaccination: Lessons learned from urban neighborhoods in four United States cities.
Vaccine. 2023 Dec 12:S0264-410X(23)01450-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

OPRIESSNIG T, Gauger PC, Filippsen Favaro P, Rawal G, et al
An experimental universal swine influenza a virus (IAV) vaccine candidate based on the M2 ectodomain (M2e) peptide does not provide protection against H1N1 IAV challenge in pigs.
Vaccine. 2023 Dec 11:S0264-410X(23)01445-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LYTRAS T, Di Gregorio AAA, Apostolopoulos D, Naziris D, et al
Effectiveness of COVID-19 vaccine mandates in raising vaccination rates among the elderly and general population in Europe: Controlled interrupted time series analysis.
Vaccine. 2023 Dec 11:S0264-410X(23)01472-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

AKMATOVA R, Dzhangaziev B, Ebama MS, Otorbaeva D, et al
Knowledge, attitudes, and practices (KAP) towards seasonal influenza and influenza vaccine among pregnant women in Kyrgyzstan: A cross-sectional study.
Vaccine. 2023 Dec 9:S0264-410X(23)01453-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MESIDOR M, Liu Y, Talbot D, Skowronski DM, et al
Test negative design for vaccine effectiveness estimation in the context of the COVID-19 pandemic: A systematic methodology review.
Vaccine. 2023 Dec 9:S0264-410X(23)01446-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SUI Y, Andersen H, Li J, Hoang T, et al
SARS-CoV-2 mucosal vaccine protects against clinical disease with sex bias in efficacy.
Vaccine. 2023 Dec 8:S0264-410X(23)01426-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

DI CHIARA C, Cantarutti A, Raffaella Petrara M, Bonfante F, et al
Stronger and durable SARS-CoV-2 immune response to mRNA vaccines in 5-11 years old children with prior COVID-19.
Vaccine. 2023 Dec 8:S0264-410X(23)01439-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CHENG DR, Reimer H, Le D, Crawford NW, et al
Analyzing an immunization resource website: User browsing trends.
Vaccine. 2023;41:7498-7502.
PubMed Abstract available

YU Y, Zhang X, Lau MMC, Lau JTF, et al
The intention to get COVID-19 booster vaccination and its association with cognitive and emotional factors: A survey of Chinese COVID-19 infected people in Hong Kong.
Vaccine. 2023 Dec 7:S0264-410X(23)01448-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

GRAMACHO W, Turgeon M, Santos Mundim P, Pereira I, et al
Why did Brazil fail to vaccinate children against COVID-19 during the pandemic? An assessment of attitudinal and behavioral determinants.
Vaccine. 2023 Dec 6:S0264-410X(23)01432-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CANEVARI JT, Cheng AC, Wu L, Rowe SL, et al
The relative effectiveness of three and four doses of COVID-19 vaccine in Victoria, Australia: A data linkage study.
Vaccine. 2023 Dec 5:S0264-410X(23)01393-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MADNI SA, Sharma AJ, Zauche LH, Waters AV, et al
CDC COVID-19 Vaccine Pregnancy Registry: Design, data collection, response rates, and cohort description.
Vaccine. 2023 Dec 5:S0264-410X(23)01423-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

PRASERT K, Praphasiri P, Lerdsamran H, Nakphook S, et al
Safety and immunogenicity of locally produced trivalent inactivated influenza vaccine (Tri Fluvac) in healthy Thai adults aged 18-64 years in Nakhon Phanom: A Phase III double blinded, three-arm, randomized, controlled trial.
Vaccine. 2023 Dec 1:S0264-410X(23)01396-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

GASHTI AB, Agbayani G, Hrapovic S, Nassoury N, et al
Production, purification and immunogenicity of Gag virus-like particles carrying SARS-CoV-2 components.
Vaccine. 2023 Dec 1:S0264-410X(23)01394-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

November 2023

WANG Y, Hu Y, Ma Y, Li P, et al
RBD class 1 and 2 antibody epitopes elicit around 70% neutralizing capacity against SARS-CoV-2 virus following boosting with inactivated virus vaccine.
Vaccine. 2023 Nov 27:S0264-410X(23)01381-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

NISHIYAMA T, Miyamatsu Y, Park H, Nakamura N, et al
Modeling COVID-19 vaccine booster-elicited antibody response and impact of infection history.
Vaccine. 2023 Nov 25:S0264-410X(23)01384-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

DUCASA N, Benencio P, Mauro E, Anders M, et al
Evaluation of the humoral response to the third dose of SARS-COV-2 vaccines in liver transplant recipients.
Vaccine. 2023 Nov 24:S0264-410X(23)01383-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

PAYNE AB, Ciesla AA, Rowley EAK, Weber ZA, et al
Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design.
Vaccine. 2023 Nov 23:S0264-410X(23)01337-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

FITZPATRICK MC, Laufer RS, Baral R, Driscoll AJ, et al
Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022.
Vaccine. 2023;41:7047-7059.
PubMed Abstract available

WANG B, McDonough J, Chen G, Ong JJ, et al
Sociodemographic factors and attitudes associated with Australian parental acceptance of paediatric COVID-19 vaccination.
Vaccine. 2023 Nov 22:S0264-410X(23)01336-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

NEELY SR, Hao F
Breakthrough COVID-19 infections and perceived vaccine effectiveness.
Vaccine. 2023 Nov 22:S0264-410X(23)01365-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ZURCHER SJ, Signorell A, Lechot-Huser A, Aebi C, et al
Childhood vaccination coverage and regional differences in Swiss birth cohorts 2012-2021: Are we on track?
Vaccine. 2023;41:7226-7233.
PubMed Abstract available

ECONOMIDOU EC, Soteriades ES
Excess mortality in Cyprus during the COVID-19 vaccination campaign.
Vaccine. 2023 Nov 22:S0264-410X(23)01361-0. doi: 10.1016/j.vaccine.2023.
PubMed

LAW AW, Judy J, Atwell JE, Willis S, et al
Maternal Tdap and influenza vaccination uptake 2017-2021 in the United States: Implications for maternal RSV vaccine uptake in the future.
Vaccine. 2023 Nov 21:S0264-410X(23)01307-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

NAUGLE D, Tibbels N, Dosso A, Benie W, et al
"I'd do it for my baby": Lessons learned from qualitative research on COVID-19 vaccination among pregnant women in Cote d'Ivoire.
Vaccine. 2023 Nov 19:S0264-410X(23)01333-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HAEDER SF
Assessing parental intention to vaccinate against COVID-19, influenza, and RSV in the United States in late 2023.
Vaccine. 2023 Nov 15:S0264-410X(23)01303-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

AMITAI N, Wertheimer R, Prais D, Wertheimer KO, et al
Influenza vaccination in children with pulmonary disease during the COVID-19 pandemic.
Vaccine. 2023 Nov 15:S0264-410X(23)01338-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CHOI Y, Park S, Lee J, Kim Y, et al
Who gets COVID-19 booster vaccination? Trust in public health institutions and promotion strategies post-pandemic in the Republic of Korea.
Vaccine. 2023 Nov 15:S0264-410X(23)01294-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SARAFIAN JT, Eucker SA, Gillman M, DeLaroche AM, et al
Impact of a hypothetical COVID-19 vaccine mandate on parental likelihood to vaccinate children: Exploring school-related concerns and vaccination decision-making.
Vaccine. 2023 Nov 14:S0264-410X(23)01334-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

PLUMB ID, Briggs Hagen M, Wiegand R, Dumyati G, et al
Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022-May 2023.
Vaccine. 2023 Nov 14:S0264-410X(23)01287-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

GUBERNOT D, Menis M, Whitaker B
Background rates for severe cutaneous reactions in the US: Contextual support for safety assessment of COVID-19 vaccines and novel biologics.
Vaccine. 2023;41:6922-6929.
PubMed Abstract available

LASRADO N, Collier AY, Hachmann NP, Miller J, et al
Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86.
Vaccine. 2023;41:6904-6909.
PubMed Abstract available

GOTO T, Chong Y, Tani N, Susai N, et al
Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection.
Vaccine. 2023;41:7019-7025.
PubMed Abstract available

CUBIZOLLES C, Barjat T, Chauleur C, Bruel S, et al
Evaluation of intentions to get vaccinated against influenza, COVID 19, pertussis and to get a future vaccine against respiratory syncytial virus in pregnant women.
Vaccine. 2023 Nov 12:S0264-410X(23)01280-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

JIANG X, Wang J, Li C, Yeoh EK, et al
Impact of the surge of COVID-19 Omicron outbreak on the intention of seasonal influenza vaccination in Hong Kong: A cross-sectional study.
Vaccine. 2023 Nov 11:S0264-410X(23)01304-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

GRABENSTEIN JD, Ferrara P, Mantovani LG, McGovern I, et al
Evaluating risk of bias using ROBINS-I tool in nonrandomized studies of adjuvanted influenza vaccine.
Vaccine. 2023 Nov 10:S0264-410X(23)01302-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HERZIG VAN WEES S, Stalgren M, Viberg N, Puranen B, et al
"Who is Anders Tegnell?" Unanswered questions hamper COVID-19 vaccine uptake: A qualitative study among ethnic minorities in Sweden.
Vaccine. 2023 Nov 10:S0264-410X(23)01328-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BRUXVOORT KJ, Sy LS, Hong V, Lewin B, et al
Factors associated with uptake of bivalent mRNA COVID-19 vaccines in a large US health care system.
Vaccine. 2023 Nov 10:S0264-410X(23)01324-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

DUDLEY MZ, Schwartz B, Brewer J, Kan L, et al
COVID-19 vaccination attitudes, values, intentions: US parents for their children, September 2021.
Vaccine. 2023 Nov 9:S0264-410X(23)01295-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ANDERSON EC, Blair PS, Finn A, Ingram J, et al
Maternal vaccination provision in NHS maternity trusts across England.
Vaccine. 2023 Nov 9:S0264-410X(23)01284-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

YANG C, Zheng Z, Zheng P, Chen J, et al
Inactivated COVID-19 vaccines in peri-pregnancy period: Evaluation of safety for both pregnant women and neonates.
Vaccine. 2023 Nov 8:S0264-410X(23)01322-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

INOUE Y, Li Y, Yamamoto S, Fukunaga A, et al
The association between antipyretic analgesics use and SARS-CoV-2 antibody titers following the second dose of the BNT162b2 mRNA vaccine: An observational study.
Vaccine. 2023 Nov 7:S0264-410X(23)01220-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SPACKMAN E, Suarez DL, Lee CW, Pantin-Jackwood MJ, et al
Efficacy of inactivated and RNA particle vaccines against a North American Clade 2.3.4.4b H5 highly pathogenic avian influenza virus in chickens.
Vaccine. 2023 Nov 4:S0264-410X(23)01285-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HANSEN LG, Larsen LE, Rasmussen TB, Miar Y, et al
Investigation of the SARS-CoV-2 post-vaccination antibody response in Canadian farmed mink.
Vaccine. 2023 Nov 4:S0264-410X(23)01288-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

JONES G, Perry M, Bailey R, Arumugam S, et al
Dimensions of equality in uptake of COVID-19 vaccination in Wales, UK: A multivariable linked data population analysis.
Vaccine. 2023 Nov 4:S0264-410X(23)01279-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

AKHTAR Z, Gotberg M, Erlinge D, Christiansen EH, et al
Optimal timing of influenza vaccination among patients with acute myocardial infarction - Findings from the IAMI trial.
Vaccine. 2023 Nov 2:S0264-410X(23)01211-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CHEN GL, Yu XY, Luo LP, Zhang F, et al
Phase I study of a non-S2P SARS-CoV-2 mRNA vaccine LVRNA009 in Chinese adults.
Vaccine. 2023 Nov 2:S0264-410X(23)01278-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BOLOTIN S, Osman S, Halperin S, Severini A, et al
Immunity of Canadians and risk of epidemics workshop - Conference report.
Vaccine. 2023;41:6775-6781.
PubMed Abstract available

DO LAH, Le NTN, Mahmud S, Mulholland K, et al
Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study.
Vaccine. 2023;41:6782-6790.
PubMed Abstract available

ALIZADEH M, Raj S, Shojadoost B, Matsuyama-Kato A, et al
In ovo administration of retinoic acid enhances cell-mediated immune responses against an inactivated H9N2 avian influenza virus vaccine.
Vaccine. 2023 Nov 1:S0264-410X(23)01261-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

JAMES WG, Stanberry LR, LaRussa PS, Grodman MD, et al
Vaccines and global health: COVID-19 vaccine development, strategy, and implementation symposium - Summary of the meeting at Vagelos College of Physicians and Surgeons (February 22-26, 2021, New York).
Vaccine. 2023 Nov 1:S0264-410X(23)01254-9. doi: 10.1016/j.vaccine.2023.
PubMed

October 2023

RAMSAY JA, Jones M, Vande More AM, Hunt SL, et al
A single blinded, phase IV, adaptive randomised control trial to evaluate the safety of coadministration of seasonal influenza and COVID-19 vaccines (The FluVID study).
Vaccine. 2023 Oct 28:S0264-410X(23)01250-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SALLOUM M, Paviotti A, Bastiaens H, Van Geertruyden JP, et al
The inclusion of pregnant women in vaccine clinical trials: An overview of late-stage clinical trials' records between 2018 and 2023.
Vaccine. 2023 Oct 28:S0264-410X(23)01259-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LIU Y, Sanchez-Ovando S, Carolan L, Dowson L, et al
Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines.
Vaccine. 2023 Oct 28:S0264-410X(23)01217-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

NYAMBAYO PPM, Gold MS, Mehta UC, Clarke S, et al
Efficacy and feasibility of SMS m-Health for the detection of adverse events following immunisation (AEFIs) in resource-limited setting-The Zimbabwe stimulated telephone assisted rapid safety surveillance (Zm-STARSS) randomised control trial.
Vaccine. 2023;41:6700-6709.
PubMed Abstract available

TANI N, Ikematsu H, Goto T, Kondo S, et al
Correlation between specific antibody response to wild-type BNT162b2 booster and the risk of breakthrough infection with omicron variants: Impact of household exposure in hospital healthcare workers.
Vaccine. 2023;41:6672-6678.
PubMed Abstract available

WALLIAR T, Khan B, Newstead S, Al-Assadi G, et al
"Fighting the pandemic!" Western Australian pharmacists' perspectives on COVID-19 vaccines: A qualitative study.
Vaccine. 2023 Oct 25:S0264-410X(23)01243-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ANASTASSOPOULOU C, Boufidou F, Hatziantoniou S, Vasileiou K, et al
Adverse events of acute nephrotoxicity reported to EudraVigilance and VAERS after COVID-19 vaccination.
Vaccine. 2023 Oct 25:S0264-410X(23)01214-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CENAT JM, Moshirian Farahi SMM, Broussard C, Dalexis RD, et al
The state of COVID-19 vaccine confidence and need in Black individuals in Canada: Understanding the role of sociodemographic factors, health literacy, conspiracy theories, traumatic stressors and racial discrimination.
Vaccine. 2023 Oct 25:S0264-410X(23)01246-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KITIKOON P, Knetter SM, Mogler MA, Morgan CL, et al
Quadrivalent neuraminidase RNA particle vaccine protects pigs against homologous and heterologous strains of swine influenza virus infection.
Vaccine. 2023 Oct 24:S0264-410X(23)01175-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

FLOR N, Garcia MI, Molineri A, Bottasso O, et al
Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection.
Vaccine. 2023 Oct 24:S0264-410X(23)01221-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BRESEE J, Koh M, Chadwick C, Jit M, et al
The need and ongoing efforts to understand the full value of improved influenza vaccines.
Vaccine. 2023 Oct 21:S0264-410X(23)01245-8. doi: 10.1016/j.vaccine.2023.
PubMed

WANGCHUK S, Prabhakaran AO, Dhakal GP, Zangmo C, et al
Introducing seasonal influenza vaccine in Bhutan: Country experience and achievements.
Vaccine. 2023 Oct 20:S0264-410X(23)01255-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

IRVING SA, Groom HC, Belongia EA, Crane B, et al
Influenza vaccination coverage among persons ages six months and older in the Vaccine Safety Datalink in the 2017-18 through 2022-23 influenza seasons.
Vaccine. 2023 Oct 20:S0264-410X(23)01206-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

TUNIS M, Deeks S, Harrison R, Quach C, et al
Canada's National Advisory Committee on immunization: Adaptations and challenges during the COVID-19 pandemic.
Vaccine. 2023;41:6538-6547.
PubMed Abstract available

MORI Y, Uchida N, Wake A, Miyawaki K, et al
Impact of a third dose of anti-SARS-CoV-2 vaccine in hematopoietic cell transplant recipients: A Japanese multicenter observational study.
Vaccine. 2023 Oct 20:S0264-410X(23)01022-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HART R, Feygin Y, Kluthe T, Quinn KG, et al
Emergency departments: An underutilized resource to address pediatric influenza vaccine coverage.
Vaccine. 2023 Oct 19:S0264-410X(23)01222-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MCCLYMONT E, Atkinson A, Albert A, Av-Gay G, et al
Reactogenicity, pregnancy outcomes, and SARS-CoV-2 infection following COVID-19 vaccination during pregnancy in Canada: A national prospective cohort study.
Vaccine. 2023 Oct 19:S0264-410X(23)01215-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HONDA-OKUBO Y, Bowen R, Barker M, Bielefeldt-Ohmann H, et al
Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants.
Vaccine. 2023 Oct 18:S0264-410X(23)01190-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

RIEFOLO F, Castillo-Cano B, Martin-Perez M, Messina D, et al
Effectiveness of homologous/heterologous booster COVID-19 vaccination schedules against severe illness in general population and clinical subgroups in three European countries.
Vaccine. 2023 Oct 17:S0264-410X(23)01181-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HAEDER SF
U.S. public support and opposition to vaccination mandates in K-12 education in light of the COVID-19 pandemic.
Vaccine. 2023 Oct 17:S0264-410X(23)01188-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

YANG H, Wang Z, Zhang Y, Xu M, et al
Effectiveness of inactivated COVID-19 vaccines against SARS-CoV-2 Omicron subvariant BF.7 among outpatients in Beijing, China.
Vaccine. 2023 Oct 17:S0264-410X(23)01219-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

PLATENBURG PPLI, Deschamps F, Jung J, Leonard C, et al
Carbohydrate fatty acid monosulphate ester is a potent adjuvant for low-dose seasonal influenza vaccines.
Vaccine. 2023 Oct 16:S0264-410X(23)01189-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LOPEZ-GOMEZ A, Pelaez-Prestel HF, Juarez I
Approaches to evaluate the specific immune responses to SARS-CoV-2.
Vaccine. 2023;41:6434-6443.
PubMed Abstract available

MOSCA S, Lin Q, Stokes R, Bharucha T, et al
Innovative method for rapid detection of falsified COVID-19 vaccines through unopened vials using handheld Spatially Offset Raman Spectroscopy (SORS).
Vaccine. 2023 Oct 13:S0264-410X(23)01182-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ARASHIRO T, Arima Y, Kuramochi J, Muraoka H, et al
Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1/BA.2 and BA.5 in Japan.
Vaccine. 2023 Oct 13:S0264-410X(23)01194-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

PARK H, Jang MS, Choi JA, Kim W, et al
Nonclinical safety assessment and immunogenicity of rVSVInd(GML)-mspSGtc vaccine for SARS-CoV-2 in rabbits.
Vaccine. 2023 Oct 9:S0264-410X(23)01178-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MO C, Li X, Wu Q, Fan Y, et al
SARS-CoV-2 mRNA vaccine requires signal peptide to induce antibody responses.
Vaccine. 2023 Oct 9:S0264-410X(23)01156-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SATHE N, Shaikh S, Bhavsar M, Parte L, et al
Safety, immunogenicity and efficacy of Relcovax(R), a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus.
Vaccine. 2023 Oct 8:S0264-410X(23)01176-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LOPEZ-ZAMBRANO MA, Pita CC, Escribano MF, Galan Melendez IM, et al
Factors associated to influenza vaccination among hospital's healthcare workers in the Autonomous Community of Madrid, Spain 2021-2022.
Vaccine. 2023 Oct 6:S0264-410X(23)01117-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

PROCTER TD, Ogasawara H, Spruin S, Wijayasri S, et al
Thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector COVID-19 vaccination in Canada.
Vaccine. 2023 Oct 6:S0264-410X(23)01159-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

OZAWA S, Schuh HB, Nakamura T, Yemeke TT, et al
How to increase and maintain high immunization coverage: Vaccination Demand Resilience (VDR) framework.
Vaccine. 2023 Oct 3:S0264-410X(23)01097-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ZACHRESON C, Tobin R, Szanyi J, Walker C, et al
Individual variation in vaccine immune response can produce bimodal distributions of protection.
Vaccine. 2023 Oct 2:S0264-410X(23)01095-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

September 2023

OKOLI GN, Righolt CH, Zhang G, Alessi-Severini S, et al
Impact of the universal seasonal influenza vaccination policy in the province of Manitoba, Canada: A population-based, province-wide record-linkage study.
Vaccine. 2023 Sep 29:S0264-410X(23)01133-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

DIONNE M, Sauvageau C, Kiely M, Rathwell M, et al
"The problem is not lack of information": A qualitative study of parents and school nurses' perceptions of barriers and potential solutions for HPV vaccination in schools.
Vaccine. 2023 Sep 28:S0264-410X(23)01140-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HARBOE ZB, Hald A, Ekenberg C, Ete Wareham N, et al
Implementation of a vaccination clinic for adult solid organ transplant candidates: A single-center experience.
Vaccine. 2023 Sep 27:S0264-410X(23)01106-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LAVELL AHA, Schramade AE, Sikkens JJ, van der Straten K, et al
25-Hydroxyvitamin D concentrations do not affect the humoral or cellular immune response following SARS-CoV-2 mRNA vaccinations.
Vaccine. 2023 Sep 27:S0264-410X(23)00957-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SHEN X, Hao Y, Wang S, Li D, et al
Sequential heterologous immunization with COVID-19 vaccines induces broader neutralizing responses against SARS-CoV-2 variants in comparison with homologous boosters.
Vaccine. 2023 Sep 26:S0264-410X(23)01100-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CASSARINO N, Ahnger-Pier KK, Wurcel A
Trends in COVID-19 and influenza vaccine ordering and distribution in Massachusetts jails.
Vaccine. 2023 Sep 25:S0264-410X(23)01115-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SANA S, Merkelbach I, Magnee T, Kollmann J, et al
Identifying barriers to vaccination intention at walk-in vaccination facilities in deprived neighbourhoods: A cross-sectional survey.
Vaccine. 2023 Sep 25:S0264-410X(23)01038-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

GOLOVKINA MI, Ertz SC, Lechnir SS, Hayney MS, et al
Providing influenza vaccines at endoscopy visits increases influenza vaccine uptake.
Vaccine. 2023 Sep 23:S0264-410X(23)01108-8. doi: 10.1016/j.vaccine.2023.
PubMed

RAISER F, Davis M, Adelglass J, Cai MR, et al
Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.
Vaccine. 2023;41:5965-5973.
PubMed Abstract available

HAO F, Shao W
Social network, political climate, income inequality, and Americans uptake of monovalent COVID-19 booster.
Vaccine. 2023;41:6077-6082.
PubMed Abstract available

NGAMCHALIEW P, Kaewkuea N, Nonthasorn N, Vonnasrichan T, et al
Acceptance of COVID-19 vaccination and vaccine confidence levels in Thailand: A cross-sectional study.
Vaccine. 2023 Sep 22:S0264-410X(23)01088-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HOMAIRA N, He WQ, McRae J, Macartney K, et al
Coverage and predictors of influenza and pertussis vaccination during pregnancy: a whole of population-based study.
Vaccine. 2023 Sep 21:S0264-410X(23)01062-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

FU Y, Wu K, Wang Z, Yang H, et al
Effectiveness of various COVID-19 vaccine regimens among 10.4 million patients from the National COVID Cohort Collaborative during Pre-Delta to Omicron periods - United States, 11 December 2020 to 30 June 2022.
Vaccine. 2023 Sep 21:S0264-410X(23)01025-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

WILKINSON B, Patel KS, Smith K, Walker R, et al
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 vir
Vaccine. 2023 Sep 20:S0264-410X(23)00871-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ALHARBI HS
Review: Factors influencing parents' decisions to vaccinate children against COVID-19.
Vaccine. 2023 Sep 19:S0264-410X(23)01090-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HAN C, Zhao ZZ, Chan P, Li F, et al
A large survey on COVID-19 vaccination in patients with Parkinson's disease and healthy population.
Vaccine. 2023 Sep 17:S0264-410X(23)01056-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

NELSON CB, Brady BL, Richards M, Lew CR, et al
Optimal site of care for administration of extended half-life respiratory syncytial virus (RSV) antibodies to infants in the United States (US).
Vaccine. 2023;41:5820-5824.
PubMed Abstract available

SHAVER N, Katz M, Darko Asamoah G, Linkins LA, et al
Protocol for a living evidence synthesis on variants of concern and COVID-19 vaccine effectiveness.
Vaccine. 2023 Sep 15:S0264-410X(23)01065-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

IRALA S, Hamid S, Penayo E, Michel F, et al
COVID-19 vaccine effectiveness against hospitalizations in Paraguay, May 2021-April 2022: A test-negative design.
Vaccine. 2023 Sep 14:S0264-410X(23)01069-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SURYAWANSHI YR
An overview of protein-based SARS-CoV-2 vaccines.
Vaccine. 2023 Sep 10:S0264-410X(23)01067-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

POTT H, Andrew MK, Shaffelburg Z, Nichols MK, et al
Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canad
Vaccine. 2023 Sep 9:S0264-410X(23)01026-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

YU J, Sreenivasan C, Sheng Z, Zhai SL, et al
A recombinant chimeric influenza virus vaccine expressing the consensus H3 hemagglutinin elicits broad hemagglutination inhibition antibodies against divergent swine H3N2 influenza viruses.
Vaccine. 2023 Sep 7:S0264-410X(23)01060-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MONTEIRO HS, Lima Neto AS, Kahn R, Sousa GS, et al
Impact of CoronaVac on Covid-19 outcomes of elderly adults in a large and socially unequal Brazilian city: A target trial emulation study.
Vaccine. 2023;41:5742-5751.
PubMed Abstract available

PATERNINA-CAICEDO A, Quevedo DS, Rios DS, Moyano D, et al
Comparative effectiveness and duration of protection of ChAdOx1, CoronaVac, BNT162b2, mRNA-1273, and Ad26.COV2.S COVID-19 vaccines for symptomatic and hospitalized Mu, Delta, and Omicron: A test-negative case-control study.
Vaccine. 2023 Sep 5:S0264-410X(23)01028-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

YUE PHR, Lau HPB, Ng SM, Chan LWC, et al
When to be vaccinated? What to consider? Modelling decision-making and time preference for COVID-19 vaccine through a conjoint experiment.
Vaccine. 2023 Sep 5:S0264-410X(23)01024-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

PHILLIPS A, Jiang Y, Walsh D, Andrews N, et al
Background rates of adverse events of special interest for COVID-19 vaccines: A multinational Global Vaccine Data Network (GVDN) analysis.
Vaccine. 2023 Sep 5:S0264-410X(23)01045-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ALSAIF F, Twigg M, Scott S, Blyth A, et al
A systematic review of barriers and enablers associated with uptake of influenza vaccine among care home staff.
Vaccine. 2023 Sep 4:S0264-410X(23)01048-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CLAESSENS T, Krouwer S, Vandebosch H, Poels K, et al
Pathways to informed choices: The impact of freedom of choice and two-sided messages on psychological reactance and vaccination intentions among individuals who express concerns.
Vaccine. 2023 Sep 3:S0264-410X(23)00948-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

WILLIS DE, Moore R, Andersen JA, Li J, et al
Correlates of COVID-19 vaccine coverage in Arkansas: Results from a weighted random sample survey.
Vaccine. 2023 Sep 1:S0264-410X(23)01039-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

PORRAS-RAMIREZ A, Sanchez-Paris R, Lopez-Devia W, Moreno-Perilla Z, et al
Confirmed cases of COVID-19 after vaccination against COVID in health personnel in Bogota, Colombia.
Vaccine. 2023 Sep 1:S0264-410X(23)00924-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

August 2023

SAKALA IG, Honda-Okubo Y, Petrovsky N
Developmental and reproductive safety of Advax-CpG55.2 adjuvanted COVID-19 and influenza vaccines in mice.
Vaccine. 2023 Aug 31:S0264-410X(23)01007-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

GRILLS LA, Wagner AL
The impact of the COVID-19 pandemic on parental vaccine hesitancy: A cross-sectional survey.
Vaccine. 2023 Aug 31:S0264-410X(23)00977-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

DUDLEY HM, O'Mara M, Auma A, Gong J, et al
Rheumatoid arthritis and older age are associated with lower humoral and cellular immune response to primary series COVID-19 mRNA vaccine.
Vaccine. 2023 Aug 31:S0264-410X(23)00965-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

REGAN AK, Fell DB, Wise LA, Vazquez-Benitez G, et al
Challenges & opportunities for the epidemiological evaluation of the effects of COVID-19 vaccination on reproduction and pregnancy.
Vaccine. 2023 Aug 31:S0264-410X(23)00964-7. doi: 10.1016/j.vaccine.2023.
PubMed

PHIRIYASART F, Aimyong N, Jirapongsuwan A, Roseh N, et al
COVID-19 vaccine hesitancy among older adult Thai Muslim people: A case-control study.
Vaccine. 2023 Aug 27:S0264-410X(23)00994-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

YANG J, Li B, Yang D, Wu J, et al
The immunogenicity of Alum+CpG adjuvant SARS-CoV-2 inactivated vaccine in mice.
Vaccine. 2023 Aug 26:S0264-410X(23)01017-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

JANSSEN ERC, van Montfoort AZ, Hollman F, Lambers Heerspink FO, et al
The prevalence and clinical course of shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccines in Dutch hospital workers.
Vaccine. 2023 Aug 25:S0264-410X(23)00975-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CHIBA S, Halfmann PJ, Iida S, Hirata Y, et al
Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2.
Vaccine. 2023 Aug 25:S0264-410X(23)01008-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CHEN IR, Wang GJ, Hsueh PR, Chou CH, et al
Immune responses and safety of COVID-19 vaccination in atypical hemolytic uremic syndrome patients in Taiwan.
Vaccine. 2023 Aug 25:S0264-410X(23)00952-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

WATERLOW NR, Procter SR, van Leeuwen E, Radhakrishnan S, et al
The potential cost-effectiveness of next generation influenza vaccines in England and Wales: A modelling analysis.
Vaccine. 2023 Aug 24:S0264-410X(23)00963-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MOHAMMED IS, Widome R, Searle KM
COVID-19 vaccine decision-making among Black women: A qualitative study.
Vaccine. 2023 Aug 24:S0264-410X(23)00920-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

DENG L, Tapper K, Thosar D, Goeman E, et al
Use of adrenaline to manage suspected anaphylaxis following COVID-19 vaccination: An Australian retrospective cohort study.
Vaccine. 2023 Aug 24:S0264-410X(23)00956-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

GOULD S, Wrzesinski C, Stebbings R, Segal L, et al
Report from an ICT 2022 workshop on toxicology for Covid19 vaccines: Industry, regulatory and CRO perspectives.
Vaccine. 2023 Aug 24:S0264-410X(23)00972-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

STRUYF F, Hardt K, Van Rampelbergh R, Shukarev G, et al
Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26.COV2.S.
Vaccine. 2023;41:5351-5359.
PubMed Abstract available

KUMRU OS, Sanyal M, Friedland N, Hickey JM, et al
Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines.
Vaccine. 2023 Aug 22:S0264-410X(23)00969-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SU Y, Guo Z, Gu X, Sun S, et al
Influenza vaccine effectiveness against influenza A during the delayed 2022/23 epidemic in Shihezi, China.
Vaccine. 2023 Aug 19:S0264-410X(23)00971-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

YAO T, Guo Y, Xu X, Zhang X, et al
Predictors of immune persistence induced by two-dose BBIBP-CorV vaccine in high-risk occupational population.
Vaccine. 2023 Aug 19:S0264-410X(23)00974-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KENIGSBERG TA, Goddard K, Hanson KE, Lewis N, et al
Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines.
Vaccine. 2023 Aug 18:S0264-410X(23)00955-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CHAIWONG W, Takheaw N, Pata S, Laopajon W, et al
Neutralizing antibody and T-cell responses against SARS-CoV-2 variants by heterologous CoronaVac/ChAdOx-1 vaccination in elderly subjects with chronic obstructive pulmonary disease.
Vaccine. 2023 Aug 18:S0264-410X(23)00966-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

PALACHE A, Billingsley JK, MacLaren K, Morgan L, et al
Lessons learned from the COVID-19 pandemic for improved influenza control.
Vaccine. 2023 Aug 17:S0264-410X(23)00960-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MORRISON K, Cullen L, James AB, Chua V, et al
Predictors of incomplete COVID-19 vaccine schedule among adults in Scotland: Two retrospective cohort analyses of the primary schedule and third dose.
Vaccine. 2023 Aug 17:S0264-410X(23)00916-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ZUR M, Shelef L, Glassberg E, Fink N, et al
Are intelligent people more likely to get vaccinated? The association between COVID-19 vaccine adherence and cognitive profiles.
Vaccine. 2023 Aug 15:S0264-410X(23)00951-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SARNA M, Gebremedhin A, Richmond P, Levy A, et al
Determining the true incidence of seasonal respiratory syncytial virus-confirmed hospitalizations in preterm and term infants in Western Australia.
Vaccine. 2023;41:5216-5220.
PubMed Abstract available

TOYAMA K, Eto T, Takazawa K, Shimizu S, et al
DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study.
Vaccine. 2023 Aug 14:S0264-410X(23)00824-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

WITTAWATMONGKOL O, Bunjoungmanee P, Kosalaraksa P, Laoprasopwattana K, et al
Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19 vaccination schedules with BNT162b2 boosters in 5-11-year-old Thai children: A multicenter, prospective, double-blind, randomized control trial.
Vaccine. 2023 Aug 14:S0264-410X(23)00953-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BERTHELEMY C, Bouche P, Lamiral Z, Boivin JM, et al
Parental acceptability of vaccinating young children against influenza and COVID-19.
Vaccine. 2023 Aug 12:S0264-410X(23)00929-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HONDA-OKUBO Y, Bart Tarbet E, Hurst BL, Petrovsky N, et al
An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection.
Vaccine. 2023 Aug 9:S0264-410X(23)00941-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BAGLIVO F, Magri M, De Angelis L, Aprile V, et al
Performance comparison between heterologous and homologous COVID19 vaccine schedules on Omicron variant incidence: A real-world retrospective cohort study in Southern Italy.
Vaccine. 2023 Aug 9:S0264-410X(23)00886-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MAC S, Shi S, Millson B, Tehrani A, et al
Burden of illness associated with Respiratory Syncytial Virus (RSV)-related hospitalizations among adults in Ontario, Canada: A retrospective population-based study.
Vaccine. 2023;41:5141-5149.
PubMed Abstract available

CHICOYE A, Crepey P, Nguyen VH, Marquez-Pelaez S, et al
Contributions of cost-effectiveness analyses (CEA) to influenza vaccination policy for older adults in Europe.
Vaccine. 2023 Aug 5:S0264-410X(23)00919-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SIMMS AJ, King KD, Tsui N, Edwards SA, et al
COVID-19 vaccine behaviour among citizens of the Metis Nation of Ontario: A qualitative study.
Vaccine. 2023 Aug 5:S0264-410X(23)00891-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

VERJOVSKY M, Barreto MP, Carmo I, Coutinho B, et al
Political quarrel overshadows vaccination advocacy: How the vaccine debate on Brazilian Twitter was framed by anti-vaxxers during Bolsonaro administration.
Vaccine. 2023 Aug 5:S0264-410X(23)00921-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CAMPBELL J, Kaur A, Gamino D, Benoit E, et al
Individual and structural determinants of COVID-19 vaccine uptake in a marginalized community in the United States.
Vaccine. 2023 Aug 5:S0264-410X(23)00923-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MOSCARA L, Venerito V, Martinelli A, Di Lorenzo A, et al
Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study.
Vaccine. 2023 Aug 4:S0264-410X(23)00874-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

XU S, Yu H, Cheng X, Wu J, et al
Inactivated SARS-CoV-2 vaccination does not disturb the clinical course of Graves' disease: An observational cohort study.
Vaccine. 2023 Aug 4:S0264-410X(23)00884-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

AUVIGNE V, Tamandjou Tchuem CR, Schaeffer J, Vaux S, et al
Protection against symptomatic SARS-CoV-2 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original monovalent vaccines - A matched cohort study in France.
Vaccine. 2023 Aug 2:S0264-410X(23)00917-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MO J, Spackman E, Swayne DE
Prediction of highly pathogenic avian influenza vaccine efficacy in chickens by comparison of in vitro and in vivo data: A meta-analysis and systematic review.
Vaccine. 2023 Aug 1:S0264-410X(23)00922-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

July 2023

HONDA-OKUBO Y, Sakala IG, Andre G, Tarbet EB, et al
An Advax-CpG55.2 adjuvanted recombinant hemagglutinin vaccine provides immunity against H7N9 influenza in adult and neonatal mice.
Vaccine. 2023 Jul 31:S0264-410X(23)00892-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

WALLACE M, Rosenblum HG, Moulia DL, Broder KR, et al
A summary of the Advisory Committee for Immunization Practices (ACIP) use of a benefit-risk assessment framework during the first year of COVID-19 vaccine administration in the United States.
Vaccine. 2023 Jul 30:S0264-410X(23)00868-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LIU B, Stepien S, Qian J, Gidding H, et al
Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection.
Vaccine. 2023 Jul 29:S0264-410X(23)00881-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

AMANI A, Njoh AA, Atuhebwe P, Ndoula S, et al
Beyond the numbers: An in-depth look at Cameroon's fifth national COVID-19 vaccination campaign through geographical and gender lenses.
Vaccine. 2023 Jul 29:S0264-410X(23)00905-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

GREEN-MCKENZIE J, Shofer FS, Kruse G, Momplaisir F, et al
COVID-19 vaccine uptake before and after a vaccine mandate at a major academic hospital: Trends by race/ethnicity and level of patient contact.
Vaccine. 2023 Jul 28:S0264-410X(23)00853-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LAVENDER B, Hooker C, Frampton C, Williams M, et al
Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naive New Zealand cohort.
Vaccine. 2023 Jul 27:S0264-410X(23)00882-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ROSA RG, Falavigna M, Manfio JL, de Araujo CLP, et al
BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study.
Vaccine. 2023 Jul 26:S0264-410X(23)00869-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KIM DH, Lee J, Youk S, Jeong JH, et al
Intramuscular administration of recombinant Newcastle disease virus expressing SARS-CoV-2 spike protein protects hACE-2 TG mice against SARS-CoV-2 infection.
Vaccine. 2023;41:4787-4797.
PubMed Abstract available

TAMADA Y, Takeuchi K, Kusama T, Maeda M, et al
Effectiveness of COVID-19 vaccines against infection in Japan: A test-negative study from the VENUS study.
Vaccine. 2023 Jul 22:S0264-410X(23)00856-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

GHAZY RM, Ibrahim SA, Taha SHN, Elshabrawy A, et al
Attitudes of parents towards influenza vaccine in the Eastern Mediterranean Region: A multilevel analysis.
Vaccine. 2023 Jul 20:S0264-410X(23)00808-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ARAUJO-CHAVERON L, Sicsic J, Moffroid H, Diaz Luevano C, et al
Impact of a COVID-19 certificate requirement on vaccine uptake pattern and intention for future vaccination. A cross-sectional study among French adults.
Vaccine. 2023 Jul 20:S0264-410X(23)00805-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KIM YA, Mousavi K, Yazdi A, Zwierzyna M, et al
Computational design of mRNA vaccines.
Vaccine. 2023 Jul 20:S0264-410X(23)00836-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KATHERINE YIH W, Daley MF, Duffy J, Fireman B, et al
Safety signal identification for COVID-19 bivalent booster vaccination using tree-based scan statistics in the Vaccine Safety Datalink.
Vaccine. 2023 Jul 19:S0264-410X(23)00823-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

PISL V, Vevera J
COVID-19 vaccine uptake in mental healthcare users: Czech nationwide register study.
Vaccine. 2023 Jul 19:S0264-410X(23)00840-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ZIMMERMAN RK, Patricia Nowalk M, Dauer K, Clarke L, et al
Vaccine effectiveness of recombinant and standard dose influenza vaccines against influenza related hospitalization using a retrospective test-negative design.
Vaccine. 2023 Jul 18:S0264-410X(23)00741-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SABAT I, Neumann-Bohme S, Barros PP, Torbica A, et al
Vaccine hesitancy comes in waves: Longitudinal evidence on willingness to vaccinate against COVID-19 from seven European countries.
Vaccine. 2023 Jul 15:S0264-410X(23)00829-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MOROS A, Prenafeta A, Barreiro A, Perozo E, et al
Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate.
Vaccine. 2023 Jul 15:S0264-410X(23)00820-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CLOUSTON SAP, Hanes DW, Link BG
Social inequalities and the early provision and dispersal of COVID-19 vaccinations in the United States: A population trends study.
Vaccine. 2023 Jul 15:S0264-410X(23)00833-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

TALOTTA R
COVID-19 mRNA vaccines as hypothetical epigenetic players: Results from an in silico analysis, considerations and perspectives.
Vaccine. 2023 Jul 13:S0264-410X(23)00819-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ALABANZA C, Gavrilov V, Scott T, Yang RS, et al
Quantitation of strain-specific hemagglutinin trimers in mosaic quadrivalent influenza nanoparticle vaccine by ELISA.
Vaccine. 2023 Jul 12:S0264-410X(23)00821-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BEYERS KCL, Rbeihat MNM, S Vasconcelos D, Pasmans D, et al
Preclinical evaluation of performance, safety and usability of VAX-ID(R), a novel intradermal injection device.
Vaccine. 2023;41:4609-4615.
PubMed Abstract available

AGRAWAL P, Damania D, Cseh A, Grab J, et al
Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study.
Vaccine. 2023 Jul 12:S0264-410X(23)00822-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MINCHIN J, Harris GH, Baumann S, Smith ER, et al
Exclusion of pregnant people from emergency vaccine clinical trials: A systematic review of clinical trial protocols and reporting from 2009 to 2019.
Vaccine. 2023 Jul 11:S0264-410X(23)00776-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

WILLIS DE, Reece S, Gurel-Headley M, Selig JP, et al
Social processes, practical issues, and COVID-19 vaccination among hesitant adults.
Vaccine. 2023 Jul 7:S0264-410X(23)00809-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

FLEMING JA, Baral R, Higgins D, Khan S, et al
Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.
Vaccine. 2023 Jul 6:S0264-410X(22)01212-9. doi: 10.1016/j.vaccine.2022.
PubMed Abstract available

ZHANG X, Shen P, Liu J, Ji X, et al
Evaluating the effectiveness and cost-effectiveness of free influenza vaccination policy for older adults in Yinzhou, China: Study protocol of a real-world analyses.
Vaccine. 2023 Jul 5:S0264-410X(23)00790-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

WAGNER A, Juvalta S, Speranza C, Suggs LS, et al
Let's talk about COVID-19 vaccination: Relevance of conversations about COVID-19 vaccination and information sources on vaccination intention in Switzerland.
Vaccine. 2023 Jul 5:S0264-410X(23)00807-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LE H, de Klerk N, Blyth CC, Gidding H, et al
Non-specific benefit of seasonal influenza vaccine on respiratory syncytial virus-hospitalisations in children: An instrumental variable approach using population-based data.
Vaccine. 2023 Jul 3:S0264-410X(23)00788-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

PATEL UC, Schultz T, Schmidt J
Veteran influenza vaccination acceptance rates after completion of the COVID-19 vaccination series among historical influenza vaccine refusers.
Vaccine. 2023 Jul 3:S0264-410X(23)00803-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ROSHCHINA Y, Rozhkova K, Roshchin S
Between nudges and mandates: The drivers of COVID-19 vaccination intentions and subsequent uptake in Russia.
Vaccine. 2023 Jul 3:S0264-410X(23)00756-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

TUCKERMAN J, Kaufman J, Overmars I, Holland P, et al
Barriers to COVID-19 vaccination of migrant populations: A qualitative interview study of immunisation providers in Victoria, Australia.
Vaccine. 2023 Jul 3:S0264-410X(23)00804-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

TROGSTAD L, Laake I, Robertson AH, Mjaaland S, et al
Heavy bleeding and other menstrual disturbances in young women after COVID-19 vaccination.
Vaccine. 2023 Jul 3:S0264-410X(23)00801-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

June 2023

LIU Z, Pang C, Deng Y, Guo C, et al
Humoral immune response following the inactivated quadrivalent influenza vaccination among HIV-infected and HIV-uninfected adults.
Vaccine. 2023 Jun 30:S0264-410X(23)00616-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SHINJOH M, Furuichi M, Tsuzuki S, Iqbal A, et al
Effectiveness of inactivated influenza and COVID-19 vaccines in hospitalized children in 2022/23 season in Japan - The first season of co-circulation of influenza and COVID-19.
Vaccine. 2023 Jun 30:S0264-410X(23)00785-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LIU Y, Zhang A, Wang Y, Yang J, et al
Immunogenicity and protective effects of recombinant bivalent COVID-19 vaccine in mice and rhesus macaques.
Vaccine. 2023 Jun 30:S0264-410X(23)00789-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KU JH, Sy LS, Qian L, Ackerson BK, et al
Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study.
Vaccine. 2023;41:4212-4219.
PubMed Abstract available

VAN DER BOOR SC, Schmitz-de Vries ETJ, Smits D, Scholl JHG, et al
Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands.
Vaccine. 2023;41:4319-4326.
PubMed Abstract available

ALVES K, Plested JS, Galbiati S, Chau G, et al
Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
Vaccine. 2023;41:4280-4286.
PubMed Abstract available

ISHIKAWA K, Nascimento MC, Asano M, Hirata H, et al
One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): Final analysis of a randomized, placebo-controlled phase 1/2 trial in Japan.
Vaccine. 2023;41:4199-4205.
PubMed Abstract available

LEE KS, Rader NA, Miller-Stump OA, Cooper M, et al
Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.
Vaccine. 2023 Jun 28:S0264-410X(23)00783-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SHENG Y, Li Z, Lin X, Ma Y, et al
The position of Spy Tag/Catcher system in hepatitis B core protein particles affects the immunogenicity and stability of the synthetic vaccine.
Vaccine. 2023 Jun 28:S0264-410X(23)00759-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

DOMNICH A, Orsi A, Ogliastro M, Trombetta CS, et al
Influenza vaccine effectiveness in preventing hospital encounters for laboratory-confirmed infection among Italian adults, 2022/23 season.
Vaccine. 2023 Jun 27:S0264-410X(23)00775-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KIM S, Ko M, Heo Y, Lee YK, et al
Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over.
Vaccine. 2023 Jun 27:S0264-410X(23)00780-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BARRIENTOS M, Vasquez-Lavin F, Rosales C, Bratti L, et al
Understanding the role of personal experiences and contextual variables in shaping risk reduction preferences.
Vaccine. 2023;41:4092-4105.
PubMed Abstract available

TORP HANSEN K, Kusk Povlsen F, Hammer Bech B, Nygaard Hansen S, et al
Immediate adverse reactions following COVID-19 vaccination among 16-65-year-old Danish citizens.
Vaccine. 2023 Jun 23:S0264-410X(23)00758-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

TURLEY CB, Tables L, Fuller T, Sanders LJ, et al
Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.
Vaccine. 2023 Jun 23:S0264-410X(23)00755-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SALEH SN, McDonald SA, Basit MA, Kumar S, et al
Public perception of COVID-19 vaccines through analysis of Twitter content and users.
Vaccine. 2023 Jun 23:S0264-410X(23)00743-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HOWARD MC
Integrating the person-centered approach with the study of vaccine hesitancy: Applying latent profile analysis to identify vaccine hesitancy subpopulations and assess their relations with correlates and vaccination outcomes.
Vaccine. 2023 Jun 23:S0264-410X(23)00742-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CHAUDHARY A, Madhavan R, Babji S, Raju R, et al
Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India.
Vaccine. 2023 Jun 23:S0264-410X(23)00744-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

AUGUSTYNIAK A, Szymanski T, Porzucek F, Mieloch AA, et al
A cohort study reveals different dynamics of SARS-CoV-2-specific antibody formation after Comirnaty and Vaxzevria vaccination.
Vaccine. 2023 Jun 21:S0264-410X(23)00665-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LUANGASANATIP N, Painter C, Pan-Ngum W, Saralamba S, et al
How to model the impact of vaccines for policymaking when the characteristics are uncertain: A case study in Thailand prior to the vaccine rollout during the COVID-19 pandemic.
Vaccine. 2023 Jun 20:S0264-410X(23)00740-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CHEN X, Lin Y, Yue S, Yang Y, et al
PD-1/PD-L1 blockade restores tumor-induced COVID-19 vaccine bluntness.
Vaccine. 2023 Jun 20:S0264-410X(23)00737-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

EKIMOV A, Arunachalam AB, Blake T, Bodle J, et al
Assessing the stability-indicating properties of alternative potency assays for inactivated influenza vaccine.
Vaccine. 2023 Jun 19:S0264-410X(23)00726-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HONDA-OKUBO Y, Li L, Andre G, Leong KH, et al
An Advax-CpG55.2 adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge.
Vaccine. 2023 Jun 19:S0264-410X(23)00748-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

UDA K, Okubo Y, Tsuge M, Tsukahara H, et al
Impacts of routine varicella vaccination program and COVID-19 pandemic on varicella and herpes zoster incidence and health resource use among children in Japan.
Vaccine. 2023 Jun 19:S0264-410X(23)00739-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

TZENG R, Huang FY, Lee J
Compliance, procrastination and refusal: American COVID-19 vaccination trust and value orientation.
Vaccine. 2023 Jun 19:S0264-410X(23)00745-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MASOUD D, Pierz A, Rauh L, Cruz AK, et al
Vaccine Trust Gauge: Mixed methods research to measure and understand vaccine trust.
Vaccine. 2023 Jun 17:S0264-410X(23)00690-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

DOYON-PLOURDE P, Przepiorkowski J, Young K, Zhao L, et al
Intraseasonal waning immunity of seasonal influenza vaccine - A systematic review and meta-analysis.
Vaccine. 2023 Jun 16:S0264-410X(23)00713-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

DUNN DT, Gilson R, McCormack S, McCoy LE, et al
Licenced doses of approved COVID-19 vaccines may not be optimal: A review of the early-phase, dose-finding trials.
Vaccine. 2023 Jun 16:S0264-410X(23)00712-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BISWAS RK, Afiaz A, Huq S, Farzana M, et al
Public opinion on COVID-19 vaccine prioritization in Bangladesh: Who gets the vaccine and whom do you leave out?
Vaccine. 2023 Jun 16:S0264-410X(23)00725-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

NISHIYAMA A, Adachi Y, Tonouchi K, Moriyama S, et al
Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous protection via Th1-polarized, non-neutralizing antibody responses.
Vaccine. 2023 Jun 15:S0264-410X(23)00685-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

PIGNATTI P, Ramirez GA, Russo M, Marraccini P, et al
Hypersensitivity reactions to anti-SARS-CoV-2 vaccines: Basophil reactivity to excipients.
Vaccine. 2023 Jun 15:S0264-410X(23)00714-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MUANGNOICHAROEN S, Wiangcharoen R, Nanthapisal S, Kamolratakul S, et al
Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
Vaccine. 2023 Jun 15:S0264-410X(23)00718-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KENIGSBERG TA, Hanson KE, Klein NP, Zerbo O, et al
Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink.
Vaccine. 2023 Jun 15:S0264-410X(23)00717-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

PUTHANAKIT T, Chokephaibulkit K, Chaithongwongwatthana S, Bhat N, et al
A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women.
Vaccine. 2023 Jun 15:S0264-410X(23)00657-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SHOAIBI A, Lloyd PC, Wong HL, Clarke TC, et al
Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S.
Vaccine. 2023 Jun 14:S0264-410X(23)00682-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CIEMINS EL, Gillen A, Tallam M
RSV: A vaccine is coming, time to educate providers.
Vaccine. 2023 Jun 14:S0264-410X(23)00695-3. doi: 10.1016/j.vaccine.2023.
PubMed

SAADATIAN-ELAHI M, Henaff L, Elias C, Nunes MC, et al
Patient influenza vaccination reduces the risk of hospital-acquired influenza: An incident test negative-case control study in Lyon university hospital, France (2004-2020).
Vaccine. 2023 Jun 13:S0264-410X(23)00621-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SALMANTON-GARCIA J, Wipfler P, Valle-Simon P, Merakou C, et al
VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe.
Vaccine. 2023;41:3915-3922.
PubMed Abstract available

WOO EJ, Gee J, Marquez P, Baggs J, et al
Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.
Vaccine. 2023 Jun 13:S0264-410X(23)00687-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MUNOZ FM, Posavad CM, Richardson BA, Badell ML, et al
COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn.
Vaccine. 2023 Jun 13:S0264-410X(23)00698-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

WATESKA AR, Nowalk MP, Lin CJ, Harrison LH, et al
Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults.
Vaccine. 2023 Jun 12:S0264-410X(23)00669-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MA D, Tian S, Qin Q, Yu Y, et al
Construction of an inhalable recombinant M2e-FP-expressing Bacillus subtilis spores-based vaccine and evaluation of its protection efficacy against influenza in a mouse model.
Vaccine. 2023 Jun 10:S0264-410X(23)00655-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MADRAN B, Kayi I, Beser A, Ergonul O, et al
Uptake of COVID-19 vaccines among healthcare workers and the effect of nudging interventions: A mixed methods study.
Vaccine. 2023 Jun 9:S0264-410X(23)00688-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

UI M, Hirama T, Akiba M, Honda M, et al
Cellular and humoral immune responses after a third dose of SARS-CoV-2 mRNA vaccine in lung transplant recipients in Japan.
Vaccine. 2023 Jun 9:S0264-410X(23)00663-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MARTINEZ MR, Gao J, Wan H, Kang H, et al
Inactivated influenza virions are a flexible vaccine platform for eliciting protective antibody responses against neuraminidase.
Vaccine. 2023 Jun 8:S0264-410X(23)00629-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

NOGAREDA F, Gharpure R, Contreras M, Velandia M, et al
Seasonal influenza vaccination in the Americas: Progress and challenges during the COVID-19 pandemic.
Vaccine. 2023 Jun 8:S0264-410X(23)00689-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

DE GIER B, van Asten L, Boere TM, van Roon A, et al
Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021-January 2022.
Vaccine. 2023 Jun 8:S0264-410X(23)00660-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ROY A, Polazzi S, Ploin D, Gillet Y, et al
The increasing age of respiratory syncytial virus-related hospitalisation during COVID-19 pandemic in Lyon was associated with reduced hospitalisation costs.
Vaccine. 2023;41:3796-3800.
PubMed Abstract available

SHAW RJ, Doyle AJ, Millen EA, Stowe J, et al
Re-evaluation of the risk of venous thromboembolism after COVID-19 vaccination using haematological criteria.
Vaccine. 2023 Jun 7:S0264-410X(23)00662-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KATO H, Hozawa T, Fukushima W, Nobusawa E, et al
Influenza vaccine viruses and the development of seasonal vaccines: A Japanese perspective.
Vaccine. 2023 Jun 6:S0264-410X(23)00640-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KIM DELUCA E, Gebremariam A, Rose A, Biggerstaff M, et al
Cost-effectiveness of routine annual influenza vaccination by age and risk status.
Vaccine. 2023 Jun 6:S0264-410X(23)00495-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KIM WJ, Roberts CC, Song JY, Yoon JG, et al
Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost.
Vaccine. 2023 Jun 6:S0264-410X(23)00683-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

PELLETIER C, Labbe F, Bettinger JA, Curran J, et al
From high hopes to disenchantment: A qualitative analysis of editorial cartoons on COVID-19 vaccines in Canadian newspapers.
Vaccine. 2023 Jun 6:S0264-410X(23)00658-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ELDER E, Bangalore Revanna C, Johansson C, Wallin RPA, et al
Protective immunity induced by an inhaled SARS-CoV-2 subunit vaccine.
Vaccine. 2023 Jun 6:S0264-410X(23)00684-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MAKANUT S, Wangteeraprasert A, Jitpewngam W, Ngoenkam J, et al
Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.
Vaccine. 2023 Jun 5:S0264-410X(23)00666-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

WESSELINK AK, Lovett SM, Weinberg J, Geller RJ, et al
COVID-19 vaccination and menstrual cycle characteristics: A prospective cohort study.
Vaccine. 2023 Jun 5:S0264-410X(23)00681-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KOZMA GT, Meszaros T, Berenyi P, Facsko R, et al
Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG.
Vaccine. 2023 Jun 5:S0264-410X(23)00667-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ERGUN T, Hosgoren Tekin S, Apti Sengun O, Akin Cakici O, et al
Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.
Vaccine. 2023 Jun 3:S0264-410X(23)00615-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

FEDDEMA JJ, Fernald KDS, Schikan HGCP, van de Burgwal LHM, et al
Upscaling vaccine manufacturing capacity - Kkey bottlenecks and lessons learned.
Vaccine. 2023 Jun 3:S0264-410X(23)00554-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

May 2023

WANG LJ, Tsai CS, Chou WJ, Li CJ, et al
Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study.
Vaccine. 2023 May 29:S0264-410X(23)00628-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ARROSPIDE A, Sagardui MG, Larizgoitia I, Iturralde A, et al
Effectiveness of the booster dose of COVID-19 vaccine in the Basque Country during the sixth wave: A nationwide cohort study.
Vaccine. 2023 May 29:S0264-410X(23)00622-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HU S, Xiong C, Zhao Y, Yuan X, et al
Vaccination, human mobility, and COVID-19 health outcomes: Empirical comparison before and during the outbreak of SARS-Cov-2 B.1.1.529 (Omicron) variant.
Vaccine. 2023 May 29:S0264-410X(23)00617-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MILLER ER, Moro PL, Shimabukuro TT, Carlock G, et al
COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office.
Vaccine. 2023 May 24:S0264-410X(23)00613-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HORI D, Keneda Y, Ozaki A, Tabuchi T, et al
Sexual orientation was associated with intention to be vaccinated with a smallpox vaccine against mpox: A cross-sectional preliminary survey in Japan.
Vaccine. 2023 May 24:S0264-410X(23)00611-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

NUGENT C, Abul Y, White EM, Shehadeh F, et al
Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers.
Vaccine. 2023;41:3403-3409.
PubMed Abstract available

JOUDEH AI, Lutf AQ, Mahdi S, Tran G, et al
Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review.
Vaccine. 2023 May 22:S0264-410X(23)00609-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ALICANDRO G, Orena BS, Rosazza C, Cariani L, et al
Humoral and cell-mediated immune responses to BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis.
Vaccine. 2023 May 22:S0264-410X(23)00590-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

GHAZNAVI C, Eguchi A, Suu Lwin K, Yoneoka D, et al
Estimating global changes in routine childhood vaccination coverage during the COVID-19 pandemic, 2020-2021.
Vaccine. 2023 May 22:S0264-410X(23)00583-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

GUO BQ, Li HB, Yang LQ
Incidence of myopericarditis after mRNA COVID-19 vaccination: A meta-analysis with focus on adolescents aged 12-17 years.
Vaccine. 2023 May 22:S0264-410X(23)00610-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BOLSEWICZ KT, Steffens MS, King C, Abdi I, et al
A qualitative study on COVID-19 pandemic impacts on parental attitudes and intentions for routine adolescent vaccinations: The role of trust.
Vaccine. 2023 May 22:S0264-410X(23)00586-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

EGER J, Kaplan LC, Sternberg H
How to reduce vaccination hesitancy? The relevance of evidence and its communicator.
Vaccine. 2023 May 22:S0264-410X(23)00298-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

EMBI PJ, Levy ME, Patel P, DeSilva MB, et al
Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021.
Vaccine. 2023 May 22:S0264-410X(23)00588-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BOING AF, Boing AC, Barberia L, Borges ME, et al
Uncovering inequities in Covid-19 vaccine coverage for adults and elderly in Brazil: A multilevel study of 2021-2022 data.
Vaccine. 2023 May 17:S0264-410X(23)00569-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ZHOU ZH, Cortese MM, Fang JL, Wood R, et al
Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination.
Vaccine. 2023 May 16:S0264-410X(23)00568-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BLACK SB, Chandler RE, Edwards KM, Sturkenboom MCJM, et al
Assessing vaccine safety during a pandemic: Recent experience and lessons learned for the future.
Vaccine. 2023 May 15:S0264-410X(23)00468-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LIMAYE RJ, Singh P, Paul A, Fesshaye B, et al
COVID-19 vaccine decision-making among pregnant and lactating women in Bangladesh.
Vaccine. 2023 May 15:S0264-410X(23)00551-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SURIE D, Bonnell LN, DeCuir J, Gaglani M, et al
Comparison of mRNA vaccine effectiveness against COVID-19-associated hospitalization by vaccination source: Immunization information systems, electronic medical records, and self-report-IVY Network, February 1-August 31, 2022.
Vaccine. 2023 May 15:S0264-410X(23)00567-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

GEORGE TK, Nair NP, Singh AK, Dilesh Kumar A, et al
Development of a Choice-framework for Covid vaccines in India using a multi-criteria decision analysis approach.
Vaccine. 2023 May 12:S0264-410X(23)00486-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KEHAGIA E, Papakyriakopoulou P, Valsami G
Advances in intranasal vaccine delivery: A promising non-invasive route of immunization.
Vaccine. 2023 May 11:S0264-410X(23)00529-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ROBERTS-MCCARTHY E, Buck PO, Smith-Ray RL, Van de Velde N, et al
Factors associated with receipt of mRNA-1273 vaccine at a United States national retail pharmacy during the COVID-19 pandemic.
Vaccine. 2023 May 11:S0264-410X(23)00383-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LANGLETE P, Tesli M, Veneti L, Starrfelt J, et al
Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 - January 2022.
Vaccine. 2023 May 10:S0264-410X(23)00549-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SMITH K, Hegazy K, Cai MR, McKnight I, et al
Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials.
Vaccine. 2023 May 10:S0264-410X(23)00543-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

VAN IERSEL SCJL, McDonald SA, de Gier B, Knol MJ, et al
Number of COVID-19 hospitalisations averted by vaccination: Estimates for the Netherlands, January 6, 2021 through August 30, 2022.
Vaccine. 2023 May 10:S0264-410X(23)00545-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

RUBIN THOMPSON LJ, Grubo M, Veller M, Badenhorst RH, et al
Building global vaccine manufacturing capacity: Spotlight on Africa.
Vaccine. 2023 May 10:S0264-410X(23)00527-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CHIAVENNA C, Leone LP, Melegaro A, Rotesi T, et al
Personal risk or societal benefit? Investigating adults' support for COVID-19 childhood vaccination.
Vaccine. 2023 May 9:S0264-410X(23)00544-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KURIYAMA K, Murakami K, Masuda T, Sugiura K, et al
Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.
Vaccine. 2023 May 8:S0264-410X(23)00519-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SUTTON WJH, Branham PJ, Williamson YM, Cooper HC, et al
Quantification of SARS-CoV-2 spike protein expression from mRNA vaccines using isotope dilution mass spectrometry.
Vaccine. 2023 May 8:S0264-410X(23)00458-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BORDALO FERREIRA F, Rafael MA, Coimbra L, Boavida N, et al
Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease.
Vaccine. 2023 May 8:S0264-410X(23)00530-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

FITZ-PATRICK D, Young M, Yacisin K, McElwee K, et al
Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults >/=65 years old.
Vaccine. 2023 May 8:S0264-410X(23)00520-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KPOZEHOUEN EB, Heywood AE, Menzies R, Seale H, et al
Informing the design of a whole of life immunisation register for Australia.
Vaccine. 2023;41:3011-3018.
PubMed Abstract available

RODRIGUEZ DM, Major CG, Sanchez-Gonzalez L, Jones E, et al
Dengue vaccine acceptability before and after the availability of COVID-19 vaccines in Puerto Rico.
Vaccine. 2023 May 5:S0264-410X(23)00516-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KU JH, Sy LS, Qian L, Ackerson BK, et al
Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study.
Vaccine. 2023 May 3:S0264-410X(23)00498-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

FUKUNAGA R, Kaplan ZE, Rodriguez T, Hagan L, et al
Attitudes towards COVID-19 vaccination among incarcerated persons in the Federal Bureau of Prisons, June-July 2021.
Vaccine. 2023 May 2:S0264-410X(23)00512-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LEFFERTS B, Bruden D, Plumb ID, Hodges E, et al
Effectiveness of the COVID-19 vaccines on preventing symptomatic SARS-CoV-2 infections and hospitalizations in Southwestern Alaska, January-December 2021.
Vaccine. 2023 May 1:S0264-410X(23)00496-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MESINA FZ, Sapinoso FAD, De Castro JAV, Vaswani PPM, et al
Hematologic adverse events reported after COVID-19 vaccination in the Philippines: A national database study.
Vaccine. 2023 May 1:S0264-410X(23)00490-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HUSSAINI L, Labberton AS, Winje BA, Kraft KB, et al
COVID-19 vaccination rates among adolescents (12-17 years) by immigrant background and sociodemographic factors: A nationwide registry study in Norway.
Vaccine. 2023 May 1:S0264-410X(23)00514-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KUHLBRANDT C, McGowan CR, Stuart R, Grenfell P, et al
COVID-19 vaccination decisions among Gypsy, Roma, and Traveller communities: A qualitative study moving beyond "vaccine hesitancy".
Vaccine. 2023 May 1:S0264-410X(23)00515-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

April 2023

MARCHESE AM, Zhou X, Kinol J, Underwood E, et al
NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial.
Vaccine. 2023 Apr 29:S0264-410X(23)00467-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

VANNI T, da Graca Salomao M, Viscondi JYK, Braga PE, et al
A randomized, double-blind, non-inferiority trial comparing the immunogenicity and safety of two seasonal inactivated influenza vaccines in adults.
Vaccine. 2023 Apr 28:S0264-410X(23)00464-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KOEN AL, Izu A, Baillie V, Kwatra G, et al
Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
Vaccine. 2023 Apr 27:S0264-410X(23)00483-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KIM C, Aminawung JA, Brinkley-Rubinstein L, Wang EA, et al
COVID-19 vaccine deliberation in individuals directly impacted by incarceration.
Vaccine. 2023 Apr 26:S0264-410X(23)00492-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ALSUHEBANY N, Alowais SA, Aldairem A, Almohareb SN, et al
Identifying gaps in vaccination perception after mandating the COVID-19 vaccine in Saudi Arabia.
Vaccine. 2023 Apr 26:S0264-410X(23)00481-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LU X, Masuda S, Horlad H, Katoh T, et al
Safety and adverse effects of the coronavirus disease 2019 vaccine among the general Japanese adult population.
Vaccine. 2023 Apr 26:S0264-410X(23)00469-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KIM SJ, Kwon SL, Lee JY, Oh J, et al
Why school is crucial to increase vaccination coverage for children: Evaluation of school vaccination check program in South Korea 2021-2022.
Vaccine. 2023 Apr 25:S0264-410X(23)00430-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

JIANG M, Vaisanen E, Kolehmainen P, Huttunen M, et al
COVID-19 adenovirus vector vaccine induces higher interferon and pro-inflammatory responses than mRNA vaccines in human PBMCs, macrophages and moDCs.
Vaccine. 2023 Apr 25:S0264-410X(23)00463-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

WALTER D, Ophir Y, Ye H
Conspiracies, misinformation and resistance to public health measures during COVID-19 in white nationalist online communication.
Vaccine. 2023;41:2868-2877.
PubMed Abstract available

TAMANDJOU C, Auvigne V, Schaeffer J, Vaux S, et al
Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France.
Vaccine. 2023;41:2754-2760.
PubMed Abstract available

MA L, Brecher M, Soufal A, Gaiotto T, et al
Structural interrogation of a trimeric prefusion RSV fusion protein vaccine candidate by a camelid nanobody.
Vaccine. 2023 Apr 19:S0264-410X(23)00413-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BAO Y, He L, Miao B, Zhong Z, et al
BBIBP-CorV vaccination accelerates anti-viral antibody responses in heterologous Omicron infection: A retrospective observation study in Shanghai.
Vaccine. 2023 Apr 19:S0264-410X(23)00377-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

PILLSBURY A, Phillips A, Deng L, Quinn H, et al
Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines.
Vaccine. 2023 Apr 18:S0264-410X(23)00441-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MAO Z, Li X, Dacosta-Urbieta A, Billard MN, et al
Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: A multi-country prospective cohort study in Europe.
Vaccine. 2023;41:2707-2715.
PubMed Abstract available

HOUTSMA C, Raines AM, Reggio A, Rushing LK, et al
COVID-19 vaccine distribution: A high reliability organization approach.
Vaccine. 2023 Apr 17:S0264-410X(23)00423-1. doi: 10.1016/j.vaccine.2023.
PubMed

GORDON SF, Lam J, Vasquez JT, Cercone R, et al
A tailored COVID-19 vaccination pathway for children 5-11 years in Victoria, Australia.
Vaccine. 2023 Apr 17:S0264-410X(23)00424-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LUDWIKOWSKA KM, Popiel A, Matkowska-Kocjan A, Biela M, et al
COVID-19 mRNA BNT162b2 vaccine immunogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS).
Vaccine. 2023 Apr 14:S0264-410X(23)00427-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

FREITAG TL, Fagerlund R, Karam NL, Leppanen VM, et al
Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
Vaccine. 2023 Apr 14:S0264-410X(23)00403-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ANDRAUD M, Herve S, Gorin S, Barbier N, et al
Evaluation of early single dose vaccination on swine influenza A virus transmission in piglets: From experimental data to mechanistic modelling.
Vaccine. 2023 Apr 13:S0264-410X(23)00401-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ESTEPHAN L, Lin YC, Lin YT, Chen YH, et al
Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial.
Vaccine. 2023 Apr 12:S0264-410X(23)00421-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

UEMURA K, Ono S, Michihata N, Yamana H, et al
Duration of influenza vaccine effectiveness in the elderly in Japan: A retrospective cohort study using large-scale population-based registry data.
Vaccine. 2023 Apr 10:S0264-410X(23)00373-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

RATHORE APS, St John AL
Promises and challenges of mucosal COVID-19 vaccines.
Vaccine. 2023 Apr 10:S0264-410X(23)00396-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HARRIS C, Cottrell S, Perry M, Meaden R, et al
A pilot intervention to improve uptake and equality of childhood influenza vaccination in an area of Wales, through the introduction of a mixed delivery model including nursery school immunisation sessions.
Vaccine. 2023 Apr 8:S0264-410X(23)00382-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LEIGH HOBBS J, Paul LA, Buchan SA, Harris T, et al
Methodological changes implemented over time to support accurate and timely COVID-19 vaccine coverage estimates: Ontario, Canada.
Vaccine. 2023 Apr 7:S0264-410X(23)00389-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HARRIS JN, Mauro CM, Morgan TL, de Roche A, et al
Factors impacting parental uptake of COVID-19 vaccination for U.S. Children ages 5-17.
Vaccine. 2023 Apr 7:S0264-410X(23)00384-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ALMAHASIS SO, Fox B, Ha D, Qian J, et al
Pharmacy-based immunization in rural USA during the COVID-19 pandemic: A survey of community pharmacists from five southeastern states.
Vaccine. 2023;41:2503-2513.
PubMed Abstract available

SMITS PD, Gratzl S, Simonov M, Nachimuthu SK, et al
Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities.
Vaccine. 2023;41:2447-2455.
PubMed Abstract available

GOLD MS, Amarasinghe A, Greenhawt M, Kelso JM, et al
Anaphylaxis: Revision of the Brighton collaboration case definition.
Vaccine. 2023;41:2605-2614.
PubMed Abstract available

BURKHOLDER B, Wadood Z, Kassem AM, Ehrhardt D, et al
The immediate impact of the COVID-19 pandemic on polio immunization and surveillance activities.
Vaccine. 2023;41 Suppl 1:A2-A11.
PubMed Abstract available

KALKOWSKA DA, Pallansch MA, Wassilak SGF, Cochi SL, et al
Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
Vaccine. 2023;41 Suppl 1:A136-A141.
PubMed Abstract available

KALKOWSKA DA, Voorman A, Pallansch MA, Wassilak SGF, et al
The impact of disruptions caused by the COVID-19 pandemic on global polio eradication.
Vaccine. 2023;41 Suppl 1:A12-A18.
PubMed Abstract available

PAYNE JR, Bose S, Kubiak RW, Nolen LD, et al
Evaluation of mortality risk after COVID-19 vaccination, Utah 2021.
Vaccine. 2023 Apr 5:S0264-410X(23)00380-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BRAEYE T, Catteau L, Brondeel R, van Loenhout JAF, et al
Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-infection, Belgian contact tracing, 2021-2022.
Vaccine. 2023 Apr 5:S0264-410X(23)00376-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KIM H, Cho HK, Kang YM, Sagong M, et al
Protective efficacy of a bivalent H5 influenza vaccine candidate against both clades 2.3.2.1 and 2.3.4.4 high pathogenic avian influenza viruses in SPF chickens.
Vaccine. 2023 Apr 4:S0264-410X(23)00311-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

PRADA E, Langbecker A, Catalan-Matamoros D
Public discourse and debate about vaccines in the midst of the covid-19 pandemic: A qualitative content analysis of Twitter.
Vaccine. 2023 Apr 4:S0264-410X(23)00375-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

FRODLUND M, Nived P, Chatzidionysiou A, Sodergren A, et al
The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA).
Vaccine. 2023 Apr 4:S0264-410X(23)00372-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

TOSHKOV D
What accounts for the variation in COVID-19 vaccine hesitancy in Eastern, Southern and Western Europe?
Vaccine. 2023 Apr 4:S0264-410X(23)00314-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ALI Y, Piche-Renaud PP, Karimi-Shahrbabak E, Farrar DS, et al
Pediatricians' perceptions, practices, and barriers regarding COVID-19 vaccine for children: A cross-sectional survey in Ontario, Canada.
Vaccine. 2023 Apr 3:S0264-410X(23)00335-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

URQUIDI C, Santelices E, Lagomarcino AJ, Teresa Valenzuela M, et al
The added effect of non-pharmaceutical interventions and lifestyle behaviors on vaccine effectiveness against severe COVID-19 in Chile: A matched case-double control study.
Vaccine. 2023 Apr 3:S0264-410X(23)00354-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MAQUILING A, Jeevakanthan A, Ho Mi Fane B
The effect of vaccine mandate announcements on vaccine uptake in Canada: An interrupted time series analysis.
Vaccine. 2023 Apr 3:S0264-410X(23)00334-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CRIADO MF, Kassa A, Bertran K, Kwon JH, et al
Efficacy of multivalent recombinant herpesvirus of turkey vaccines against high pathogenicity avian influenza, infectious bursal disease, and Newcastle disease viruses.
Vaccine. 2023 Apr 1:S0264-410X(23)00349-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LYTRAS T, Athanasiadou M, Demetriou A, Stylianou D, et al
Lack of association between vaccination rates and excess mortality in Cyprus during the COVID-19 pandemic.
Vaccine. 2023 Apr 1:S0264-410X(23)00316-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

March 2023

XU S, Zhang B, Yao J, Ruan W, et al
A new H9 influenza virus mRNA vaccine elicits robust protective immunity against infection.
Vaccine. 2023 Mar 31:S0264-410X(23)00343-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

DATAR RS, Fette LM, Hinkelman AN, Hammershaimb EA, et al
Factors associated with COVID-19 vaccination during June-October 2021: A multi-site prospective study.
Vaccine. 2023 Mar 31:S0264-410X(23)00352-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HU Y, Wang Y, Shao T, Tang W, et al
Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes.
Vaccine. 2023 Mar 30:S0264-410X(23)00350-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

FUKUDA H, Maeda M, Murata F
Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS study.
Vaccine. 2023 Mar 29:S0264-410X(23)00353-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SU WJ, Arnold Chan K, Chuang JH, Wang TA, et al
Acute reactions after a homologous primary COVID-19 vaccination series: Analysis of Taiwan V-Watch data.
Vaccine. 2023 Mar 28:S0264-410X(23)00336-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SANTI LAURINI G, Montanaro N, Broccoli M, Bonaldo G, et al
Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database.
Vaccine. 2023 Mar 28:S0264-410X(23)00348-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

GIDENGIL CA, Parker AM, Markowitz LE, Gedlinske AM, et al
Health care provider knowledge around shared clinical decision-making regarding HPV vaccination of adults aged 27-45 years in the United States.
Vaccine. 2023 Mar 27:S0264-410X(23)00186-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HU B, Yang W, Bouanchaud P, Chongo Y, et al
Determinants of COVID-19 vaccine acceptance in Mozambique: The role of institutional trust.
Vaccine. 2023 Mar 27:S0264-410X(23)00347-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KANG SW, Park H, Yeun Kim J, Bae JY, et al
Comparison of culture-competent virus shedding duration of SARS-CoV-2 Omicron variant in regard to vaccination status: A prospective cohort study.
Vaccine. 2023 Mar 27:S0264-410X(23)00339-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CESUR F, Atasever Z, Ozoran Y
Impact of vitamin D3 supplementation on COVID-19 vaccine response and immunoglobulin G antibodies in deficient women: A randomized controlled trial.
Vaccine. 2023 Mar 27:S0264-410X(23)00341-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

DUGOVICH AM, Cox TH, Weeda ER, Garner SS, et al
First hepatitis B vaccine uptake in neonates prior to and during the COVID-19 pandemic.
Vaccine. 2023 Mar 27:S0264-410X(23)00333-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

PANNUS P, Depickere S, Kemlin D, Georges D, et al
Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naive nursing home residents and healthy adults.
Vaccine. 2023 Mar 27:S0264-410X(23)00340-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CIAPPONI A, Berrueta M, P K Parker E, Bardach A, et al
Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis.
Vaccine. 2023 Mar 27:S0264-410X(23)00332-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

VAN KESSEL R, Forman R, Milstein R, Mastylak A, et al
Divergent COVID-19 vaccine policies: Policy mapping of ten European countries.
Vaccine. 2023 Mar 22:S0264-410X(23)00320-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

YANG J, Huo X, Jiang Q, Liao Y, et al
Preclinical safety evaluation of intradermal SARS-CoV-2 inactivated vaccine (Vero cells) administration in macaques.
Vaccine. 2023 Mar 21:S0264-410X(23)00317-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

PHOOLCHAROEN W, Shanmugaraj B, Khorattanakulchai N, Sunyakumthorn P, et al
Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant.
Vaccine. 2023 Mar 21:S0264-410X(23)00312-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SATO R
Vaccine hesitancy against COVID-19 vaccine over time in Nigeria.
Vaccine. 2023 Mar 21:S0264-410X(23)00313-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ATMAR RL, Bernstein DI, Winokur P, Frey SE, et al
Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial.
Vaccine. 2023 Mar 18:S0264-410X(23)00285-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SHEN AK, Browne S, Srivastava T, Kornides ML, et al
Trusted messengers and trusted messages: The role for community-based organizations in promoting COVID-19 and routine immunizations.
Vaccine. 2023;41:1994-2002.
PubMed Abstract available

PEREZ MA, Hsiao HM, Chen X, Kunkel A, et al
Serologic responses to COVID-19 vaccination in children with history of multisystem inflammatory syndrome (MIS-C).
Vaccine. 2023 Mar 15:S0264-410X(23)00283-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LIN JH, Huang YT, Yu JC, Chan KA, et al
Mediation and instrumental variable analyses for vaccine-induced antibody titer against influenza B.
Vaccine. 2023 Mar 14:S0264-410X(23)00261-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LAMUDA PA, Azar A, Taylor BG, Balawajder EF, et al
Latent class analysis of medical mistrust and COVID-19 vaccine hesitancy among adults in the United States just prior to FDA emergency use authorization.
Vaccine. 2023 Mar 13:S0264-410X(23)00263-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KELLY D, O'Donnell K, Marron L, Dwyer R, et al
Immunocompromise among vaccinated versus unvaccinated COVID-19 cases admitted to critical care in Ireland, July to October 2021.
Vaccine. 2023 Mar 13:S0264-410X(23)00258-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KWAK HW, Park HJ, Jung SY, Oh EY, et al
Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants.
Vaccine. 2023;41:1892-1901.
PubMed Abstract available

LIU YC, Munoz FM, Izurieta HS, Tamborska AA, et al
Anosmia: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
Vaccine. 2023;41:1902-1910.
PubMed Abstract available

SRIVASTAV A, Lu PJ, Amaya A, Dever JA, et al
Prevalence of influenza-specific vaccination hesitancy among adults in the United States, 2018.
Vaccine. 2023 Mar 10:S0264-410X(23)00255-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SANCHEZ L, Nakama T, Nagai H, Matsuoka O, et al
Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults >/= 60 years of age: Results from a phase III, randomized clinical trial.
Vaccine. 2023 Mar 9:S0264-410X(23)00225-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

PLUMB ID, Fette LM, Tjaden AH, Feldstein L, et al
Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March-October, 2021.
Vaccine. 2023 Mar 9:S0264-410X(23)00253-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

IKEWAKI N, Kurosawa G, Levy GA, Preethy S, et al
Antibody dependent disease enhancement (ADE) after COVID-19 vaccination and beta glucans as a safer strategy in management.
Vaccine. 2023 Mar 8:S0264-410X(23)00252-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HART RJ, Baumer-Mouradian S, Bone JN, Olson P, et al
Factors associated with US caregivers' uptake of pediatric COVID-19 vaccine by race and ethnicity.
Vaccine. 2023 Mar 6:S0264-410X(23)00242-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BAEK YJ, Kim WJ, Ko JH, Lee YJ, et al
A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen.
Vaccine. 2023;41:1694-1702.
PubMed Abstract available

GRIGNOLIO CORSINI A, Zagarella RM, Adamo M, Caporale C, et al
From COVID-19 vaccine candidates to compulsory vaccination: The attitudes of Italian citizens in the key 7-month of vaccination campaign.
Vaccine. 2023 Mar 3:S0264-410X(23)00243-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ESTEPHAN L, Liu LT, Lien CE, Smith ER, et al
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine.
Vaccine. 2023 Mar 3:S0264-410X(23)00245-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

XIE S, Monteiro K, Gjelsvik A
The association between maternal influenza vaccination during pregnancy and adverse birth outcomes in the United States: Pregnancy risk Assessment Monitoring System (PRAMS).
Vaccine. 2023 Mar 2:S0264-410X(23)00228-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LUDWIKOWSKA KM, Popiel A, Matkowska-Kocjan A, Olbromski MJ, et al
COVID-19 mRNA BNT162b2 vaccine safety and B-cell and T-cell reactogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS) - preliminary study.
Vaccine. 2023 Mar 2:S0264-410X(23)00227-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HURSTAK EE, Paasche-Orlow MK, Hahn EA, Henault LE, et al
The mediating effect of health literacy on COVID-19 vaccine confidence among a diverse sample of urban adults in Boston and Chicago.
Vaccine. 2023 Mar 2:S0264-410X(23)00202-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

GOLDMAN RD, Hart RJ, Bone JN, Seiler M, et al
Willingness to vaccinate children against COVID-19 declined during the pandemic.
Vaccine. 2023 Mar 2:S0264-410X(23)00223-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

NA L, Banks S, Wang PP
Racial and ethnic disparities in COVID-19 vaccine uptake: A mediation framework.
Vaccine. 2023 Mar 1:S0264-410X(23)00241-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

February 2023

MALTEZOU HC, Hatziantoniou S, Theodoridou K, Vasileiou K, et al
Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance.
Vaccine. 2023 Feb 27:S0264-410X(23)00221-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

TAMANDJOU TCHUEM CR, Auvigne V, Vaux S, Montagnat C, et al
Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
Vaccine. 2023 Feb 27:S0264-410X(23)00216-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

O'KENNEDY MM, Abolnik C, Smith T, Motlou T, et al
Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits.
Vaccine. 2023 Feb 27:S0264-410X(23)00185-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ITAMOCHI M, Yazawa S, Inasaki N, Saga Y, et al
Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
Vaccine. 2023 Feb 27:S0264-410X(23)00222-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

GETANEH AM, Li X, Mao Z, Johannesen CK, et al
Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries.
Vaccine. 2023;41:1623-1631.
PubMed Abstract available

FEITSMA EA, Janssen YF, Boersma HH, van Sleen Y, et al
A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.
Vaccine. 2023 Feb 23:S0264-410X(23)00200-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KABIR SULAIMAN S, Sale Musa M, Isma'il Tsiga-Ahmed F, Muhammad Dayyab F, et al
COVID-19 vaccine hesitancy among people living with HIV in a low-resource setting: A multi-center study of prevalence, correlates and reasons.
Vaccine. 2023 Feb 23:S0264-410X(23)00199-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CANNON K, Cardona JF, Yacisin K, Thompson A, et al
Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial.
Vaccine. 2023 Feb 22:S0264-410X(22)01459-1. doi: 10.1016/j.vaccine.2022.
PubMed Abstract available

MOORE KA, Leighton T, Ostrowsky JT, Anderson CJ, et al
A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy.
Vaccine. 2023 Feb 21:S0264-410X(23)00167-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ZHANG H, Chen L, Huang Z, Li D, et al
The effects of parent's health literacy and health beliefs on vaccine hesitancy.
Vaccine. 2023 Feb 21:S0264-410X(23)00161-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HAMBURG M, Poland GA
The time is now for committed and comprehensive action to attain more broadly protective coronavirus vaccines: The coronavirus vaccines R&D roadmap.
Vaccine. 2023 Feb 21:S0264-410X(23)00196-2. doi: 10.1016/j.vaccine.2023.
PubMed

MOTTA M, Callaghan T, Lunz-Trujillo K, Lockman A, et al
Erroneous Consonance. How inaccurate beliefs about physician opinion influence COVID-19 vaccine hesitancy.
Vaccine. 2023 Feb 20:S0264-410X(23)00195-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

GEOGHEGAN S, Acosta F, Stephens LC, Gillan H, et al
Maternity care provider acceptance of a future Group B Streptococcus vaccine - A qualitative study in three countries.
Vaccine. 2023 Feb 18:S0264-410X(23)00172-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

FORD A, Hwang A, Mo AX, Baqar S, et al
Meeting Summary: Global Vaccine and Immunization Research Forum, 2021.
Vaccine. 2023 Feb 18:S0264-410X(23)00163-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

DUDLEY MZ, Gerber JE, Budigan Ni H, Blunt M, et al
Vaccinomics: A scoping review.
Vaccine. 2023 Feb 18:S0264-410X(23)00135-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

RANADE D, Jena R, Patil K, Dogar V, et al
A novel high throughput plate-based method for 2-PE quantification in novel multidose vaccines (R21 malaria, Covishield and Covovax) and combination vaccines (Hexavalent).
Vaccine. 2023 Feb 17:S0264-410X(23)00174-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

PARODI A, Martini M
History of vaccine and immunization: Vaccine-hesitancy discussion in Germany in XIX century.
Vaccine. 2023 Feb 17:S0264-410X(23)00164-0. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MEYER C, Goffe L, Antonopoulou V, Graham F, et al
Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England.
Vaccine. 2023 Feb 17:S0264-410X(23)00182-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MORAIS A, Morais J, Felix M, Neto Z, et al
Genetic and epidemiological description of an outbreak of circulating vaccine-derived polio-virus type 2 (cVDPV2) in Angola, 2019-2020.
Vaccine. 2023 Feb 17:S0264-410X(23)00170-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ZIMMERMANN BM, Paul KT, Araujo ER, Buyx A, et al
The social and socio-political embeddedness of COVID-19 vaccination decision-making: A five-country qualitative interview study from Europe.
Vaccine. 2023 Feb 16:S0264-410X(23)00139-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

CAMPMAN SL, van Rossem G, Boyd A, Coyer L, et al
Intent to vaccinate against SARS-CoV-2 and its determinants across six ethnic groups living in Amsterdam, the Netherlands: A cross-sectional analysis of the HELIUS study.
Vaccine. 2023 Feb 13:S0264-410X(23)00165-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BARNES K, Faasse K, Colagiuri B
The impact of side effect framing on COVID-19 booster vaccine intentions in an Australian sample.
Vaccine. 2023 Feb 13:S0264-410X(23)00158-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SAELEE R, Chandra Murthy N, Patel Murthy B, Zell E, et al
Minority Health Social Vulnerability Index and COVID-19 vaccination coverage - The United States, December 14, 2020-January 31, 2022.
Vaccine. 2023 Feb 13:S0264-410X(23)00157-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

WANKHEDE D, Grover S, Hofman P
Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: A systematic review and meta-analysis.
Vaccine. 2023 Feb 13:S0264-410X(23)00115-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

AFREH OK, Angwaawie P, Attivor E, Boateng LA, et al
Examining confidence and hesitancy towards COVID-19 vaccines: A cross-sectional survey using in-person data collection in rural Ghana.
Vaccine. 2023 Feb 13:S0264-410X(23)00159-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

DE VRIES M, Claassen L, Lambooij MS, Timen A, et al
Did the temporary suspension of Vaxzveria vaccinations influence COVID-19 vaccination intentions, vaccination perceptions and trust in the vaccination campaign? A repeated survey study in the Netherlands.
Vaccine. 2023 Feb 10:S0264-410X(23)00138-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HOSAIN R, Aquino P, Baccarini C, Smolenov I, et al
Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in adults: A phase 2/3, double-blind, randomized study.
Vaccine. 2023 Feb 10:S0264-410X(23)00144-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SHEN AK, Browne S, Srivastava T, Kornides ML, et al
Persuading the "Movable Middle": Characteristics of effective messages to promote routine and COVID-19 vaccinations for adults and children - The impact of COVID-19 on beliefs and attitudes.
Vaccine. 2023 Feb 9:S0264-410X(23)00141-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

SILVA VASCONCELOS G, da Conceicao Rodrigues Fernandes M, Cardoso Matsui T, Claudia Dos Santos Luciano M, et al
Persistent SARS-COV-2 infection in vaccinated individual with three doses of COVID-19 vaccine.
Vaccine. 2023 Feb 9:S0264-410X(23)00145-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BUNTINX E, Brochado L, Borja-Tabora C, Yu CY, et al
Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naive and exposed individuals in a phase 2/3, double-blind, randomized study.
Vaccine. 2023 Feb 9:S0264-410X(23)00143-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

FEIKIN DR, Higdon MM, Andrews N, Collie S, et al
Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization.
Vaccine. 2023 Feb 9:S0264-410X(23)00146-9. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BUGHIN J, Cincera M, Peters K, Reykowska D, et al
Make it or break it: On-time vaccination intent at the time of Covid-19.
Vaccine. 2023 Feb 8:S0264-410X(23)00140-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

WATANABE A, Iwagami M, Yasuhara J, Takagi H, et al
Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis.
Vaccine. 2023 Feb 8:S0264-410X(23)00134-2. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

FELL DB, Torok E, Sprague AE, Regan AK, et al
Temporal trends and determinants of COVID-19 vaccine coverage and series initiation during pregnancy in Ontario, Canada, December 2020 to December 2021: A population-based retrospective cohort study.
Vaccine. 2023 Feb 3:S0264-410X(23)00114-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HASSAN RAZA S, Yousaf M, Zaman U, Waheed Khan S, et al
Unlocking infodemics and mysteries in COVID-19 vaccine hesitancy: Nexus of conspiracy beliefs, digital informational support, psychological Well-being, and religious fatalism.
Vaccine. 2023 Feb 3:S0264-410X(23)00079-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LI R, Liu H, Fairley CK, Ong JJ, et al
mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia.
Vaccine. 2023 Feb 3:S0264-410X(23)00126-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MALTEZOU HC, Basoulis D, Bonelis K, Gamaletsou MN, et al
Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece.
Vaccine. 2023 Feb 2:S0264-410X(23)00109-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HAMADA H, Futamura M, Ito H, Yamamoto R, et al
Association of a third vaccination with antibody levels and side reactions in essential workers: A prospective cohort study.
Vaccine. 2023 Feb 1:S0264-410X(23)00082-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

JOHNSON R, Djaafara B, Haw D, Doohan P, et al
The societal value of SARS-CoV-2 booster vaccination in Indonesia.
Vaccine. 2023 Feb 1:S0264-410X(23)00110-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

ANDREJKO KL, Myers JF, Fukui N, Nelson L, et al
Real-world uptake of COVID-19 vaccination among individuals expressing vaccine hesitancy: A registry-linkage study.
Vaccine. 2023 Feb 1:S0264-410X(23)00108-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

January 2023

UWAMINO Y, Yokoyama T, Sato Y, Shibata A, et al
Humoral and cellular immune response dynamics in Japanese healthcare workers up to six months after receiving a third dose of BNT162b2 monovalent vaccine.
Vaccine. 2023 Jan 31:S0264-410X(23)00081-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

GRESSENS SB, Wiedemann A, Dechenaud M, Dupuis J, et al
Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies.
Vaccine. 2023 Jan 30:S0264-410X(23)00095-6. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HARBIN A, Laventhal N, Navin M
Ethics of age de-escalation in pediatric vaccine trials: Attending to the case of COVID-19.
Vaccine. 2023 Jan 27:S0264-410X(23)00087-7. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

GROSSMAN-GIRON A, Tzur Bitan D, Shemesh S, Mayer Y, et al
COVID-19 vaccine hesitancy scale and its association with actual COVID-19 vaccine uptake in Israel.
Vaccine. 2023 Jan 23:S0264-410X(23)00065-8. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

MALLAH SI, Alawadhi A, Jawad J, Wasif P, et al
Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.
Vaccine. 2023 Jan 23:S0264-410X(23)00053-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

STRATHDEE SA, Abramovitz D, Vera CF, Artamonova I, et al
Predictors of COVID-19 vaccine uptake among people who inject drugs.
Vaccine. 2023 Jan 23:S0264-410X(23)00063-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

KALRA S, Kalra D, Grafova I, Rubin JS, et al
Association of death or illness from COVID-19 among family and friends on vaccine uptake within four months of the Emergency Use Authorization. Findings from a national survey in the United States.
Vaccine. 2023 Jan 13:S0264-410X(23)00035-X. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

TSUCHIYA Y, Tamura H, Fujii K, Numaguchi H, et al
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan.
Vaccine. 2023 Jan 5:S0264-410X(23)00006-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

FORD JS, Rouleau SG, Wagner JL, Adams CB, et al
Assessment of a COVID-19 vaccination protocol for unhoused patients in the emergency department.
Vaccine. 2023 Jan 2:S0264-410X(22)01598-5. doi: 10.1016/j.vaccine.2022.
PubMed Abstract available

December 2022

SONOYAMA T, Iwata S, Shinkai M, Iwata-Yoshikawa N, et al
Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults.
Vaccine. 2022 Dec 16:S0264-410X(22)01540-7. doi: 10.1016/j.vaccine.2022.
PubMed Abstract available

OLAYINKA F, Sauer M, Menning L, Summers D, et al
Building and sustaining public and political commitment to the value of vaccination: Recommendations for the Immunization Agenda 2030 (Strategic Priority Area 2).
Vaccine. 2022 Dec 15:S0264-410X(22)01451-7. doi: 10.1016/j.vaccine.2022.
PubMed Abstract available

SALVATORE PP, Lee CC, Sleweon S, McCormick DW, et al
Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July-August 2021.
Vaccine. 2022 Dec 13:S0264-410X(22)01458-X. doi: 10.1016/j.vaccine.2022.
PubMed Abstract available

HALL PA, Meng G, Boudreau C, Hudson A, et al
Social cognitive predictors of vaccination status, uptake and mitigation behaviors in the Canadian COVID-19 Experiences survey.
Vaccine. 2022 Dec 12:S0264-410X(22)01526-2. doi: 10.1016/j.vaccine.2022.
PubMed Abstract available

WALLACE AS, Ryman TK, Privor-Dumm L, Morgan C, et al
Leaving no one behind: Defining and implementing an integrated life course approach to vaccination across the next decade as part of the immunization Agenda 2030.
Vaccine. 2022 Dec 8:S0264-410X(22)01452-9. doi: 10.1016/j.vaccine.2022.
PubMed Abstract available

November 2022

MCCORMICK DW, Hagan LM, Salvatore PP, Magleby R, et al
SARS-CoV-2 viral shedding in vaccinated and unvaccinated persons: A case series.
Vaccine. 2022 Nov 18:S0264-410X(22)01428-1. doi: 10.1016/j.vaccine.2022.
PubMed Abstract available

October 2022

HALL PA, Meng G, Sakib MN, Quah ACK, et al
Do the vaccinated perform less distancing, mask wearing and hand hygiene? A test of the risk compensation hypothesis in a representative sample during the COVID-19 pandemic.
Vaccine. 2022 Oct 20. pii: S0264-410X(22)01289.
PubMed Abstract available

HUDSON A, Hall PA, Hitchman SC, Meng G, et al
Cognitive predictors of COVID-19 mitigation behaviors in vaccinated and unvaccinated general population members.
Vaccine. 2022 Oct 13. pii: S0264-410X(22)01242.
PubMed Abstract available

March 2022

SNIDER CJ, Boualam L, Tallis G, Takashima Y, et al
Concurrent outbreaks of circulating vaccine-derived poliovirus types 1 and 2 affecting the Republic of the Philippines and Malaysia, 2019-2021.
Vaccine. 2022 Mar 22. pii: S0264-410X(22)00145.
PubMed Abstract available

October 2021

BOZORGI A, Fahimnia B
Micro array patch (MAP) for the delivery of thermostable vaccines in Australia: A cost/benefit analysis.
Vaccine. 2021;39:6166-6173.
PubMed Abstract available

BOZORGI A, Fahimnia B
Transforming the vaccine supply chain in Australia: Opportunities and challenges.
Vaccine. 2021;39:6157-6165.
PubMed Abstract available

September 2021

MOLODECKY NA, Jafari H, Safdar RM, Ahmed JA, et al
Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in Pakistan and Afghanistan to inform outbreak control strategies in the context of the COVID-19 pandemic.
Vaccine. 2021 Sep 25. pii: S0264-410X(21)01228.
PubMed Abstract available

LIU D, Leung K, Jit M, Wu JT, et al
Cost-effectiveness of strategies for preventing paediatric lower respiratory infections associated with respiratory syncytial virus in eight Chinese cities.
Vaccine. 2021;39:5490-5498.
PubMed Abstract available

KOHL-HECKL WK, Schroter M, Dobos G, Cramer H, et al
Complementary medicine use and flu vaccination - A nationally representative survey of US adults.
Vaccine. 2021;39:5635-5640.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.